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Abstract 
 
Work from our group has identified an important role for the pericellular matrix (PCM) of 
cartilage in mechanotransduction. This region of the matrix sequesters regulatory molecules 
such as fibroblastic growth factor 2 (FGF2) and releases them upon mechanical stimulation. 
By carrying out a proteomic analysis of PCM proteins we identified an additional regulatory 
molecule, connective tissue growth factor (CTGF). CTGF was of interest to us as this protein 
is up-regulated in osteoarthritis but its function in chondrocytes is unknown.  
I confirmed the pericellular localisation of CTGF in cartilage and showed that it binds to 
heparan sulphate perlecan and like FGF2, CTGF is rapidly released from the PCM upon 
cartilage injury. 
In order to determine its function in chondrocytes, I expressed recombinant CTGF and 
performed a microarray study in isolated human chondrocytes. Four genes were up-
regulated by CTGF and all were known to be transforming growth factor beta (TGFβ) 
inducible. Recombinant CTGF was able to activate SMAD2 in porcine chondrocytes 
indicating that it can activate the canonical TGFβ signalling pathway. Both CTGF induced 
gene expression and SMAD2 phosphorylation was abrogated by TGFβ neutralising antibody 
and the TGFβ receptor inhibitor SB431542, suggesting that the activity of CTGF is TGFβ 
dependent. Adding exogenous CTGF to rested porcine cartilage increased TGFβ protein 
accumulation without affecting TGFβ mRNA levels, suggesting that CTGF may control TGFβ 
protein’s bioavailability. Injured porcine cartilage caused rapid release of endogenous CTGF 
as well as a delayed accumulation of TGFβ in the conditioned medium (CM). 
TGFβ proteins are synthesised and secreted in a latent complex associated with the latency-
associated peptide (LAP). When I analysed the explantation CM under non-reducing 
conditions, CTGF resolved at a high molecular weight (~150kDa), and a high molecular 
weight fraction of this CM contained SMAD2 activity suggesting that CTGF may be in 
complex with latent TGFβ. This was supported by the identification of LAP in CTGF 
immunoprecipitates. Injured cartilage from CTGF knockout mice released reduced levels of 
CTGF but apparently normal levels of TGFβ suggesting that CTGF is not necessary for 
release of latent TGFβ. However, SMAD2-phosphorylating ability of the medium was 
compromised indicating that CTGF controls TGFβ bioavailability principally by facilitating 
activation of latent complex at the surface of the chondrocyte. These data unveil a novel role 
for CTGF in cartilage through controlling TGFβ bioavailability. 
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1.1 Background 
Articular cartilage is an avascular tissue, consisting of articular chondrocytes isolated by an 
extensive extracellular matrix (ECM), rich in collagen, proteoglycans and water. One 
common disease associated with cartilage is osteoarthritis (OA), which is characterised by 
the loss of ECM and clustering of chondrocytes in enlarged lacunae, resulting in the 
degeneration of the tissue and exposure of the bone (see later for details). Mechanical injury 
on cartilage such as cutting or wear and tear predisposes the joint to OA, but how tissues 
respond to these mechanical insults is largely unknown.  
I will start the thesis by giving an introduction to cartilage, its development and structure and 
how it is turned over in health and disease. 
 
 !!!!!!!!!!!!
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1.2 Articular cartilage 
Cartilage is classified in the three groups: elastic cartilage, hyaline cartilage and 
fibrocartilage. Articular cartilage is hyaline cartilage. It is the smooth and white tissue covers 
the ends of bones where they meet together to form joints. Its principle role is to provide a 
lubricated surface for articulation and to facilitate the transmission of loads with a low friction 
coefficient. Articular cartilage is devoid of blood vessels, lymphatics, and nerves and is 
thought to have a limited capacity for intrinsic healing and repair (Pearle et al. 2005). In this 
regard, preservation of the integrity and health of articular cartilage is important for long term 
joint health. 
1.2.1 Development of articular cartilage 
Cartilage is formed by a process called chondrogenesis from condensed mesenchyme 
tissue that differentiates into clusters of cartilage cells called chondrocytes that begin 
secreting the molecules that form the extracellular matrix. Multipotential mesenchymal cells 
that are derived from the mesoderm germ layer receive signals that determine the shape, 
size and number of mesenchymal condensations. These signals are initiated by cell-cell and 
cell-matrix interactions. Adhesion molecules, neural cell adhesion molecule (N-CAM) and N-
cadherin, are thought to have important roles in this process (DeLise et al. 2000; Goldring et 
al. 2006). The condensation process is followed by differentiation, a process controlled by a 
number of factors including the transcription factors Sox5, 6 and 9 and runt-related 
transcription factor 1 (RUNX1) and growth factors including fibroblast growth factors (FGFs) 
and transforming growth factor beta (TGFβ) (Cole 2011; Bi et al. 1999). Differentiated 
chondrocytes then undergo a process of proliferation and maturation which results in the 
production of an ECM characterised by the cartilaginous molecules type II collagen and 
aggrecan (Archer, 1994). The fate of developing chondrocytes varies depending on their 
location and origin. Some cells survive and remain as active and functional articular 
chondrocytes whereas those that comprise the epiphyseal growth plates go through a 
Chapter 1   Introduction 
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proliferative phase and eventually become hypertrophic (Pacifici et al., 2000). Hypertrophic 
chondrocytes then undergo terminal differentiation which results in cell death, followed by 
growth of osteoblasts and blood vessels, and formation of a mineralised matrix. The process 
by which the cartilage template is gradually replaced with a calcified bone matrix through the 
invasion of osteoblasts is termed endochondral ossification (Shimizu et al., 2007). 
1.2.2 Components and structure of articular cartilage 
Articular cartilage is composed of chondrocytes embedded in a highly ordered extracellular 
matrix of collagen, proteoglycans and non-collagenous proteins. Its highly organised 
structure allows it to function as a frictionless gliding surface that cushions compressive, 
tensile and shearing forces from articulation of synovial joints. Articular cartilage is typically 
depicted in four zones which vary in matrix composition and cell morphology (Figure 1.1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic, cross-sectional diagram of normal articular cartilage (hand drawn, inspired by an 
image from Jazrawi et al. 2011). A: Cellular organisation in the zones of articular cartilage. B: Collagen fibres 
architecture. !
The superficial zone includes a cell-free gliding surface that adjoins a layer consisting of 
elongated chondrocytes and densely packed collagen fibrils. These cells and fibrils have a 
highly organised alignment that is parallel to the articular surface. The middle zone (also 
Superficial zone 
Middle zone 
Deep zone 
Calcified zone 
Subchondral bone 
A B 
Gliding surface 
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called the transitional zone) consists of a less organised arrangement of the collagen fibrils 
and the chondrocytes in this zone are mostly rounded. The deep zone (or radial zone) 
consists of large diameter collagen fibrils orientated perpendicular to the articular surface. 
This layer contains the highest proteoglycan and lowest water content. The chondrocytes 
are typically arranged in columnar fashion parallel to the collagen fibrils and perpendicular to 
the joint line. The calcified zone contains cells expressing a hypertrophic phenotype that are 
able to synthesise a calcified matrix that provides an interface between uncalcified cartilage 
and the underlying subchondral bone (Akizuki et al. 1986; Kempson et al. 1973; Poole et al. 
2001). 
1.2.3 Articular chondrocytes 
Chondrocytes are normally morphologically rounded or polygonal except at tissue 
boundaries where they may be flattened such as within the superficial layer of articular 
cartilage (Villar-Suárez et al. 2004). Chondrocytes are not capable of cell division, however, 
they are metabolically active to synthesise and turn over a large volume of the extracellular 
matrix (Archer and Francis-West 2003). Articular chondrocytes are embedded in an 
extensive extracellular matrix with an extremely long diffusion distance from the nourishing 
arteries. As a result, chondrocytes must reply on diffusion from articular surface to obtain 
nutrients and metabolites and adapt highly effective mechanisms to the hypoxia 
environments (Distler et al. 2004). The majority of the cell’s energy requirements come from 
glycolysis that occurs in the cytoplasm and, as a result, chondrocytes normally do not 
contain abundant mitochondria (Archer and Francis-West 2003). 
1.2.4 The extracellular matrix  
The extracellular matrix (ECM) of articular cartilage consists of collagen (predominately type 
II collagen), proteoglycan aggregates containing glycosaminoglycans (GAGs), and 
multiadhesive glycoproteins (noncollagenous proteins).  
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Collagens are the most abundant protein in the ECM and play important biological and 
mechanical roles in articular cartilage. Type II, IX and XI collagens form a fibrillar network 
that provides tensile strength throughout the ECM (Buckwalter and Mankin 1998; Yingst et al. 
2009). Type VI collagen is thought to form hexagonal networks in close proximity to the 
chondrocytes (pericellular matrix, see later), enabling the cells to attach to the ECM via 
integrins (on cell membrane) and biglycan (in the ECM) (Buckwalter and Mankin 1998), and 
acting as a transducer of biomechanical and biochemical signals in the articular cartilage 
(Guilak et al. 2006; Roughley and Lee 1994). 
Embedded in the collagen mesh are large aggregated proteoglycans (aggrecan attached to 
hyaluronan through link protein), which together give cartilage its stiffness and resilience for 
its long-term durability (Kiani et al. 2002; Roughley and Lee 1994). Aggrecan is the most 
abundant proteoglycan that exhibits a bottlebrush structure, in which chondroitin sulphate 
(CS) and keratan sulphate (KS) chains are attached to an extended protein core (Fosang et 
al. 1992). These CS and KS chains are negatively charged GAGs that interact with positive 
sodium ions thus attracting water molecules (60% to 80% of wet weight of articular cartilage) 
through osmosis (Pearle et al. 2005). The resulting hydrated aggrecan provides lubrication 
within the joint and contributes to the load-bearing capacity of articular cartilage. Small 
proteoglycans in cartilage include decorin (Krusius and Ruoslahti 1986), fibromodulin 
(Antonsson et al. 1991), biglycan (Fisher et al. 1989), proline/arginine-rich end leucine-rich 
repeat protein (PRELP) (E Bengtsson et al. 1995) and chondroadherin (Neame et al. 1994). 
Decorin and fibromodulin both interact with the type II collagen fibrils in the matrix and 
participate in fibrillogenesis and interfibril interactions. Biglycan is mainly found in the 
immediate surroundings of the chondrocytes, where it may interact with type VI collagen 
(Roughley and Lee 1994; Buckwalter and Mankin 1998). PRELP and chondroadherin are 
able to facilitate adhesion of chondrocytes to matrix proteins by binding to the 
transmembrane receptor proteins syndecans and integrins (Beauvais and Rapraeger 2004). 
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Other non-collagenous proteins in articular cartilage such as cartilage oligomeric matrix 
protein (COMP) (thrombospondin family protein) are markers of ECM turnover and 
degeneration (Di Cesare et al. 1996). Thrombospondin-1, tenascin and fibronectin influence 
interactions between the chondrocytes and the ECM (Buckwalter and Mankin 1998; Burton-
Wurster et al. 1997). Some of the key fibrillar and non-fibrillar collagens, proteoglycans, and 
non-collagenous proteins present in the ECM of cartilage are illustrated in figure 1.2.  
 
 
 
 
 
 
 
 
Figure 1.2 Molecular composition of the ECM of articular cartilage. The schematic diagram shows the major 
collagenous and non-collagenous components of cartilage ECM. !
As there is little cell-cell contact within cartilage, communications between cells occurs 
mainly through the ECM (Mitrovic et al., 1983; Poole et al., 2001). The ECM of articular 
cartilage can be defined according to its spatial relationship to the chondrocyte. There are 
two broad regions recognised: the pericellular matrix (PCM), which surrounds individual 
chondrocytes throughout the tissue, and the further removed matrix, which is divided into the 
territorial matrix (TM) and interterritorial matrices (ITM). The later two make up most of the 
volume of the mature articular cartilage. One of our major interests is the role of the PCM in 
articular cartilage; therefore the PCM will be discussed further. 
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1.2.5 The pericellular matrix and its structure 
The pericellular matrix (PCM) is described as a lucent zone that surrounds individual 
chondrocytes throughout articular cartilage. A unit comprising a chondrocyte and its 
surrounding PCM is termed the ‘chondron’, which was first identified by Benninghoff in a 
range of hyaline cartilages (Poole 1997). Little research about the PCM was done until the 
development of mechanical and enzymatic methods to isolate intact chondrons by Poole’s 
group (Alexopoulos et al. 2003). These methods have allowed a number of biological and 
biomechanical assays for studying the composition and structure of the PCM. The PCM is 
distinct from the type II collagen rich TM and it is made up of type VI collagen and other non-
collagenous proteins such as perlecan (Melrose et al. 2006), laminin (Dürr et al. 1996), 
fibrillin (Keene et al. 1997) and previously mentioned ECM components including biglycan, 
hyaluronan, link protein, fibronectin, and decorin. Our group has previously studied the 
structure of the PCM and organisation of some of the major components of the PCM using 
electron microscopy (Figure 1.3A and B) and confocal microscopy (Figure 1.3C). 
 
 
 
                             
 
 
Figure 1.3 The pericellular matrix by electronic microscopy (A 5000X and B 12000X) and confocal 
microscopy (C 60X). Courtesy of Celia McLean (PhD 2009) 
 
In the electron microscopic images, the PCM (white arrow, Figure 1.3B) is the lucent matrix 
layer that surrounds the chondrocyte and separates the cell from the TM. The TM is denser 
due to the presence of type II collagen fibers (black arrow, Figure 1.3A), whereas the PCM is 
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devoid of these fibrils. Cell processes can be seen extending from the chondrocytes into the 
PCM where they presumably mediate interactions between the cell and the matrix. 
Fluorescent images from confocal microscopy show the localisation of perlecan, type VI 
collagen and link protein within the PCM (Figure 1.3C). 
1.2.5.1 Perlecan and its binding regulatory molecules 
Perlecan, also known as heparan sulfate proteoglycan 2, is localised exclusively within the 
PCM of articular cartilage. To the protein core of perlecan three long chains of GAG are 
attached. These can be heparan sulphate (HS) or chondroitin sulphate (CS) (Melrose et al. 
2006; Noonan et al. 1991), although our unpublished work has shown that perlecan in adult 
articular cartilage is almost exclusively substituted with HS, and it is the major HS 
proteoglycan of articular cartilage (Vincent et al. 2007). Perlecan binds to a number of matrix 
proteins such as type VI collagen, fibronectin and PRELP (Bengtsson et al. 2002; Melrose et 
al. 2006; Hopf et al. 1999). Perlecan also functions as a ligand reservoir for numerous 
regulatory molecules through attachments to its protein core or GAG chains. The matrix 
metalloproteinases (MMP) 2, 7, 9 and 13 have been shown to bind HS in the extracellular 
space and are released in culture upon heparitinase or heparin treatment (Yu and Woessner 
2000). Tissue inhibitor of metalloproteinase (TIMP) 3 is sequestered in the pericellular 
environment by perlecan (Langton et al. 1998). Perlecan also sequesters a large number of 
heparin binding growth factors including FGF2 (Whitelock et al. 1996), vascular endothelial 
growth factor (VEGF) (Savore et al. 2005) and connective tissue growth factor (CTGF) 
(Nishida et al. 2003). These findings suggest that perlecan acts as a docking station for 
these matrix-modelling molecules and may play a prominent role in controlling their actions 
in cartilage. The interaction of FGFs and HS chains of perlecan has been shown to be 
important in regulating presentation of FGFs to FGF receptors (FGFRs) and their 
subsequent oligomerisation and activation. The HS chains of perlecan act as co-receptors 
for FGF18 signalling in articular cartilage (Melrose et al. 2006). There are also reports 
showing the interaction of perlecan and growth factors through its protein core. Mongiat et al 
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(2000) reported that FGF7 binds to perlecan’s protein core, and influences the effect of 
FGF7 on cancer growth and tissue remodelling (Mongiat et al. 2000). Smith et al (2007) 
observed that in addition to the HS chains, FGF18 also binds to perlecan via its protein core, 
which altered its mitogenic effect in growth plate chondrocytes (Smith et al. 2007). Work 
from our group shows that perlecan sequesters FGF2, and allows it to be liberated upon 
injury and mechanical loading (Vincent et al. 2007; Vincent et al. 2002). The released FGF2 
activates the mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 
(ERK) pathway and induces the expression of chondroprotective genes including activin A, 
tumor necrosis factor-inducible gene 6 (TSG6) and TIMP1 (Chong et al. 2013). Activin A is a 
TGFβ family protein that has anti-catabolic effects in vitro and plays roles in inflammation 
and tissue repair (see later). TSG6 plays anti-inflammatory role in vivo and TIMP1 is a 
natural inhibitor of MMPs that involved in degradation of the ECM. We showed that FGF2 
was chondroprotective as FGF2 null mice developed accelerated OA following joint 
destabilisation (Chia et al. 2009). In FGF2 null mice, those FGF2 dependent 
chondroprotective genes (such as activin A and TIMP1) were suppressed in the knee tissue 
following joint destabilisation (Chong et al. 2013). 
1.2.6 Matrix maintenance and turnover 
The integrity of articular cartilage in normal and healthy adult is maintained through a steady 
state between synthesis of the ECM by chondrocytes and the rate of cartilage degradation.  
Cartilage is constantly remodelled, which is critical for development and normal physiology. 
Any change in this homeostatic steady state could rapidly affect the normal function of the 
cartilage and may lead to excessive degradation, which is characteristic of the pathogenesis 
of osteoarthritis (Tetlow et al. 2001; Walter et al. 1998). ECM turnover depends on the ability 
of chondrocytes to detect changes in the microenvironment. These changes include 
alternations in matrix composition such as degraded matrix molecules, presence of 
inflammatory cytokines and other ‘danger’ sensors. Spontaneous matrix degradation results 
in the release of matrix macromolecules and associated regulatory molecules, which trigger 
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responses from chondrocytes. For example, insulin like growth factor 1 (IGF1) is 
constitutively sequestered in the ECM by binding to its IGF-binding protein (IGFBP) and 
fibronection. Release of IGF1 as a result of matrix degradation increases local bioavailability 
of IGF1, which stimulates chondrocyte anabolic activity (Martin and Buckwalter 2000). FGF2 
release from the PCM of articular cartilage upon mechanical compression appears to occur 
in a protease independent fashion and results in a rapid (<30sec) activation of the 
chondrocytes (Vincent et al. 2007). The exact role of these presumed anabolic regulatory 
molecules will be discussed later in this chapter. ECM degradation is also accompanied by 
the release of catabolic molecules. MMPs for example, may be sequestered in the PCM, are 
released and activated upon injurious signals (Gepstein et al. 2002). Conversely, TIMP3, the 
principle metalloproteinase inhibitor is also heparin sulphate bound in the PCM (Troeberg et 
al. 2014). 
Mechanical loading is arguably the most important pathological as well as physiological 
stimulus in cartilage. Mechanical loading creates mechanical, electrical, and 
physicochemical signals that help to direct the synthesis and degradation of cartilage 
(Mobasheri et al. 2002). Prolonged and severe decrease in joint use leads to alterations in 
the composition of the ECM and eventually tissue atrophy and changes to its specific 
biomechanical properties.  On the other hand, normal physical strain stimulates the 
synthesising activity of chondrocytes and possibly internal tissue remodelling (Joseph et al. 
2004; Maffulli and King 1992). In this context, the ECM acts as a signal transducer for 
chondrocytes (Millward-Sadler and Salter 2004). 
Although articular cartilage is able to tolerate a significant amount of intensive and repetitive 
physical stress, it shows limited ability to heal in the event of even a minor injury (Newman 
1998; Martin et al. 2004). This makes joints particularly sensitive to degenerative processes. 
Furthermore, aging also leads to alterations in the ECM composition and alters the activity of 
chondrocytes, including their ability to respond to a variety of stimuli such as growth factors 
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(Ralphs and Benjamin 1994; Hudelmaier et al. 2001). All these alterations increase the 
probability of cartilage degeneration (Sarzi-Puttini et al. 2005; Poole 1999), which may 
eventually result in OA. 
1.3 Osteoarthritis 
Osteoarthritis (OA) is a common disease of joints causing pain and loss of function. It is 
characterised by cartilage degeneration and osteosclerosis with formation of bone cysts and 
osteophytes (Conaghan et al. 2008). In the early stage of disease the cartilage surface 
becomes fibrillated, which then gradually extends into the middle and eventually the deep 
zones of the cartilage. This process involves degradation of cartilage ECM molecules 
including proteoglycans and collagens. In advanced stages, the organisation of the cartilage 
becomes completely disordered and may be replaced by scar-like fibrocartilage. In some 
weight bearing surfaces of the joint, cartilage may be lost down to the subchondral bone. 
Where tissue remains, cells are arranged in clusters in enlarged lacunae. Sometimes, these 
lacunae are surrounded by regions of intense metachromatic staining indicating increased 
proteoglycan formation, suggesting attempted repair of the damaged cartilage (Pearle et al. 
2005; Martel-Pelletier et al. 2008). 
1.3.1 Risk factors in osteoarthritis 
The development of OA is dependent on interactions between several factors and thus this 
process may be considered the product of a combination of risk factors including advancing 
age, genetics, trauma, knee malalignment, increased biomechanical loading of joints 
through obesity, augmented bone density and an imbalance in physiological processes 
(Heidari 2011). The pathogenesis of OA at the molecular and cellular level is not understood. 
Once considered a simple disease of wear and tear, it is now regarded as being due to 
active degrading processes associated with the regulation and activity of specific 
proteinases. There is evidence of up-regulation of MMP1 and MMP13 transcripts (Aigner et 
al. 2001) and increased collagenase (Billinghurst et al., 1997) and aggrecanase (Malfait et al. 
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2002) activity in late OA cartilage. Although a number of enzymes are able to degrade 
aggrecan in vitro (e.g. MMP3), the principal enzymes that drive this process in disease are 
members of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 
family (especially ADAMTS4 and 5). What drives these enzymes in vivo is not known, 
although our group has shown that mechanical factors per se are able to drive protease 
expression in the articular cartilage following surgical induction of OA (McNamee et al. 2010; 
Burleigh et al. 2012). These enzymes are strongly induced by cytokines in vitro, raising the 
possibility that inflammatory cytokines could be important in disease. Proinflammatory 
cytokines such as interleukin 1 (IL1) and tumor necrosis factor alpha (TNFα) induce 
chondrocytes, through the activation of nuclear factor kappa B (NF-κB) pathway, to express 
degrading enzymes such as MMPs and cyclooxygenase 2 (COX2) (Shakibaei et al. 2007). 
Dysregulation of anabolic signals such as TGFβ, which amongst other things is able to 
inhibit IL1 induced degradation of cartilage, is also observed in late OA (Finnson et al. 2010; 
Parker et al. 2007). The combination of accelerated catabolic activity along with breach of 
the cartilage homeostatic balance results in the development of OA.  
1.3.2 Growth factor expression in OA tissue 
In early OA, chondrocytes proliferate and synthesise enhanced amounts of matrix molecules 
possibly through the action of known anabolic factors including IGF1, TGFβ and FGF2 in an 
attempt to repair damaged matrix (Sandell and Aigner 2001). IGF1 has been shown to 
increase expression of collagen and proteoglycan in vitro in human cartilage and cultured 
chondrocytes (Franchimont and Bassleer 1991), and antagonise  the catabolic effects of IL1 
pathway by up-regulating the IL1 decoy/type II receptor (IL1RII) (Wang et al. 2003a). 
Expression of IGF1 and its receptors are increased in OA cartilage compared with normal 
human cartilage (Wang et al. 2003b), but so too are the IGF binding proteins which are able 
to inhibit IGF by competing with it binding to its receptor (Olney et al. 1996).  
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TGFβ and bone morphogenetic proteins (BMPs) have demonstrable anabolic effects on 
chondrocytes acting in a paracrine manner, where TGFβ family ligands signal through a pair 
of transmembrane serine/threonine kinase receptors, transmitting an intracellular signal 
through a cascade of SMAD pathways (canonical) to induce the synthesis of a range of 
ECM molecules (Finnson et al. 2010). The SMAD pathways have been found to play a 
critical role during OA development. A single-nucleotide polymorphism in the intron region of 
human smad3 gene has been linked to the incidence of hip and knee OA in a 527 European 
patient cohort (Valdes et al. 2010). Mice deficient for genes encoding any of the three TGFβ 
isoforms (TGFβ1, 2 and 3) show embryonic lethality, and loss of TGFβ2 or TGFβ3 genes 
leads to numerous bone defects affecting limbs and craniofacial bones, suggesting that 
TGFβ plays an important role in skeletogenesis (Dünker and Krieglstein 2000). TGFβ can 
also counteract the actions of IL1 by inhibiting the synthesis of IL1 signalling/type I receptor 
(IL1RI) (Redini et al. 1993). The expression of TGFβ is increased in early OA perhaps in an 
attempt to repair the damaged matrix, but TGFβ transcript levels are low in late OA cartilage 
(Blaney Davidson, et al. 2006). In vivo chondroprotection by TGFβ has also been suggested 
by Blaney Davidson et al (Blaney Davidson et al. 2007).  
FGF2 is an abundant matrix bound growth factor in articular cartilage that is released 
following mechanical loading and injury (Vincent et al. 2007; Vincent et al. 2002). FGF2 
knockout mice exhibited accelerated spontaneous and surgically induced OA (Chia et al. 
2009). FGF2 was able to inhibit IL1 dependent degradation of cartilage in vitro, possibly 
through the induction of activin A. Activin A is another TGFβ family protein and increased 
significantly in OA cartilage (Hermansson et al. 2004). However its molecular role in 
cartilage is not clear. TGFβ family proteins and CTGF will be introduced in more detail later 
in this chapter. 
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1.4 Connective tissue growth factor 
1.4.1 CTGF structure and binding 
CTGF is the second member of Cyr61, CTGF, Nov (CCN) protein family (also known as 
CCN2). These proteins are characterised by 4 homologous modules: the insulin like growth 
factor binding protein (IGFBP) like, von Willebrand factor type C repeat (VWC) with 
conservation of 38 cysteine residues, thrombospondin type I repeat (TSP1) and the C-
terminal (CT) module (Brigstock et al. 1997; Lau and Lam 1999; Moussad and Brigstock 
2000; Nakanishi et al. 1997a) (Figure 1.4). Each of these modules interacts with a range of 
molecules involved in a number of different cellular activities (Figure 1.4 lower part). CTGF 
was once classified as a low density IGF binding protein (IGFBP) superfamily protein. The 
interaction between CTGF and IGF has been proposed to modulate the activity of IGF in 
promoting normal and neoplastic cell growth (Kim et al. 1997). The VWC module is thought 
to mediate interactions with TGFβ and BMP4, and controls their activity in Mv1Lu (mink lung 
epithelial) and 10T1/2 (mouse embryo) cell lines respectively (Abreu et al., 2002). The TSP1 
module has been implicated in enabling binding of CTGF to ECM proteins, MMPs and 
integrins (Bornstein 2001; Lau and Lam 1999). In certain cell types, the interaction of CTGF 
with integrins promotes cell survival, adhesion and migration (Babic et al. 1999). This 
module is also involved in binding to heparin, heparan sulphate proteoglycan and low-
density lipoprotein receptor related protein (LRP). CTGF has been reported to be 
internalised and degraded in the endosome through the LRP receptor in a heparin 
dependent manner (Gao and Brigstock 2004). Our observations show that addition of 
heparin to cells in culture leads to increased CTGF protein in the medium. Heparin can block 
the normal LRP-mediated re-uptake mechanism, as has been described for LRP-mediated 
uptake of TIMP3 (Troeberg et al. 2008). CTGF has been reported to co-localise with 
perlecan in the PCM of the chondrosarcoma cell line, HCS-2/8 (Nishida et al. 2003). The 
TSP1 module also interacts with VEGF in control of angiogenesis through the assistance of 
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the CT module (Ivkovic et al. 2003). The CT module has been implicated in heparin and 
integrin binding (Ball et al. 2003) and dimerization (Bork 1993). 
 
 
 
 
 
Figure 1.4 The modular structure of CTGF protein and its binding molecules. Upper part of the figure shows 
the four modules in the structure of human CTGF protein.  IGFBP: insulin like growth factor binding protein, VWC: 
von Willebrand factor type C repeat, TSP1: thrombospondin type I repeat and CT: C- terminal. Lower part of the 
figure shows the molecules that bind to CTGF at each module of the structure respectively. 
 
1.4.2 Role of CTGF 
CTGF was first identified as a factor secreted by human umbilical vein endothelial cells 
(HUVEC) that competed with platelet derived growth factor (PDGF) binding to its cell surface 
receptor and had PDGF like biological activity (Bradham et al. 1991). A 38kDa cysteine rich 
secreted protein was shown to be the major PDGF related mitogen and termed connective 
tissue growth factor (Bradham et al. 1991). CTGF is highly expressed during embryonic 
development and during healing suggesting that CTGF is important in growth and 
regeneration of skeletal and vascular tissues (Ivkovic et al. 2003). The generation of CTGF 
knockout mice showed that deficiency of CTGF leads to lethal skeletal dysmorphisms 
including defects within the axial skeleton, shortening of sterna, deformation of limb cartilage 
and the craniofacial skeleton (Ivkovic et al. 2003). These defects are likely to be due to 
impaired chondrocyte proliferation and extracellular matrix composition within the 
hypertrophic zone (Ivkovic et al. 2003). CTGF has also been implicated in pathogenesis of 
fibrosis. Fibrotic diseases are characterised by scarring due to excessive production, 
deposition, and contraction of collagen (Leask and Abraham 2004). CTGF is constitutively 
overexpressed in dermal fibrotic lesions and its role in fibrosis is thought to be in mediating 
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downstream effects of TGFβ (Grotendorst 1997), which is considered a mediator of the 
elevated production of matrix proteins including collagen and fibronectin (Leask and 
Abraham, 2004). 
In articular cartilage, we have observed that CTGF protein is up-regulated in OA cartilage 
(Hermansson et al. 2004). Administration of recombinant CTGF protein has been reported to 
promote repair of damaged cartilage in a murine model of OA (Nishida et al. 2004). 
Treatment of rabbit articular chondrocytes in vitro suggested that CTGF was able to 
stimulate the gene expression of type II collagen and aggrecan, providing evidence that 
CTGF may have a role in cartilage anabolism (Nakanishi et al. 2000). Transgenic mice that 
overexpress CTGF under the Col2a1 promoter showed increased staining for proteoglycan 
and reduced staining for type X collagen and MMP13, when compared with wild-type mice. 
Observation of up-regulation of Col1a1, ColXa1, Mmm13 and Mmp9 mRNA in wild-type 
chondrocytes under cyclic tension stress was not seen in the CTGF transgenic chondrocytes 
(Itoh et al. 2013). As type X collagen and MMP13 are up-regulated in OA (Van der Kraan 
and Van den Berg 2012), these findings suggest that CTGF may have a beneficial role in 
articular cartilage. However, the molecular response and exact mechanism by which CTGF 
signals remains unclear and the existing literature is complicated by conflicting reports of the 
effect of CTGF on mature cartilage.  
There have also been a number of theories proposed about the mechanism by which CTGF 
mediates its cellular effect. Firstly that CTGF acts as a matricellular protein, which means 
that it does not activate the cell in a classical sense (signaling through a cell surface receptor) 
but helps the cell to interact with matrix proteins (Gao and Brigstock, 2004). Secondly, it acts 
as a cofactor for TGFβ family members, by binding directly to the TGFβ family ligand and 
affecting responses at the receptor (Abreu et al. 2002). Finally it may activate the cell via the 
tyrosine kinase receptor A (TrKA) (Wahab et al. 2005), LRP receptors or integrins (Gao and 
Brigstock 2003; Gao and Brigstock 2004). In order to understand by which mechanism 
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CTGF conducts its cellular response in articular chondrocytes, further in vitro investigation is 
required. 
1.5 TGFβ  family molecules 
The transforming growth factor beta (TGFβ) superfamily is a large family of structurally 
related cell regulatory proteins that was named after its first member, TGFβ1, originally 
described in 1983 (Assoian et al. 1983). TGFβ family proteins include TGFβ, activin/inhibin, 
BMPs and myostatin (Vale et al. 1988). Most of TGFβ family proteins, if not all, are produced 
as latent complexes. The bioavailability of these factors is controlled through binding to ECM 
proteins. TGFβ pro-peptide dimerises through disulfide bonds during secretion. The pro-
region of TGFβ (known to be a latency-associated peptide LAP) is cleaved by a furin-like 
protease and remains associated with the mature TGFβ through non-covalent interaction in 
a complex known as small latent complex (SLC). LAP forms disulfide bonds with latent TGF 
binding protein (LTBP1, 3 & 4). The resulting complexes (known as large latent complexes 
LLCs) bind to fibrillins and fibronectins in the ECM through LTBP. Figure 1.5 shows a 
schematic structure of SLC and LLC of TGFβ. TGFβ can be activated in a number of ways in 
vitro (see more detail in chapter 5), however, the study of its activation in articular cartilage is 
limited. There may be a different mechanism of activation in cartilage, which is suggested by 
the fact that the integrin alpha v, an important component of the activation complex in many 
cell types, is very little expressed in chondrocytes (Woods et al. 1994). Activin A is also 
produced in a complex with a latent pro-peptide and its biological activity may be modulated 
by the ECM. In Xenopus, activin A has been shown to act as a long range dorsalising signal 
to establish a concentration gradient, suggesting the potential associations of activin A with 
ECM components (McDowell et al. 1997). Li et al (2010) observed that recombinant activin 
A protein was able to bind to perlecan directly through its pro-region in vitro (Li et al. 2010). 
Heparitinase treatment of perlecan abolished the binding, suggesting that activin A binds to 
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perlecan through its heparan sulphate chains (Li et al., 2010). BMP2, 4, 7 and 10 also bind 
to fibrillin through their N terminal pro-region (Sengle et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Schematic structures of pre-pro-peptide, SLC and LLC of TGFβ . TGFβ is synthesised as a pre-
pro-peptide containing a N-terminal signal peptide (yellow) which is proteolytically processed in the rough 
endoplasmic reticulum. The pro-peptide form a dimer through disulfide bonds, which is cleaved by a furin-like 
protease. The pro-region of the peptide (LAP, green) remains associated with mature TGFβ (red) to form a SLC. 
LAP form disulfide bonds with LTBP (blue) to form LLC, which associates with fibrillin through non-covalent 
interaction and fibronectin through disulfide bond in the ECM. Inspired by an image from Dijke and Arthur 2007. !
1.5.1 Role of TGFβ  
TGFβ exists in at least three isoforms i.e. TGFβ1, TGFβ2 and TGFβ3, which show a 70% to 
80% structural homology (Hall et al. 2013). TGFβ is secreted by many cell types and has 
been extensively reported to play numerous roles in different cell types including regulation 
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of early development, differentiation, extracellular matrix formation, hematopoiesis, 
angiogenesis, chemotaxis, immune response, and the induction of apoptosis. TGFβ 
mediated growth inhibition and apoptosis can be correlated with its function as a tumor 
suppressor (Schuster and Krieglstein 2002). TGFβ exerts tumor-suppressive effects that 
cancer cells must elude for malignant evolution. Yet, paradoxically, TGFβ also modulates 
processes such as cell invasion, immune regulation, and microenvironment modification that 
cancer cells may exploit to their advantage (Massague 2008). In the immune system, TGFβ 
induces lymphocyte growth arrest and apoptosis via the SMAD pathway. TGFβ1 knockout 
mice die 2 to 3 weeks after birth and show massive inflammation (Kulkarni et al. 1993; Shull 
et al. 1992). Transgenic mice overexpressing a dominant negative mutant of the TGFβ type 
II receptor (TGFβRII), specifically on T cells, show a hyperplasia of T cells resulting in 
massive expansion of lymph nodes and spleen (Lucas et al. 2000). 
Another important molecular activity of TGFβ is to induce the expression of matrix 
molecules. In many tissues, the release and activation of TGFβ upon injury stimulates the 
production of extracellular matrix proteins and inhibits the degradation of these matrix 
proteins. These actions of TGFβ contribute to tissue repair, which under ideal circumstances 
leads to the restoration of normal tissue architecture and may involve a component of tissue 
fibrosis. In many diseases, excessive TGFβ contributes to a pathologic excess of tissue 
fibrosis that compromises normal organ function (Branton and Kopp 1999). Excessive 
activity of TGFβ in Marfan syndrome occur as a result of misfolding of fibrillin1 so that it is 
unable to control the bioavailability of latent TGFβ in the ECM. This causes deleterious 
effects on lungs, heart valves and aorta leading to weaker connective tissues (Kainulainen et 
al. 1994). In articular cartilage, TGFβ likely plays a role in maintaining normal cartilage 
homeostasis by inducing expression of ECM molecules. Up-regulation of TGFβ mRNA 
observed in early OA implicates its role in attempted cartilage repair (Kenneth et al. 2012).  
Chapter 1   Introduction 
! 34 
1.5.2 Role of activin A  
Activin A was originally discovered as a molecule in ovarian follicular fluid that caused 
pituitary cells in culture to secrete follicle-stimulating hormone. Inhibins, which share the β 
chain with activin but form heterodimers with α chain subunits, were found to be inhibitors of 
this process (Werner and Alzheimer 2006). Activin A has been shown to be important in 
embryogenesis; activin A deficient mice die within 24 hours after birth and develop severe 
craniofacial abnormalities including lack of whiskers and lower incisors, and defects in the 
second palate (Matzuk et al. 1995a). Like some of the other TGFβ family proteins, activin A 
is also involved in tissue repair. It has been shown that activin A is strongly induced after 
skin injury and high levels persist following wounding (Matzuk et al. 1995b). This induction is 
thought to be caused by released serum growth factors such as epidermal growth factor 
(EGF) and PDGF during haemorrhage as well as pro-inflammatory cytokines derived from 
neutrophils and macrophages (Hubner and Werner 1996). Overexpression of activin A in 
mice leads to increased proliferation of the basal keratinocytes and significant enhancement 
of granulation tissue formation (Munz et al. 1999). Overexpression of its sequestering 
inhibitor follistatin in the basal epidermis of skin was found to delay wound healing in mice 
(Munz et al. 1999).   
In cartilage injury, induction of activin A is FGF2 dependent (Alexander et al. 2007). Activin A 
is elevated in synovial fluid of patients with rheumatoid arthritis and osteoarthritis. It is 
induced by inflammatory stimuli such as IL1, TGFβ and bacterial lipopolysaccharide (LPS) in 
cultured synoviocytes and chondrocytes (Yu et al. 1998). Proteomic analysis of the proteins 
secreted by human articular cartilage in vitro showed activin A protein is up-regulated in OA 
compared to normal tissue (Hermansson et al. 2004). Activin A is up-regulated after 
cartilage injury through an ERK dependent pathway caused by release of FGF2 (Alexander 
et al. 2007; Vincent et al. 2002). Activin A may be chondroprotective as it inhibits IL1 
induced cartilage degradation (Alexander et al. 2007), but its molecular activities in cartilage 
chondrocytes are poorly understood. 
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1.5.3 TGFβ family proteins activate SMAD signalling pathways 
The TGFβ family signalling pathway is involved in many cellular activities, in both adult and 
embryo, including cell proliferation, differentiation, cellular homeostasis and apoptosis. TGFβ 
family ligands bind to their specific type II receptor (Figure 1.6), a serine/threonine receptor 
kinase, which recruits and phosphorylates the type I receptor (also called activin like kinase, 
ALK) (Miyazono et al. 2001). The activin type II receptor (ACVR2) binds to ALK 4, the BMP 
type II receptor (BMPR2) binds to ALK3 and 6 and the TGFβ type II receptor (TGFβR2) 
binds to ALK5. The type II and type I receptors form a heterotetrametric complex with the 
ligand and phosphorylate receptor regulated SMADs (collectively known as R-SMADs) 
(Massagué et al. 2005). TGFβs and activins activate SMAD2 and SMAD3, while BMPs 
activate SMAD1, SMAD5 and SMAD8. Precent studies on endothelial cells have identified 
ALK1 as a second type I TGF-beta receptor and have shown that ALK1 and ALK5 have 
opposing functions in these cells (Finnson et al. 2008). ALK1 activates SMAD1 and SMAD5 
phosphorylation, which is dependent on the activity of ALK5 (Goumans et al. 2003). The 
phosphorylated R-SMADs have high affinity for the co-SMAD (SMAD4) with which they form 
a complex and enter the nucleus. Nuclear SMAD complexes control gene transcription by 
binding to regulatory elements on the target DNA. These include the DNA of an inhibitory 
SMAD (SMAD7), which negatively modulates the signal pathway by competing with R-
SMAD from binding to type I receptor, which will then be degraded through ubiquitination 
(Massagué et al. 2005; Ishisaki et al. 1999). TGFβ can also activate other pathways 
including MAPK and phosphoinositide 3 kinase (PI3K) pathways, which are collectively 
referred to as ‘non‐canonical’ TGFβ signalling and complement SMAD action. The 
biochemical links between TGFβ receptors and the MAPK and PI3K pathways involve tumor 
necrosis factor receptor-associated factor 6 (TRAF6), mammalian target of rapamycin 
(mTORC) and other mediators. However, the molecular mechanism is unclear due to a lack 
of structural information (Massagué 2012). In cartilage the non-canonical pathways have 
been reported to be necessary for proper cartilage and joint development (Gunnell et al. 
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2010). Figure 1.6 shows a schematic diagram of the canonical SMAD signalling pathway of 
TGFβ, activin A and BMPs. 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Schematic diagram of SMAD signalling pathway shared by TGFβ, activin A and BMPs. 
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1.6 Aims and objectives 
Previously, Tonia Vincent found that cutting cartilage rapidly activated the ERK1 and 2 in 
chondrocytes, which was caused by the release of FGF2 from a sequestered extracellular 
pool bound to perlecan in the PCM (Vincent et al. 2002). In this context, the PCM acts as a 
mechano-transduction platform, transforming mechanical stimuli into a chemical signal 
(released FGF2) that leads to cellular responses. To extend these observations, the group 
sought to identify other PCM bound molecules whose activities could be controlled in a 
similar way. Celia McLean (a previous PhD student in our group) carried out a mass 
spectrometry study of PCM proteins using porcine articular cartilage. Amongst the known 
matrix components of the PCM, she identified CTGF. Previous work from our laboratory had 
shown that CTGF was highly expressed in articular cartilage and over expressed in OA 
(Hermansson et al. 2004). Little is known about the role of CTGF in mature articular cartilage, 
although it is essential for musculoskeletal development and the knockout animals 
demonstrate perinatal lethality and severe musculoskeletal defects (Ivkovic et al. 2003).  
The aims of this project were to characterise CTGF as a candidate of pericellular protein in 
normal mature articular cartilage, and to investigate its role in articular cartilage in response 
to mechanical injury. 
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2.1 Reagents and chemicals 
2.1.1 General reagents: Materials were purchased from the following sources: Trizma® 
base, sodium chloride, beta glycerophosphate, sodium vanadate, sodium deoxycholate, 
IGEPAL CA-630, proteases inhibitor, Tris-HCl, sodium dodecyl sulphate (SDS), Tween 20, 
glycine, sodium thiosulphate, sodium pyrophosphate, Ammonium persulfate, ammonium 
acetate, tetramethyl-ethylenediamine and imidazole from Sigma-Aldrich Company Ltd 
(Dorset, UK); phosphate buffered saline (PBS), acetic acid, chloroform, 
ethylenediaminetetraacetic acid (EDTA), glycerol, methanol, formaldehyde, boric acid and 
acetone from VWR International (Leicestershire , UK); bovine serum albumin (BSA), trypsin-
EDTA, fetal calf serum (FCS), penicillin/streptomycin, amphotericin B and HEPES from PAA 
(Les Mureaux, France); agarose and SYBR®-Safe DNA gel stain from Invitrogen (Paisley, 
UK); orange/blue DNA dye and 100bp DNA ladder from Promega (Southampton, UK); 
collagenase A from Roche (Mannheim, Germany); chondroitinase ABC and heparitinase 
from Seikagaku (Tokyo, Japan). 
 
2.1.2 Table of recombinant proteins and chemicals used in cell/tissue culture: 
Table 1 Recombinant proteins and chemicals used in cell/tissue cultures 
Proteins/inhibitors Specificity Source 
CTGF Human protein Purified in house 
Activin A Human protein R&D systems. Minneapolis, USA 
TGFβ1 Human protein Peprotech EC Ltd. London, UK 
BMP2 Human protein Peprotech EC Ltd. London, UK 
SB431542 ALK4 and ALK5 inhibitor R&D systems 
RAP LRP inhibitor Gift of Linda Troeberg 
Heparin Porcine glycosaminoglycan Isolated in house 
Cycloheximide Protein synthesis inhibitor Sigma-Aldrich 
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2.1.3 Table of antibodies used for western blotting, immunofluorescence, neutralising 
or immunoprecipitation 
Antibody 
against 
Use Type Source Dilution 
Perlecan Immunofluorescence 
Rat 
monoclonal 
Chemicon 
(MAB1948) 
1:1000 
CTGF 
Immunofluorescence 
Western blot 
Immunoprecipitation 
Goat 
polyclonal 
Santa Cruz 
(sc-14939) 
1:500 
FGF2 Immunofluorescence 
Mouse 
monoclonal 
Upstate 
(05-118) 
1:1000 
Type VI 
collagen 
Immunofluorescence 
Rabbit 
polyclonal 
Abcam 
(ab6588) 
1:1000 
Activin A 
Immunofluorescence 
Neutralisation 
Goat 
polyclonal 
R&D systems 
(AF338) 
1:500 
1µg/ml 
LAP1 
Western blotting 
Immunofluorescence 
Goat 
polyclonal 
R&D systems 
(AB-246-NA) 
1:500 
LAP1 
Western blotting 
Immunoprecipitation 
Mouse 
monoclonal 
Santa Cruz 
(sc-34830) 
1:500 
TGFβ -1, -2, -3 Western blotting 
Rabbit 
polyclonal 
Cell signalling 
(3711) 
1:1000 
TGFβ -1, -2, -3 Neutralisation 
Mouse 
monoclonal 
R&D systems 
(MAB1835) 
1µg/ml 
LTBP1 Western blotting 
Mouse 
monoclonal 
Santa Cruz 
(sc-271140) 
1:500 
Protein G HRP Western blotting 
Bacterial 
protein 
Bio-RAD 
(1706425) 
1:1000 
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Table 2 Antibodies used for western blot, immunohistochemistry, neutralising and immunoprecipitation. 
 
Phospho 
SMAD2 
Western blotting 
Rabbit 
polyclonal 
Cell signalling 
(138D4) 
1:1000 
Phospho 
SMAD1/5 
Western blotting 
Rabbit 
polyclonal 
Cell signalling 
(41D10) 
1:1000 
Tubulin 
Western blotting 
(Loading control) 
Rabbit 
polyclonal 
Cell signalling 
(2144) 
1:50000 
Goat IgG HRP 
Western blotting 
(Secondary) 
Rabbit anti 
goat 
DAKO 
(P0160) 
1:2000 
Mouse IgG 
HRP 
Western blotting 
(Secondary) 
Rabbit anti 
mouse 
DAKO 
(P0218) 
1:2000 
Rabbit IgG 
HRP 
Western blotting 
(Secondary) 
Swine anti 
rabbit 
DAKO 
(P0217) 
1:2000 
Rat IgG HRP 
Western blotting 
(Secondary) 
Rabbit anti rat 
DAKO 
(P0450) 
1:2000 
Alexa 488- 
conjugated goat 
IgG 
Immunohistochemistry 
(Secondary) 
Rabbit anti 
goat 
Invitrogen 
(A-11078) 
1:2000 
Alexa 647- 
conjugated 
mouse IgG 
Immunohistochemistry 
(Secondary) 
Rabbit anti 
mouse 
Invitrogen 
(A-21239) 
1:2000 
Alexa 647- 
conjugated 
rabbit  IgG 
Immunohistochemistry 
(Secondary) 
Goat anti rabbit 
Invitrogen 
(A-31852) 
1:2000 
Alexa 647 
conjugated rat 
IgG 
Immunohistochemistry 
(Secondary) 
Goat anti rat 
Invitrogen 
(A-21247) 
1:2000 
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2.2 Cell culture 
2.2.1 Cell culture reagents: Cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 4.5 g/l glucose and L-glutamine (Lonza, Verviers, Belgium). DMEM was 
always supplemented with 25mM HEPES buffer (pH7.0-7.6), 100U/ml penicillin, 100µg/ml 
streptomycin and 0.5µg/ml amphotericin B. Heat inactivated FCS was added at a final 
concentration of 10% when cells were cultured. All cell culture plastics were purchased from 
Beckton-Dickinson (Oxford, UK). 
 
2.2.2 Normal human skin dermal fibroblasts (NHDFs): Normal human skin dermal 
fibroblasts (NHDFs) were obtained from American Type Culture Collection (ATCC) and 
cultured in DMEM with 10% (v/v) FCS. Cells were cultured in a humidified atmosphere with 
5% CO2 at 37ºC. All cell culture was carried out in class II laminar flow cabinets. For 
passaging, cells were washed three times with sterile PBS. Trypsin-EDTA was added to the 
cells, which were then incubated at 37ºC for 5min. Once cells had detached they were 
centrifuged in an equal volume of DMEM at 235x g at room temperature for 5min. The cell 
pellet was then resuspended in DMEM prior plating. Cells were passaged for general 
maintenance every week by plating them at a density of 1 x 106 cells per 15cm cell culture 
plate (50% confluence). Cells were plated in 6 well plates at a density of 3 x 105 cells per 
well for siRNA oligo transfection and stimulation (50% confluence). NHDFs were passaged 
to a maximum of P15. 
 
2.2.3 Primary human articular chondrocytes (HACs): Normal human knee cartilage was 
obtained from patients at the Royal National Orthopaedic Hospital (RNOH, Stanmore, UK) 
who were undergoing surgery for tumors involving the lower leg (not involving the knee joint). 
Samples were obtained from individuals of different ages ranging from 8-76 years and were 
used with consent from the local ethics committees (Riverside Research Ethics Committee 
and Joint RNOH institute of Orthopaedics and Musculoskeletal Science Research Ethics 
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Committee). Written informed consent was obtained from all patients. Dissected cartilage 
explants were incubated with 1mg/ml/g collagenase for 5-6hr at 37ºC. The digest was then 
strained and centrifuged at 235x g for 5min. Finally the cell pellet was washed 3 times and 
resuspended in 10% FCS containing DMEM. Cells were plated (50% confluence) and grown 
to confluence in 15cm culture plates. They were passaged 1 or 2 (P1 or P2) times before 
use. 
 
2.2.4 Human chondrons: Human articular cartilage was dissected as described above and 
allowed to rest in serum free DMEM overnight at 37ºC. Chondrons were obtained using 
0.3% collagenase and 0.2% dispase in Ca2+- and Mg2+- free PBS at 37 ºC with constant 
agitation for 4hr. The resulting chondrons suspension was filtered through a 70µm nylon cell 
strainer and centrifuged at 528x g for 15min. The resulting pellet was resuspended in 5ml 
PBS. 200µl was used for confocal microscopy to stain for perlecan to assess the 
maintenance of the pericellular matrix. The suspension was then centrifuged at 528x g for 
5min to obtain the chondrons pellet (Lee et al. 1997). 
 
2.2.5 Primary porcine articular chondrocytes: Porcine articular cartilage was dissected 
from the trotter metacarpophalangeal joints of 3-6 month old pigs obtained fresh from a local 
abattoir within 24hr of slaughter. For chondrocytes isolation, freshly dissected cartilage 
explants were digested in FCS DMEM containing 1mg/ml/g collagenase for 5hr at 37ºC with 
agitation. The digest was strained through a cell strainer (BD Falcon™, New Jersey, US) to 
remove debris and the flow-through was collected in a new 50ml falcon tube. Cells in the 
medium were pelleted by centrifugation at 235x g for 5min at room temperature and washed 
three times with fresh DMEM. After the last spin, the cell pellet was resuspended in certain 
amount of 10% FCS DMEM that gives desired cell density for cell culture experiment.  Cells 
were plated in 12 well or 24 well plates at a density of approximately 2 million cells or 1 
million cells per well respectively. Chondrocytes were serum starved overnight prior to 
stimulation. 
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2.2.6 Porcine articular cartilage: Porcine articular cartilage was obtained from trotter 
metacarpophalangeal joints as mentioned above. For tissue culture experiments, cartilage 
explants were cut into similar size by a biopsy punch (4mm) (Stiefel® Laboratories Ltd, 
Bucks, UK) in serum free DMEM. 5 explant pieces were incubated in 200µl of DMEM per 
well of a 48 well plate. After 48hr, the cartilage explantation conditioned medium was 
collected for protein analysis and fresh DMEM was replaced for further stimulation or 
recutting. In recutting experiment, each cartilage explant was further cut into 6 pieces using 
a No.15 disposable scalpel (Swann Morton, Sheffield, UK). The recutting conditioned media 
were then collected at different time courses for further analysis. 
 
2.2.7 Mouse articular cartilage: CTGF floxed mice (Liu et al. 2011) were acquired from 
collaboration with Professor David Abraham, London and Professor George Bou-Gharios, 
Liverpool. Conditional CTGF knockout mice were generated by crossing the floxed mice with 
the Ubiquitin Cre ERT2 mice (purchased from The Jackson Laboratory). Litters were 
genotyped and at the age of 4 weeks treated with tamoxifen for 2 weeks to induce the 
deletion. At the age of 6 weeks, these mice were culled and their cartilages were obtained 
from hip joints. Two hip explants were obtained per mouse and cultured separately in 50µl of 
serum free DMEM in a 96 well plate. One of these rested hip explants was recut and the 
other remained intact as control. The injury-conditioned media were then collected for further 
analysis. 
 
2.3 Confocal microscopy: Normal human or osteoarthritic cartilages were obtained from 
patients at the RNOH, Stanmore and Charing Cross Hospital, Hammersmith, respectively.  
Explants were washed in serum free DMEM and snap frozen using liquid nitrogen. All frozen 
tissue sections were processed and mounted in OCT (optimal cutting temperature 
compound) and 7µm frozen cryostat sections were cut onto Surgipath snowcoat Xtra slides, 
air dried for 1h and then left for a further hour at 60°C to ensure tissue adherence. Tissue 
sections were fixed in methanol for 10min and pretreated with chondroitinase ABC (10mu/ml) 
Chapter 2   Materials and methods 
! 45 
for 120min at 37°C. The sections were blocked with 10% goat serum/PBS for 60min at room 
temperature, and then incubated with primary antibody for 1hr at room temperature or 
overnight at 4°C. Sections were washed three times with PBS and incubated (in dark) with 
secondary fluorescein-labelled antibodies for 1h at room temperature. Sections were further 
washed and mounted using 50% glycerol. Florescence signals were detected by Ultraview 
confocal microscopy (Perkin-Elmer, x60 oil immersion lens). 
 
2.4 ELISA-like binding assay: ELISA plates (Corning 96 wells, Sigma, US) were coated 
with 0.5µg/ml of perlecan (purified in house) in PBS for 3hr at room temperature or overnight 
at 4°C. Plates were washed three times with PBS/Tween and then blocked with 1% 
BSA/PBS (100µl/well) for 1hr at room temperature. Plates were washed again with PBS and 
incubated with 0 to 10µg/ml of CTGF in PBS for further 3hr at room temperature. After 
washes, plates were incubated with primary antibody (perlecan or CTGF) in 1% BSA/PBS 
for 2hr at room temperature or overnight at 4°C, then secondary antibody in 1% BSA/PBS 
for 1h at room temperature. After washing, TMB peroxidase substrate (Microwell peroxidase 
substrate system, KPL, USA) was added to the plates to generate a colour change reaction, 
which was stopped by sulphuric acid (0.2M). The intensity of transmitted light through each 
well was detected by Spectramax fluorometer (Molecular Devices, USA) at 450nm. In some 
experiments plates were also treated with heparintinase or chondroitinase ABC (10mu/ml) 
for 2hr at 37°C prior to incubation with 0.5µg/ml CTGF. 
2.5 Sample preparation, Gel electrophoresis, Western Blotting, silver staining and 
protein extraction from unstained SDS-PAGE gel. 
2.5.1 Protein sample preparation from cell lysates: Cultured NHDFs and HACs were 
lysed with dissociative RIPA buffer consisting of 100 mM Trizma base (pH 7.4), 300 mM 
NaCl, 20mM NaF, 2mM EDTA, 0.2mM beta glycerophosphate, 2% (w/v) Na vanadate, 2% 
(w/v) Na deoxycholate, 0.5% SDS and 1% (v/v) IGEPAL. RIPA buffer was also 
supplemented with a cocktail of proteases inhibitors containing 1mM phenylmethlsulfonyl 
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fluoride (PMSF), 10µM E64, 2µg/ml pepstatin A, 10µg/ml aprotinin and 1µM microcystin with 
broad specificity for the inhibition of serine, cysteine, aspartic proteases and amino 
peptidases. The inhibitor cocktail was mixed with RIPA buffer at a 1:100 ratio (v/v) according 
to the manufacturer’s instructions. For cell lysates, 100µl of ice-cold RIPA buffer containing 
protease inhibitors was added to the cell layer of each well. After 10min incubation at 4ºC 
the cell lysate in each well was collected into an eppendorf tube and spun at 16200x g at 
4°C for 10min to remove cell debris. 80µl of supernatant was removed and mixed with 20µl 
of 5 x reducing SDS sample buffer containing 0.2M Tris HCl pH 6.8, 20% (v/v) glycerol, 10% 
(w/v) SDS, 10mM dithiothreitol (DTT) and 0.05% (w/v) bromophenol blue. After mixing, the 
samples were boiled for 10min prior to electrophoresis.  
 
2.5.2 Protein sample preparation from cell/tissue medium: Medium from cultures was 
collected and processed with or without acetone precipitation. For precipitation, samples 
were mixed with ice-cold acetone at 1:5 ratio (v/v) at -20ºC. After 30min, the samples were 
centrifuged at 16200x g at 4°C for 10min and the supernatant was removed. The resulting 
protein pellet was dried in a vacuum dryer and then dissolved in 50µl of 1 x SDS sample 
buffer (with or without DTT for reducing or non-reducing respectively) and boiled prior to 
electrophoresis.  
 
2.5.3 Gel electrophoresis: Proteins were separated by gel electrophoresis either using pre-
cast NuPAGE 4-12% Bis-Tris gradient polyacrylamide mini gels (1.5mm thickness) (Novx, 
San Diego, CA) or laboratory prepared 8% acrylamide gels (1.5mm thickness). The pre-cast 
gels were composed of a 4% acrylamide stacking gel and a 4-12% gradient resolving gel. 
The laboratory made gels used were composed of a 5% stacking gel (125mM Tris-HCl 
pH6.8, 0.1% (w/v) SDS, and 5% (w/v) acrylamide) and 8% resolving gel (380mM Tris-HCl 
pH8.8, 0.1% (w/v) SDS and 8% (w/v) acrylamide). 50µl of prepared protein sample 
(described above) was loaded onto the wells of the stacking gel. Pre-stained molecular 
weight markers (All blue standards, Biored, Hercules, CA) were run alongside the samples 
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to allow size determination of proteins. The gels were then run at 120V (laboratory made 
gels) or 140V (Pre-cast gels) for approximately 1.5hr in Tris glycine running buffer (25mM 
Trizma-base, 192Mm glycine, 0.1% (w/v) SDS) or NuPAGE MOPS-SDS running buffer 
(Invitrogen, UK) respectively in the XCell SureLock Mini gel electrophoresis apparatus 
(Novex, CA). After separating the proteins the gels were either further western blotted, silver 
or coomassie blue stained.  
 
2.5.4 Western blotting: The proteins on the gel were transferred onto Polyvinyldifluoride 
(PVDF) membranes (Millipore, Bedford, MA). The PVDF membranes were first pre-hydrated 
in 100% methanol for 1min and then washed in transfer buffer (25mM Trizma base, 190mM 
glycine and 20% (v/v) methanol). Proteins were transferred in a sandwich between wet filter 
paper and sponges in a trans-blot chamber (Biored, Hercules, CA) containing transfer buffer 
at 100V for 80min. The transfer buffer was kept at 4º C by a water circulating cooling pump. 
After the transfer, the membranes were blocked in 5% (w/v) Marvel made up with 1 x TBS-
tween buffer (1x Tris buffered saline and 0.1% tween-20) for 1hr at room temperature. The 
membranes were then incubated with primary antibody made up in 5% BSA/TBS-tween 
solution overnight at 4ºC. Membranes were then washed three times with TBS-tween (3 x10 
min) before being incubated with 5% Marvel/TBS-tween containing secondary horseradish 
peroxidase conjugated antibody (1:2000). Finally the membranes were washed again for 
three times with TBS-tween, and the signal was developed by enhanced chemiluminescence 
(ECL) (Amersham, Little Chalfont, UK). The luminescence of protein bands was then 
exposed onto a blue sensitive film (Fuji film Super RX, Fuji Film, Bedford, UK) in a safe light 
room. 
 
2.5.5 Stripping and re-blotting: In some instances, membranes were required for re-
blotting with a different antibody. Antibodies were first stripped from membrane by incubating 
in Stripping buffer (Millipore, Billerica, USA) at room temperature for 20min. Extensive 
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washes in TBS-tween were required before blocking and then re-blotting with another 
primary antibody. 
 
2.5.6 Silver staining: Silver staining was performed in order to determine the purity of the 
purified His-tagged recombinant CTGF protein. After proteins were separated by gel 
electrophoresis, the gel was first fixed in 50% (v/v) methanol/ 5% (v/v) acetic acid for 20min. 
Following fixation, the gel was washed in 50% (v/v) methanol for 20min and then in distilled 
water for 2hr. The gel was incubated in sensitiser solution (0.02% (w/v) sodium thiosulphate) 
for 1min followed by 2 x 1min washing with distilled water and then incubated at 4ºC for 
20min with silver reagent (0.1% (w/v) pre-cooled silver nitrate solution). The gel was washed 
2 x 1min with distilled water and then incubated with the developing solution (2% (w/v) 
sodium carbonate and 0.04% (v/v) 35% formaldehyde). The developing reaction was 
stopped with 5% (v/v) acetic acid when protein bands were clearly visible. Finally, the gel 
was washed and stored in distilled water at 4ºC.  
 
2.5.7 Coomassie Brilliant Blue G-250 staining: SDS-PAGE gels were placed in the 
staining solution containing 0.1% (w/v) CBB, 50% (v/v) methanol and 20% (v/v) acetic acid 
for 45min and destained with 30% (v/v) methanol and 1% (v/v) formic acid. The destaining 
solution was changed every 10min for 1hr and the gels were further destained overnight at 
room temperature. The gels were either dried or the protein bands of interest were cut from 
the gel in distilled water in an eppendorf tube and sent for mass spectrometry analysis.  
 
2.5.8 Protein extraction from unstained SDS-PAGE gel: For protein extraction, samples 
were loaded on the SDS-PAGE gel in duplicates. After gel electrophoresis, the gel was cut 
into two. One half was quickly stained with coomassie blue to determine the position of the 
desired protein. On the other half unstained gel, gel pieces were cut out by referring to the 
position on the coomassie stained gel. In eppendorf tubes gel pieces were minced and 
incubated with an elution buffer containing 50Mm Tris-HCl, 150mM NaCl, 0.1mM EDTA, 1% 
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SDS and 10mM DTT pH7.5 at 30ºC overnight with constant agitation. The gel pieces were 
then centrifuged to the bottom of the tubes and the supernatant was collected and mixed 
with sample buffer before gel electrophoresis. 
2.5.9 Protein extraction of chondrons for mass spectrometry 
The protein extraction method from chondrons was established by previous PhD student 
Celia McLean. Human chondrons were processed and the proteins were electrophoresed by 
Dr. Thanos Didangelos. 
Chondron pellets were obtained as described in 2.2.4. The pellets were extracted for 15min 
at room temperature in 1ml RIPA lysis buffer containing protease inhibitors. Following 
centrifugation at 16200x g at room temperature for 5min, the supernatant was retained and 
the pellets were further extracted using 4M guanidine hydrochloride (GnHCl) with constant 
agitation at 4°C for 1h and the supernatant was analysed by gel electrophoresis. The gel 
containing the extracted proteins were coomassie blue stained and the bands were cut in 
clean eppendorf tubes for mass spectrometry (Cambridge Centre for Proteomics, Cambridge, 
UK).  
2.6 Purification of CTGF from HEK293 conditioned medium 
The method of CTGF purification from the cultured medium of stably transfected HEK293 
cells was also established by Celia McLean. The protocol is as follows: 
 
2.6.1 Stable transfection of HEK293-EBNA cells:  Stably transfected human embryonic 
kidney 293 (HEK293) cells expressing His-tagged human CTGF protein were already 
available in our group (Celia McLean PhD thesis, 2009). HEK293-EBNA cells were originally 
obtained from Invitrogen (Groningen, Netherlands). These cells have Epstein-Barr virus 
nuclear antigen 1 (EBNA-1) gene inserted into the chromosome. As a result, these cells 
have the ability to induce high-level expression of an inserted plasmid containing an Epstein-
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Barr virus origin (oriP) and maintain the plasmid as an extrachromosomal episome within 
transfected cells. These cells contain a neomycin resistance gene and therefore cells were 
maintained in the presence of the G418 (PAA laboratories Ltd, UK) to enable selection of 
EBNA-1 positive cells. The ctgf construct was subcloned from a pcDNA3.1-ctgf vector 
(provided by Prof. Roger Mason) into a pCEP4 expression vector. pCEP4 is an episomal 
mammalian expression vector carries an oriP and a hygromycin resistance gene to permit 
extrachromosomal replication and be selected by an antibiotic hygromycin B (Invitrogen, 
Paisley, UK). Stably transfected HEK293 cells were stored in liquid nitrogen until use. 
Frozen cells were quickly thawed in a 37ºC water bath, mixed with 20ml of warm DMEM in a 
falcon and centrifuged at 235x g at room temperature for 5min. The pellet was then 
resuspended and cultured in 15cm dishes with 10% FCS DMEM containing 250µg/ml of the 
antibiotic G418 and 100µg/ml hygromycin B. After reaching confluence, cells were washed 
and cultured in fresh serum free medium containing 250µg/ml G418 for 24hr. The 
conditioned medium (containing secreted CTGF) was removed and stored at -20ºC until 
purification.  
 
2.6.2 Nickel affinity chromatography (ÄKTA system, GE Healthcare, Little Chalfond, 
UK): 150ml of the conditioned medium from the HEK293 cell culture (described above) was 
supplemented with 20mM imidazole before being filtered and loaded onto a 5ml nickel 
affinity column (GE Healthcare Ltd, Buckinghamshire, UK) which has been equilibrated in 
the binding buffer containing 20mM sodium pyrophosphate, 0.5M sodium chloride and 
20mM imidazole, pH7.4. The flow-through was collected and the column was washed with 
binding buffer until the absorbance returned to the background level. The proteins were then 
eluted in 1ml fractions by a 10ml linear gradient ranging from 20mM to 500mM imidazole. 
Fractions were western blotted for the presence of CTGF and silver stained to assess purity. 
 
2.6.3 Dialysis and ultrafiltration: Positive fractions identified by western blot were pooled 
together and dialysed using a 10kDa molecular weight cut off SpectraPor Float-A-Lyzers 
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(Fisher scientific, Hampton, NH) in 1 x PBS for 8-12hr at 4ºC prior to be used in cell culture. 
Dialysed protein solution was then centrifuged in a 10kDa cut off ultrafiltration spin column 
(Vivaspin, Sartorius, Goettingen, Germany) to concentrate the protein by 10 times. The 
retained fractions were resolved by electrophoresis and then coomassie blue stained. The 
concentration of CTGF was determined by NanoDrop Spectrophotometer (Thermo Scientific, 
Wilmington, USA) and confirmed by comparing to a range of known concentrations of BSA 
on a coomassie blue stained gel. The fraction was then aliquoted and stored at -20ºC until 
use. The yield of the recombinant CTGF production was 12µg from 150ml of HEK293 
conditioned medium. 
2.7 Partial protein purification of TGFβ/CTGF complex from cartilage injury 
conditioned medium (CM) 
2.7.1 Ion exchange chromatography (ÄKTA system): 1ml of cartilage explantation CM 
was mixed with 4ml binding buffer containing 20mM Tris-HCl pH 7.4 and passed through a 
1ml HiTrap SP HP column (GE Healthcare, Little Chalfond, UK). The flow-through was 
collected and the column was washed with binding buffer until the absorbance returned to 
the background level. The proteins were then eluted in 1ml fractions by a 10ml linear 
gradient ranging from 0 to 1M NaCl. Fractions were electrophoresed and western blotted for 
CTGF, TGFβ and LAP1. 
2.7.2 Gel filtration chromatography (SMART system, Artisan Technology Group, 
Champaign, USA): Either the positive ion exchange fractions or crude cartilage recutting 
CM was processed in gel filtration chromatography. Sample proteins were concentrated to 
0.5mg/ml so that 50µl of sample contains 25µg protein. First, 15µl of mixed standard 
proteins were injected into a Superose 12 PC3.2/30 column (GE Healthcare, Little Chalfond, 
UK) and the column was continuously loaded with 1 x PBS until the UV absorbance reached 
the basal level (at least 2 column volume has passed through (4.8ml)). Then 50µl of the 
sample proteins was injected into the system and the flow-through was collected in 200µl 
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fractions until the absorbance reached basal level (approximately 24 fractions). By 
comparing to the standard protein profile, the fractions within the range of correct sizes were 
analysed by gel electrophoresis and western blotted for CTGF, TGFβ and LAP. 
 
2.8 Molecular biology 
2.8.1 RNA extraction from cells: After stimulations of NHDFs or HACs, medium was 
removed and the cell layer was washed twice with 1 x PBS. The cell layer was lysed and 
RNA was extracted using Qiagen RNeasy kit (Qiagen, Clawley, UK) according to 
manufacturer’s instruction. RNA was eluted in 40µl of RNase free water and its 
concentration and purity was determined by measuring the absorbance at 260nm, 280nm 
and 230nm using a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, USA).  
 
2.8.2 Reverse transcription: Complementary DNA (cDNA) was generated from the purified 
RNA using the ABI high capacity cDNA Reverse Transcription Kits (Applied Biosystems Inc.). 
According to manufacturer’s instructions, 200ng of RNA was reversely transcribed into cDNA 
in a total volume of 20µl mixture containing 10µl of RNA, 2µl of 10 x reverse transcription 
buffer, 2µl of random primer, 0.8µl dNTP, 1µl RNase inhibitor, 1µl reverse transcriptase and 
3.2µl RNase free water, using a following programme: 25ºC for 10min, then 37ºC for 120min 
and finally 85ºC for 5min. 
 
2.8.3 Quantitative reverse transcription polymerase chain reaction (RT PCR): cDNA 
was processed using TaqMan® RT PCR system (Applied Biosystems Inc.). 5µl of 5 times 
diluted cDNA was mixed with 7µl of RT-PCR master mix containing 6µl TaqMan® 2 x 
universal PCR mix (Applied Biosystems Inc.), 0.6µl TaqMan® primer/probe (Applied 
Biosystems Inc.) and 0.4µl RNase free water. All samples were in triplicates. The 
thermocycling condition were as follows: hold at 50ºC for 2min for optimal activity of 
UNGerase enzyme, then 40 cycles of denaturation at 95ºC for 2min, followed by an 
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annealing step at 60ºC for 30s. The thermocycling reaction was carried out in a Rotor-Gene 
6000 real time rotary analyser (Corbett Life Science, Corbett Research UK Ltd) and all data 
analysis was carried out using Rotor Gene 6000 software version 1.7 (Corbett Life Science, 
Corbett Research UK Ltd). The expression levels of the genes of interest were normalised to 
the gene expression of a house keeping gene, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Table 3 summarises the TaqMan® primers used for RT PCR. 
 
Table 3 TaqMan® Gene Expression Assay primer/probe mixes (Applied Biosystems) used in TaqMan®  
RT-PCR.  
 
2.8.4 Microarray study: Purified RNA from experiments was sent to Cambridge genomic 
centre for microarray study. Quality of the RNA was first determined using Agilent 2100 Bio-
analyser (Agilent Technologies, Inc. CA) following the manufacturer’s instruction to ensure 
RNA integrity (RIN), purity (260/280 for protein contamination, 260/230 for carbohydrates or 
phenol contamination) and concentration. RNA quality should satisfy the criteria of 
microarray analysis: RIN >8, 260/280 = ~2.0 and 260/230 >2. The microarray study was 
Gene 
ABI catalogue 
number 
Amplicon size (bp) Genbank number 
GAPDH Hs99999905_ml 122 NM_002046.3 
CTGF/CCN2 Hs01026927_gl 70 NM_001901.2 
PMEPA1 Hs00375306_m1 77 NM_199170.1 
BMPR2 Hs00176148_m1 69 NM_001204.6 
LTBP2 Hs00166367_m1 78 NM_000428.2 
Perlecan Hs00194179_m1 70 NM_005529.5 
Col1A1 Hs00164004_m1 66 NM_000088.3 
FN1 Hs00365052_m1 81 NM_002026.2 
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carried out using Illumina platform on 2 HumanHT-12 v4 chips which covers more than 
47,000 human genes. Briefly, prepared RNA was transcribed into cDNA which incorporates 
biotin-labelled nucleotides. Following the steps of array hybridization, washing, blocking and 
streptavidin-Cy3 staining, the chips were then scanned by BeadArray reader (Illumina Inc.) 
and the scanned images were quantified to determine the signal intensity of each spot. The 
acquired microarray raw data were first filtered and normalized to remove noise. An 
unsupervised clustering analysis was carried out by using the GenomeStudio Data Analysis 
software (Illumina, San Diego, CA). 
 
2.8.5 CTGF silencing RNA transfection: 3 x 105 NHDFs or HACs were plated in a 6 well 
plate as described above and transfected with CTGF siRNA oligos (Applied Biosystem Inc.) 
in Opti-Mem reduced serum medium (Gibco, Life Technology, NK, USA) at a final volume of 
2.5ml. siRNA oligo was first mixed with Lipofectamin 2000 transfection reagent (Invitrogen, 
NY,USA) at 1:20 ratio (v/v) in 0.5ml of Opti-Mem medium for 20min, which was then added 
to the each well of the culture plate containing 2ml of Opti-Mem drop by drop with gentle 
shaking. siRNA oligo will reach a final concentration of 15nM. After 4hr transfection at 37°C, 
cell culture was changed with fresh serum containing DMEM and cultured for further 24hr 
before stimulation.  
 
2.8.6 Genomic DNA extraction from mice ear biopsy for genotyping: 2mm wide tissue 
was biopsied from a mouse ear at age around 4 weeks and kept frozen. Upon extraction, the 
ear tissue was digested in 100µl of a lysis buffer containing 50mM Tris-HCl, pH8.0, 0.1M 
NaCl, 1% SDS, 20mM EDTA and 8u/ml proteinase K (Promega, Southampton, UK) at 55ºC 
for 18hr. The digests were mixed with 100µl of 3.75M NH4OAc (Sigma, Dorset, UK) and 
100µl of chloroform (VWR International, Leicestershire, UK) and then centrifuged at 15600x 
g at room temperature for 5min to turn the digest into three layers. Liquid from the top layer 
was carefully pipetted into a clean eppendorf tube containing 500µl of 100% ethanol, which 
was inverted to mix well. Precipitated DNA was then centrifuged at 15600x g for 10min. After 
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discarding the supernatantthe pellet was dried using a vacuum dryer and resuspended in 
50µl TE buffer containing 10mM Tris-HCl and 1mM EDTA pH8.0. 
 
2.8.7 The polymerase chain reaction (PCR) for genotyping: PCR master ready beads 
(GE healthcare, Buckinghamshire, UK) were used for PCR reaction. Each ready mix bead 
was dissolved in 25µl of distilled water and then split into two 0.5ml tubes. Each reaction 
(12.5µl) was mixed with 1µl of each primer (10µM) (both sense and anti-sense) (Eurofins 
MWG Operon, Ebensburg, Germany) and 1µl of DNA in TE buffer (50mg/ml). The reaction 
tubes were then incubated in a thermocycler to allow PCR reaction to take place. Table 4 
below shows the primers sequence and the PCR program used for genotyping. 
 
   Table 4 Primer sequences and PCR programmes for CTGF and Ub Cre genotyping. 
 
Primers Sequences 
CTGF sense 5’-AAT ACC AAT GCA CTT GCC TGG ATG G-3’ 
CTGF antisense 5’-GAA ACA GCA ATT ACT ACA ACG GGA GGG G-3’ 
Ub Cre sense 5’-GCA TTA CCG GTC GAT GCA ACG AGT GAT GAG-3’ 
Ub Cre antisense 5’-GAG TGA ACG AAC CTG GTC GAA ATC AGT GCG-3’ 
PCR programmes 
CTGF  Ub Cre 
Step 1:     94ºC     3min 
Step 2:     94 ºC    30sec 
Step 3:     65 ºC    30sec  
Step 4:     72 ºC    1min   
Go to Step 2 for 34 more cycles 
Step 5:     72 ºC    10min 
Step 6:     4ºC        ∞ 
Step 1:     93ºC     3min 
Step 2:     93ºC    30sec 
Step 3:     68 ºC    30sec 
Go to step 2 for 29 more cycles 
Step 4:     4ºC        ∞ 
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2.8.8 DNA electrophoresis:  The PCR products are analysed on 1.5% DNA Agarose gel 
(Invitrogen, Parsley, UK) in 0.5 x TBE buffer containing 45mM Tris-borate and 1mM EDTA at 
100V for 1.5hr. PCR samples were mixed with 6x blue/orange dye (Thermo Scientific, 
Wilmington, USA) before loaded onto the gel. After the run, bands on the gel were visualised 
in a Gel Doc machine (Bio-Rad, Hemel Hempstead, UK).!The sizes of the DNA fragments 
were determined by comparing to the size of the DNA ladder (100bp) (Invitrogen, Parsley, 
UK). The ctgf primers can produce two DNA fragments during PCR reaction. A larger DNA 
fragment (1000bp) is produced when ctgf exon is franked by two Lox P sites i.e. floxed ctgf, 
whereas a smaller fragment (800bp) is produced from a wild type ctgf allele. Therefore, the 
genotype can be determined by the size of the resulted PCR bands, i.e. wild type (a single 
band at 800bp), homozygous floxed ctgf (a single band at 1000bp) or heterozygous floxed 
ctgf (two bands at 1000bp and 800bp). The presence of the Cre allele was determined by 
the observation of a 400bp band.   
 
2.8.9 Statistical analysis: All statistical analysis was performed using Prism 4 programme 
(Graphpad Software Inc., USA). Significance was calculated using t- test. Not significant (ns) 
when p value > 0.05, significant (*) when p value ≤ 0.05, very significant (**) when p ≤ 0.01 
and highly significant (***) when p ≤ 0.001. 
!!!!
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3.1 Introduction 
My project started as an extension of the work performed by Celia McLean, a previous PhD 
student. In her studies she determined that CTGF was an abundant PCM protein of porcine 
cartilage and characterised a successful method for the expression and purification of the 
recombinant protein. These results, taken together with the known in vivo role of CTGF in 
the musculoskeletal development (Ivkovic et al. 2003) as well as the increased expression of 
CTGF in OA cartilage (Hermansson et al. 2004), have justified the further study of this 
interesting protein. 
In this chapter I determine that CTGF is also present in the PCM of human cartilage and 
investigate to what is it bound in the PCM.   
 
3.2 Results 
3.2.1 Proteomic analysis of the PCM of human articular cartilage 
3.2.1.1 Isolation of human cartilage chondrons 
In early studies of the molecular composition of the PCM, Celia McLean developed a method 
of isolating chondrons from porcine cartilage and successfully extracting PCM proteins for 
mass spectrometry. Her optimised method involved limited enzymatic digestion of cartilage 
with a combination of dispase and collagenase for 4hr. I repeated a similar analysis only this 
time in human tissue. Human chondrons were isolated from normal human articular cartilage 
using Celia’s methods described in 2.2.4. Chondron preparations were fixed onto chamber 
slides using methanol and then immunostained with antibodies against the known PCM 
protein perlecan to confirm the integrity of the PCM. Figure 3.1 shows the 
immunofluorescent staining of isolated human chondrons. Staining (purple) reveals a 
perlecan-rich coat around individual chondrocytes (red nuclei staining) confirming the 
presence of an intact PCM. 
Chapter 3                            Identification and binding of CTGF in the PCM of human articular cartilage 
! 59 
 
 
 
 
 
Figure 3.1 Immunofluorescent staining of perlecan in enzymatically isolated chondrons. Chondrons were 
isolated from human articular cartilage with a combination of dispase (0.2%) and collagenase (0.3%) for 4hr at 
37ºC. Following isolation, chondrons were suspended in PBS and a small volume was allowed to adhere to Lab 
Tek II chamber slides. The chondrons were fixed in methanol, treated for 1.5hr with chondroitinase (10mu/ml) 
and then incubated with primary antibodies to perlecan (1:1000) (A) (purple) or rat non-immune control antibody 
(NI) (B). The chondrons were washed and incubated with secondary FITC labelled antibodies and propidium 
iodide (PI) (red). Fluorescence signals were detected using Ultraview confocal microscopy. 
 
3.2.1.2 Purification of the PCM from isolated chondrons. 
Chondrons contain both the chondrocyte and their surrounding PCM. In order to investigate 
the PCM by mass spectrometry, removal of chondrocytes from the chondron preparation 
was necessary to reduce contamination by intracellular proteins. Chondrons were incubated 
with a dissociative lysis buffer for 15min in an attempt to lyse intracellular proteins and wash 
them from the remaining PCM. The remaining pellet, enriched for PCM proteins, was then 
solubilised by guanidine hydrochloride (8M) to allow analysis by SDS-PAGE and mass 
spectrometry.  
3.2.1.3 Identification of PCM proteins using mass spectrometry 
Solubilised chondron proteins were separated on a 4-12% Bis-Tris gradient gel and stained 
with Coomassie Blue in a clean glass tray. Small gel pieces containing protein bands were 
cut into eppendorf tubes. Mass spectrometry analysis was performed by Cambridge Centre 
for Proteomics at the University of Cambridge. Table 5 shows all growth factors and ECM 
Perlecan & PI                          Rat NI & PI   A                                            B 
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proteins identified in the proteomic analysis of the human chondrons. Most of these proteins 
have already been described previously in human PCM (Wilusz et al. 2014; Hedman et al. 
1979; Vincent et al. 2007; Omoto et al. 2004; Guo et al. 2010). Some of these molecules 
were also identified in Celia McLean’s proteomic analysis using porcine cartilage, which are 
indicated in the table. There were also a large number of presumed non-specific proteins 
identified, which are not shown here in the table. These include intracellular proteins (e.g. 
histones and glutamine synthetase) from incomplete cell lysis or wash of the PCM pellet; 
secreted or transmembrane proteins that are commonly found in other tissues (e.g. 
claudin17, clusterin and lactadherin); foreign proteins (e.g. keratin and trypsin) from 
contamination of sample handling and uncharacterised proteins.  
Selective PCM proteins identified 
from human articular cartilage 
 
Previously 
identified in 
porcine PCM 
(by Celia 
McLean) 
 
Previously described 
human PCM (Wilusz et al. 
2014; Hedman et al. 1979; 
Vincent et al. 2007; Omoto 
et al. 2004; Guo et al. 2010) 
 Fibronectin Yes Yes  
Fibroblast growth factor-2 (FGF2) No Yes 
Hyaluronan binding protein Yes Yes 
Chondroadherin Yes Yes 
Cartilage oligomeric matrix protein 
(COMP) 
Yes Yes 
Thrombospondin-1 No Yes 
Hyaluronan & proteoglycan link 
protein -1 
Yes Yes 
Decorin Yes Yes 
Biglycan Yes Yes 
Collagen II Yes ECM 
Collagen VI Yes Yes 
Collagen IX No Yes 
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Table 5 All growth factors and ECM proteins identified in the human chondrons by mass spectrometry. 
Solubilised human chondron proteins were analysed on gradient gel and cut in small pieces. The mass 
spectrometry study was performed by Cambridge Centre for Proteomics at University of Cambridge. 
 
3.2.2 Localisation of CTGF in human articular cartilage 
Having identified CTGF from the proteomic analysis of the PCM of human articular cartilage, 
we sought to confirm that CTGF localised to the PCM using immunofluorescent staining. 
Celia McLean developed a protocol for confocal microscopy of articular cartilage. Frozen 
tissue was processed as described in 2.3 and then immunostained for perlecan, type VI 
collagen, FGF2 or CTGF. Figure 3.2 shows the localisation of CTGF in adult human normal 
articular cartilage.  Perlecan and type VI collagen were used as markers of the PCM as they 
are well-described pericellular proteins. The immunofluorescent staining of these molecules 
revealed a distinct pericellular pattern around each chondrocyte. The staining of CTGF co-
localised with other PCM proteins such as perlecan and type VI collagen (Figure 3.2A and B). 
FGF2, which is known to bind to perlecan in the PCM, also demonstrated significant co-
localisation with CTGF suggesting that they lie close to one another in the PCM (Figure 3.2C) 
Collagen XI Yes ECM 
Collagen XII No ECM 
A disintegrin and metallopeptidase 
domain&7 (ADAM7) No ECM 
ADAM metallopeptidase with 
thrombospondin type 1 motif -12 
(ADAMTS12) 
No Yes 
Heparin sulfate proteoglycan -2 
(HSPG2/perlecan) protein core 
Yes Yes 
Aggrecan protein core No ECM 
Hepatocyte growth factor (HGF) No Yes 
Connective tissue growth factor 
(CTGF) 
Yes Yes 
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Figure 3.2 Immunolocalisation of CTGF and other known PCM proteins in human articular cartilage. 
Frozen sections (7µm) of human articular cartilage were pre-treated with chondroitinase ABC (10mU/ml for 
120min). Sections were stained with primary antibodies to CTGF (1:500) (green), perlecan (1:1000) (red) (A), 
collagen VI (1:1000) (red) (B) and FGF2 (1:1000) (red) (C). Sections were washed and incubated with secondary 
FITC-labeled antibodies (1:1000) and propidium iodide (PI) (1:2000) (blue). Fluorescence signals were detected 
by UltraView confocal microscopy (n=3). 
 
3.2.3 CTGF binds to perlecan in vitro via heparan sulphate chains 
Immunohistochemistry confirmed that CTGF localised to the PCM of human chondrocytes, 
but did not indicate to what it was bound. CTGF has been described as binding to heparan 
sulphate (HS) in human chondrosarcoma-derived chondrocytic cell line HCS-2/8 in vitro 
A CTGF                      Perlecan                         PI                          Merged 
C CTGF                         FGF2                            PI                         Merged 
B CTGF                        COL VI                          PI                          Merged 
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(Nishida et al. 2003), so I sought to determine whether this was the case in cartilage. To test 
this, I carried out an in vitro binding assay. Perlecan has different sulphation patterns 
according to the tissue from which it has been extracted. Commercial perlecan is from a 
variety of tissue sources that are known to have different sulphation patterns when 
compared with articular cartilage. These sulphation patterns determine the ability to bind to 
ligands. The perlecan used in my experiment was previously purified from adult (porcine) 
articular cartilage by Celia McLean. She used a method described by Hassell et al, involving 
extraction with guanidine hydrochloride (6M) followed by a series of caesium chloride 
gradient steps (Hassell et al. 1980). Perlecan is further purified by ion exchange 
chromatography and detected by dot blot (Celia Mclean’s thesis, 2009). I then set up an 
ELISA-style assay in which perlecan (0.5 µg/ml) was plated onto the ELISA plate and 
following washing and blocking, incubated with different concentrations of recombinant 
CTGF (from 0 to 10 µg/ml). Bound CTGF was detected using an anti-CTGF antibody to 
which an enzyme-linked secondary antibody was attached. Figure 3.3A shows the detection 
sensitivity of this assay. CTGF binds to perlecan in a linear fashion with a larger slope from 0 
to 1µg/ml, which then decreased from 1µg/ml to 10µg/ml. As mentioned previously, perlecan 
is substituted by both heparan sulphate (HS) and chondroitin sulphate (CS) chains. I 
determined whether CTGF bound to perlecan through either of these chains. The plates was 
coated with perlecan (0.5µg/ml) or 1% BSA as control. Heparitinase (H’ase) or 
chondroitinase ABC (C’ase) was used to remove the HS or CS chains respectively from the 
core protein of perlecan before CTGF (0.5µg/ml) was added to the assay plate and the 
amount of bound CTGF was measured. We found that in the presence of H’ase, the amount 
of bound CTGF was greatly reduced compared with the non-H’ase treated control, whereas 
C’ase did not change the binding of CTGF to perlecan (Figure 3.3B (CTGF)). Detection of 
perlecan (using an antibody against perlecan protein core) in the presence or absence of 
H’ase was carried out to ensure that the enzyme treatment did not reduce the amount of 
coated perlecan on the ELISA plates (Figure 3.3B (perlecan)).   
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Figure 3.3 Dose dependent binding of CTGF to perlecan, which was abolished by heparitinase. An ELISA 
plate was coated with 0.5µg/ml of recombinant perlecan at 4°C for 18hr. After washing with PBS and blocking 
with 1% BSA in PBS, the plate was incubated with increasing concentrations of recombinant CTGF (0 to 10µg/ml) 
for 3hr in 1 x PBS at room temperature. After three washes in PBS-tween, the plate was incubated with primary 
and secondary antibodies to detect bound CTGF (A). For enzyme treatments, H’ase or C’ase (10mu/ml) was 
added to perlecan coated plates for 2hr at 37°C prior to addition of CTGF (0.5µg/ml). Perlecan or CTGF was 
detected using specific antibodies to the protein core followed by enzyme linked secondary antibodies (B). (A: 
n=3; B: n=3). **p<0.01 ns=not significant. !
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3.2.4 CTGF release following cartilage injury 
FGF2 is also bound to the HS of perlecan, and it is from this bound pool that FGF2 released 
from the PCM in response to cartilage injury (Vincent et al. 2007). To test whether this is 
also the case for CTGF, I explored whether CTGF was also released upon cartilage injury. 
Porcine articular cartilage explants were dissected from pig trotter joints using a biopsy 
punch to ensure equal size. The dissected cartilage explants were immediately rested in 
serum free medium for 48hr to allow injury-induced responses to return back to basal level. 
The rested cartilage were then further cultured in fresh medium for another hour (this 
conditioned medium was used as control) before being recut in fresh medium. The 
conditioned medium (CM) was collected before (control CM) and after recutting at various 
time points (recut CM). Figure 3.4A shows the recut CM collected cumulatively (collect 
everything during the period) after 5min, 4hr and 24hr following recutting, alongside the 
control CM (1hr collection before recutting). The western blot showed strong CTGF detection 
in the recut CM of all the time points in contrast to the resting control. FGF2 release occurs 
very rapidly (within a few minutes of cutting) so I next determined whether this was also the 
case for CTGF release. Sequential recut CM (collect several times in sequence following 
recutting) was collected to determine the dynamic of CTGF release. Figure 3.4B shows the 
western blot of recut CM collected between 0 and 5min, then 5 and 30min following recutting. 
Strong CTGF was detected in the recut CM within the first 5min following recutting. The level 
of CTGF accumulating in medium beyond 5min was much lower.  
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Figure 3.4 The western blots of recutting CM show accumulation of CTGF. Porcine cartilage explants were 
rested in serum free medium for 48hr, further cultured in fresh medium for another hour (Ctrl) and recut. The 
recutting CM (Recut) was collected cumulatively (A) or sequentially (B) after various time points following 
recutting and western blotted for CTGF.  
 
Such rapid accumulation of CTGF in the recut CM (within 5min) following cartilage injury 
implies that CTGF is released from pre-made pool rather than from protein synthesis. To 
confirm this, I then carried out the recutting experiment in the presence of protein synthesis 
inhibitor cycloheximide (CHX). Porcine articular cartilage explants were again rested for 48hr 
and then further cultured for one extra hour, only this time some were in the presence of 
CHX (10µg/ml). Following recutting, medium was conditioned and collected for various times 
in the presence or absence of CHX (10µg/ml). Figure 3.5 shows the western blot of a 
sequential collection of recut CMs, which captures the protein generated from 0 to 1hr, 1 to 
2hr, 3 to 4hr and 7 to 8hr following recutting. The results show that large amounts of CTGF 
protein accumulated in the CM within the first hour upon recutting irrespective of whether 
CHX was present. In the absence of CHX, the levels of CTGF detected in the following time 
points were significantly reduced, while in the presence of CHX there was no CTGF detected 
in the subsequent time points (Figure 3.5), suggesting that the protein produced in these 
later time points were newly synthesised.  
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Figure 3.5 Porcine cartilage recutting caused release of CTGF from matrix either with or without CHX 
(10µg/ml). Rested porcine cartilage explants were recut and the conditioned medium was collected sequentially 
from 0 to1hr, 1 to 2hr, 3 to 4hr and 7 to 8hr. Fresh medium was replaced after each time point. The CM was 
analysed for CTGF by western blot. One representative result from 3 experiments (n=3). 
 
Medium conditioned following cartilage explantation (without 48hr resting) was also analysed. 
This is a medium that captured proteins released from the injured cartilage that directly 
dissected from a joint. Dissected porcine cartilage explants were immediately cultured in 
serum free medium and these explantation conditioned media (explantation CM) were 
collected at various time points and analysed for CTGF release. Figure 3.6 shows the 
western blot of explantation CM collected sequentially from 0 to 1hr, 1 to 2hr, 3 to 4hr and 7 
to 8hr following explantation in the presence or absence of CHX (10µg/ml). Again CTGF 
accumulation was strongly detected within the first hour of explantation with or without CHX. 
The amount started to decrease beyond the second hour in both cases. By the eighth hour 
following explantation the amount in the CHX treated group was significantly reduced. Taken 
together these results suggest that there is a rapid burst of CTGF protein release upon 
cartilage injury and this protein is passively released from a pre-made, most likely, the 
pericellular matrix pool. The protein accumulating at later time points is likely to be newly 
synthesised as this can be abrogated in the presence of CHX. 
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Figure 3.6 Porcine cartilage explantation caused release of CTGF from matrix either with or without CHX. 
Porcine cartilage explants were dissected from pig trotter joint and cultured in serum free medium for sequential 
time points 0-1hr, 1-2hr, 3-4hr and 7-8hr. Fresh medium was replaced after each time point. The CM was 
analysed for CTGF by western blot. One representative result from 3 experiments (n=3). 
 
Secreted CTGF is rapidly internalised by cells through the low-density lipoprotein receptor-
related protein 1 (LRP1) in a heparan sulphate dependent manner (Gao and Brigstock 2003). 
Therefore it was possible that the CTGF accumulation we observed upon injury was due to 
failure of LRP1 mediated re-uptake. To test this, we blocked LRP1 using its antagonist, 
receptor associated protein (RAP), or by adding an excess of soluble heparin. The same 
recutting experiment was carried out but this time the cartilage was pre-cultured and recut in 
the presence of these LRP1 blockers. The CM was collected after 15min at the beginning of 
each one hour period following recutting. As expected, RAP and heparin increased the 
resting levels of CTGF prior to recutting. They also increased the amounts released after 
recutting. They did not appear to alter appreciably the amount of CTGF released 
immediateltly upon injury. This may be because that LRP1 had been maximally saturated by 
CTGF or the action of recutting somehow disables the action of LRP1.  
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Figure 3.7 RAP and heparin increased CTGF protein accumulation in the CM. Explanted porcine cartilage 
were rested for 48hr, pre-incubated in the presence or absence of RAP (500nM) or heparin (100µg/ml) for 1hr 
and then recut. Recut CM was collected after 15min at the beginning of each hour (-1-0hr, 0-1hr, 1-2hr and 3-4hr) 
in the presence or absence of RAP (500uM) or Heparin (100µg/ml). Fresh medium was replaced after the 15min 
collection and at beginning of each hour. The CM was analysed for CTGF by western blot (n=1). 
 
3.3 Discussion 
From the proteomic analysis of human cartilage chondrons we identified a number of 
proteins that have been previously identified in the PCM of cartilage, including FGF2 and 
CTGF. Most of the identified proteins are pericellular matrix proteins, for example, perlecan, 
decorin, biglycan and type VI collagen. From previous confocal and electron microscopic 
studies it appeared that the PCM was rich in type VI collagen but not in type II collagen 
(Söder et al. 2002). The identification of type II collagen as well as aggrecan and type XI 
collagen may indicate incomplete removal of the further removed matrix upon enzymatic 
digestion or protein that is transiting through the PCM. The assemblies of type VI collagen 
and other small proteoglycan such as decorin and biglycan, which are specific to the PCM, 
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have been reported to participate in the assembly of aggrecan prior to their release into the 
ECM (Sandy et al. 1989; Larson et al. 2002). Some intracellular proteins, such as pyruvate 
kinase, were also identified in the study, which may represent contamination of intracellular 
proteins due incomplete cell lysis or washing. Most of the identified PCM proteins had also 
been identified previously in porcine chondrocytes by Celia McLean. By repeating the PCM 
proteomic analysis, alongside confocal studies, I have been able to confirm the pericellular 
localisation of CTGF in human articular cartilage. This is consistent with other studies in 
mice (Oka et al. 2007; Itoh et al. 2013). I also identified other interesting proteins which were 
not identified in porcine cartilage before, for examples, ADAMST12 and HGF. Their roles in 
human cartilage could be interesting to investigate.  
Confocal microscopy showed co-localisation of CTGF with other known PCM molecules, 
perlecan, type VI collagen and FGF2. Binding assays were carried out to establish whether 
CTGF binds to perlecan. Administration of heparitinase significantly reduced the amount of 
bound CTGF but not chondroitinase, suggesting that CTGF binds to the heparan sulfate 
chains of perlecan as predicted. This finding is consistent with the observation described in 
HCS2/8 cell system (Nishida et al. 2003). 
Molecules that are sequestered in the PCM can be made available to the cells very rapidly 
given the correct physiological stimuli (mechanical load in the case of FGF2). Sequestration 
may also act as a negative control of growth factor activity by holding ligands back from the 
cell surface until they are required. This was proved by the cartilage injury experiment, in 
which CTGF became rapidly available in the cultured medium upon cartilage recutting. This 
is consistent with the observation of FGF2 release, which in turn activates ERK MAPK and 
drive several cellular responses including induction of chondroprotective proteins such as 
activin A and TIMP1 (Vincent et al. 2007; Chong et al. 2013; Alexander et al. 2007). 
Increased protein releases in response to cartilage injury reported by others are mainly from 
newly protein synthesis. Anabolic proteins such as activin A was found elevated in response 
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to in vitro cartilage injury and OA (Stevens et al. 2009; Hermansson et al. 2004), which may 
play a role in tissue repair or a role in early inflammation and acute tissue injury response 
(Jones et al. 2004). Bone morphogenetic protein BMP13 was also found elevated in 
response to cartilage injury with a decrease in BMP antagonists including gremlin and 
chordin (Stevens et al. 2009). Elevated CTGF protein level was also found by others, but this 
was thought be actively mediated by other factors such as BMP2, TGFβ or macrophage 
colony-stimulating factor (M-CSF) (Nakao et al. 2005; Nakanishi et al. 1997b). There are 
also studies that show release of pre-existing proteins in response to cartilage injury, but 
these are mainly structural matrix proteins such as COMP and aggrecan (Lohmander et al. 
1994; Stevens et al. 2009), which is thought to be the result of cartilage degradation 
mediated by MMPs. Injurious compression on bovine cartilage caused increased release of 
pre-existing aggrecan protein as well as increased synthesis of MMP1, 3, 9 and 13 in the 
same injury conditioned medium (Stevens et al. 2009). There is a substantial literature that is 
emerging from the Marfan syndrome field where TGFβ, which is normally sequestered on 
fibrillin in the matrix, is inappropriately active when fibrillin is misfolded (Neptune et al. 2003). 
The presence of regulatory factors in the PCM suggests that they are having important 
cellular functions with tightly controlled bioavailability. My finding of rapid CTGF release from 
pre-existing PCM matrix pool upon cartilage injury implies that CTGF is important in an early 
response following cartilage injury. The mechanism by which this is changing cellular 
behaviour will be addressed in later chapters.  
!!!
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Part I: Investigating the role of CTGF in human articular chondrocytes 
4.1 Introduction 
CTGF is described as a matricellular protein. Matricellular proteins are non-structural 
proteins that are dynamically expressed in the ECM, serving regulatory roles. They are 
thought to function by modulating cellular responses through their ability to interact with 
multiple cell surface receptors, cytokines, growth factors, proteases, and structural proteins 
(Bornstein et al. 2002). CTGF, as described in chapter 1, contains 4 conserved modular 
domains that can bind to a large number of molecules. These interactions enable CTGF to 
participate in many essential biological functions including cell communication, proliferation, 
differentiation, adhesion and migration, regulation of skeletal growth and development, 
wound healing and angiogenesis (Oemar and Lüscher 1997).   
4.1.1 In vitro studies of CTGF 
The majority of published data on the role of CTGF has been from in vitro studies. CTGF has 
been described to exhibit numerous effects in different cell types including fibroblasts, 
chondrocytes, osteoblasts and vascular endothelial cells. Depending on the type of the cell 
with which it interacts, CTGF promotes cell proliferation, adhesion, chemotaxis, migration 
and extracellular matrix formation. CTGF has been shown to promote cell proliferation and 
migration of mesangial cells (Crean et al. 2004) and to induce apoptosis and caspase-3 
activity in human vascular smooth muscle cells (Hishikawa et al. 2000). Takigawa’s group 
has shown that CTGF promotes the proliferation of human chondrosacoma derived 
chondrocytic cell line (HCS2/8) and primary articular chondrocytes from rabbit cartilage, with 
increased gene expression of aggrecan, type II and type X collagen in these cells (Nakanishi 
et al. 2000). CTGF has also been reported to activate a number of signalling pathways for 
example ERK1/2 and Junk signalling in mesangial cells (Wahab et al. 2007) and to inhibit for 
example BMP and Wnt signalling in mesenchymal stem cells (Luo et al. 2004).  
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4.1.2 In vivo studies of CTGF 
A wide variety of methods have been reported for investigating the role of CTGF. With 
regards to in vivo studies, the generation of CTGF null mice has suggested a role for CTGF 
in growth plate angiogenesis, skeletal development and chondrogenesis (Ivkovic et al. 2003). 
In vivo delivery of recombinant CTGF into the femoral marrow cavity of rat induced 
osteogenesis with increased angiogenesis (Safadi et al. 2003). Overexpression of CTGF in 
Xenopus embryos modulated Wnt signaling, suggesting a role in embryonic development 
(Mercurio et al. 2004). Another study using transgenic mice that overexpressed CTGF under 
the control of the Col2α1 promoter showed increased cartilage and bone growth, with a 4% 
increase in the length of the tibial diaphysis in postnatal day 1 transgenic mice and increased 
proteoglycan and type II collagen accumulation (Tomita et al. 2013).  
A number of studies have investigated the role of CTGF using animal models of disease. 
Increased expression level of CTGF has been found associated with chronic obstructive 
pulmonary fibrosis in rats (Tannheimer et al. 2012), human thyroid carcinoma (Wang et al. 
2013), human renal allograft fibrosis (Metalidis et al. 2013) and human osteoarthritis 
(Hermansson et al. 2004), suggesting the involvement of CTGF in these diseases. In a 
mouse skin fibrosis model, injection of recombinant CTGF into the subcutaneous tissue of 
newborn mice caused the development of persistent fibrosis (Mori et al. 1999). Transgenic 
mice overexpressing CTGF after 20 weeks showed 100% protection from aging induced OA 
whereas 50% of wild-type mice developed an OA-like phenotype (Itoh et al. 2013). Another 
study using the monoiodoacetic acid induced OA in which recombinant CTGF was injected 
into rat knee joints, showed repair to cartilage defects implicating the role of CTGF in the 
regeneration of articular cartilage (Nishida et al. 2004).  
These findings suggest that CTGF may have a beneficial role in articular cartilage. However, 
other reports investigating the effects of overexpression of CTGF in mouse knee joints 
showed increased gene expression of catabolic molecules including MMP3, MMP13, 
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ADAMTS4 and ADAMST5, suggesting its involvement in cartilage destruction (Blaney 
Davidson et al. 2006). Treatment with anti-CTGF neutralising antibody significantly 
ameliorated collagen induced arthritis in mice (Nozawa et al. 2013). These reports are 
contradictory and early attempts in our group were unable to confirm (see later also) the 
induction of any of these genes in human articular chondrocytes. Therefore we designed a 
microarray study to investigate the role of CTGF in human articular chondrocytes. 
Prior to investigating cellular responses of CTGF, it was essential for us to obtain high 
quality recombinant protein. Overexpression of CTGF either by transient or adenoviral 
transfection methods have been used in a number of cell types (Hishikawa et al. 2000; 
Hishikawa et al. 1999; Liu et al. 2011; Luo et al. 2004; Wahab et al. 2001; Safadi et al. 2003). 
Many other groups used the recombinant protein from FibroGen, a company involved in the 
development of therapeutics for fibrotic disease, but they later scaled back their operation 
and the recombinant protein was no longer available. Other commercial sources were 
regarded as unreliable by others in the field (personal communications). The generation of 
our own recombinant CTGF became a prerequisite for our planned studies. Celia McLean 
established a method by which recombinant histidine tagged (His-tagged) CTGF can be 
generated from stably transfected HEK293 cells. I adopted this technique to generate the 
recombinant CTGF used in all the following experiments.  
4.2 Results 
4.2.1 Purification of His-tagged CTGF using nickel affinity chromatography 
There are a number of published methods for the generation of recombinant human CTGF 
including: the use of transformed HeLa cells followed by purification with a combination of 
heparin and antibody affinity chromatography (Nakanishi et al. 2000); expression in a 
bacculoviral system followed by purification using heparin affinity chromatography (Frazier et 
al. 1996); expression in competent M15 [pREP4] E.coli followed by nickel affinity 
chromatography (Tong and Brigstock 2006); expression in transformed human mesengial 
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cells, followed by purification with either metal or heparin affinity chromatography (Wahab et 
al. 2001). Celia McLean attempted to purify CTGF protein using the different reported 
methods. None of the reported methods produced high yield of homogenous protein. After a 
series of optimisations, she established a highly successful method which involved stably 
transfecting human embryonic kidney 293 (HEK293) cells with His-tagged CTGF pCEP4 
plasmid DNA (acquired from Prof. Roger Mason, Imperial College London) followed by 
nickel affinity chromatography. The polyhistidine (His) –tag is an amino acid motif consisting 
of six histidine residues. Metal ion affinity chromatography utilises the ability of histidine 
residues to interact with positively charged metal ions such as nickel.  
Prior to investigating the function of CTGF, I first purified His-tagged human CTGF 
recombinant protein using Celia’s method (Celia McLean PhD thesis, 2009). 150ml 
conditioned medium from stably transfected HEK293 cell culture was collected, filtered, 
supplemented with 20mM imidazole and passed through a 5 ml column containing charged 
nickel (Ni2+) beads. After a series of washes, protein fractions were eluted by a linear 
gradient of imidazole (20-500mM). From the chromatographic trace (Figure 4.1A) there 
appeared to be a single absorbance peak corresponding to fraction 5 and 6. The increase in 
absorbance appeared after the peak was likely due to absorbance of imidazole at 
wavelength 280nm. Following elution, fractions were assayed using an anti-CTGF antibody 
(Figure 4.1B). In order to estimate losses following purification, eluted fractions, flow through 
(FT) and starting material (SM) were loaded in equivalent amounts (taking into consideration 
the difference in volumes). CTGF (37-39kDa) was detected within the SM and also the FT. 
This may indicate that the capacity of the column had been exceeded. However, detection of 
CTGF in fraction 5 and 6 showed bands with similar intensity as the band in the SM, 
suggesting good recovery. The source of the immunoreactive materials in the FT could also 
be endogenously expressed CTGF (not His-tagged) from the cultured HEK293 cells. In the 
silver stained gel, 20ul of each fraction (1ml) and 40µl of the SM (not equivalent) were 
loaded to determine protein purity. The amount of SM loaded was 20 times less than the 
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amount loaded for fractions (4 to10). A clear doublet band resolving at 38KDa was apparent 
in both fraction 5 and 6 with some weak protein staining seen at higher molecular weight in 
fraction 5 (Figure 4.1C). 
 
 
 
.  
 
 
 
 
 
 
 
Figure 4.1 Purification of CTGF from conditioned medium of stably transfected HEK293 cells using a 5ml 
Ni2+ affinity column. Conditioned medium (150ml) from stably transfected HEK293 cells was applied to a 5ml 
nickel affinity column. Protein was eluted using a linear gradient ranging from 20-500mM imidazole. Figure A 
shows the chromatographic trace of purification for His-tagged recombinant CTGF (A). Samples were collected in 
1ml fractions. Fractions (1µl for western blot or 20ul for silver staining of 1 ml) were run on 4-12% Bis-Tris gels 
and western blotted with an anti CTGF antibody (B) or silver stained (C). 
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4.2.2 Purified CTGF is retained upon dialysis and ultrafiltration 
As indicated in Materials and Methods, purified CTGF fractions after elution contained 
approximately 150mM imidazole and 0.5M NaCl. Therefore, it was necessary to remove the 
contaminating salt before using it for experiments. The optimised de-salting method is to 
dialyse the protein solution in 1x PBS which is isotonic and non-toxic to cells. Fractions 5, 6 
and 7 were pooled together and dialysed against 1x PBS across a 10kDa dialysing 
membrane. The resulting solution was concentrated using a 10kDa cut-off ultrafiltration spin 
column. The concentrated protein was loaded onto a gel with an equivalent amount of pre-
dialysed material and protein was visualised by western blot (Figure 4.2). Eluted fractions 
from the nickel column were successfully retained upon dialysis and concentration. The 
activity of the purified CTGF was examined by looking at its effect on the gene expression of 
candidate matrix molecules in human chondrocytes. This will be addressed in section 4.2.4. 
!
 
 
 
 
Figure 4.2 Purified CTGF is retained upon dialysis and spin concentration. Three fractions (3ml) positive for 
CTGF were pooled (PO) together, dialysed against 1x PBS across a 10kDa membrane for 18hr and concentrated 
5 times using a 10kDa ultrafiltration column (CON). 1µl of pooled fraction, 0.2µl of concentrated solution and 50ul 
of starting material and flow through solution were loaded onto a gel and western blotted using an anti- CTGF 
antibody. 
 
4.2.3 Quantification of purified CTGF following dialysis and ultrafiltration 
The concentration of the purified protein was determined by comparing the intensities of 
CTGF bands to that of known concentrations of BSA (as standard protein) on a colloidal 
Coomassie Brilliant Blue G-250 stained gel. The concentration of protein in the preparation 
was first estimated by measuring the absorbance at 280nm using NanoDrop 
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spectrophotometer, where the measured concentration was 25µg/ml (25ng/µl). According to 
this, 200ng to 1000ng of BSA were loaded on a 4-12% gradient gel, along with 5µl, 10µl and 
30µl of purified CTGF solution. The gel was stained with colloidal Brilliant Blue G-250 and 
the relative intensity (intensity per mm2) of the bands was measured using Quantity One 
software (Figure 4.3A). Intensity and dose values of BSA bands were plotted to generate a 
standard curve, and the concentration of the purified CTGF was determined by coordinating 
to its intensity values (Figure 4.3B). As indicated, 30µl of purified material contained 600ng 
of CTGF, thus the concentration of CTGF was estimated at 20µg/ml. The final yield of 
protein obtained was 12µg from 150ml of conditioned medium. 
  
    
 !!!!!!!!
 
 
 
 
 
Figure 4.3 Quantification of purified CTGF. Purified material was dialysed and concentrated. Purified material 
(5,10 and 30µl) was loaded onto a 4-12% Bis-Tris gel alongside known concentrations of a standard protein 
(BSA). The gel was then coomassie stained and the intensity of the bands was measured using Quantity One 
(Bio-Rad ltd, USA) (A) and the values were plotted (B) to estimate the concentration of purified CTGF. 
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4.2.4 Purified CTGF did not affect the gene expression of candidate matrix genes in 
human chondrocytes 
CTGF has been reported to regulate the expression of a number of matrix proteins including 
type I collagen, type II collagen, aggrecan and fibronectin, as well as molecules involved in 
matrix remodelling such as MMP1, MMP2, MMP3, TIMP1, ADAMTS4 and ADAMTS5 
(Blaney Davidson et al. 2006; Chen et al. 2001; Fan et al. 2009; Frazier et al. 1996). 
Therefore it was decided to investigate whether stimulation of HACs with purified CTGF 
would reveal changes in the expression pattern of these molecules. HACs (passage1, P1) 
were stimulated with TGFβ1 (10ng/ml) as a positive control or purified recombinant CTGF at 
100ng/ml for 24hr. This time point and concentrations were chosen on the basis of other 
publications (Tomita et al. 2013). RNA was then extracted and gene expression was 
measured relative to GAPDH using RT-PCR. TGFβ at 10ng/ml induced gene expression of 
type I collagen by 2 fold and perlecan by 2.5 fold while no significant response was seen 
with CTGF stimulation (Figure 4.4). Similar experiments looking at other matrix proteins such 
as type II collagen, fibronectin and aggrecan were also carried out in HACs (one experiment 
for each gene, results are not shown). Again no significant regulation was observed in 
response to CTGF. The failure to demonstrate the effect of CTGF in regulating candidate 
genes could have been due to a lack of biological activity in the expressed protein or due to 
high constitutive expression of CTGF in human chondrocytes (Celia McLean had shown 
previously that these cells make CTGF constitutively). Therefore it was decided to stimulate 
cells in which endogenous CTGF had been silenced using siRNA.  
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Figure 4.4 Purified CTGF did not affect gene expression of type I collagen and perlecan in HACs. HACs 
were starved for 18hr in serum free DMEM and stimulated with TGFβ1 (10ng/ml) or recombinant CTGF 
(100ng/ml) for 24hr. RNA was extracted and purified, relative gene expression of perlecan and type I collagen to 
GAPDH were measured using RT-PCR. Left panel shows the expression of perlecan and the right panel figure 
shows expression of type I collagen. Each bar represents the mean of three experiments with error bars 
representing standard error of the mean (n=3). *p<0.05, ns= not significant. 
 
4.2.5 CTGF knockdown using siRNA  
HACs were transfected with either of the two CTGF siRNA oligos (siCTGF A and B) or a 
scrambled siRNA (siSCR) as control. Following 48hr transfection, RNA was extracted from 
the cells and gene expression for CTGF was measured relative to GAPDH. Both CTGF 
siRNA oligos effectively reduced the relative RNA level of CTGF, compared to the siSCR 
transfected cells (90% for oligo A, 80% for oligo B). siSCR had a small non-specific effect on 
the gene expression of CTGF, compared to untransfected cells (Figure 4.5A). 
Protein level of CTGF upon knockdown using siCTGF oligo A and B was also determined. 
First, the assay was optimised to detect secreted CTGF. TGFβ1 is known to induce CTGF in 
chondrocytes and fibroblasts (Grotendorst et al. 1996; Nakanishi et al. 1997b). Adding 
heparin into the medium blocks LRP-mediated uptake of CTGF allowing it to accumulate in 
the medium (Celia McLean PhD thesis, 2009; Troeberg et al. 2008). Therefore, cells were 
treated with TGFβ1 in the presence or absence of heparin, following siRNA knockdown of 
Perlecan 
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n/
G
A
PD
H
 
!
Gene expression of perlecan in HAC
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
of
 p
er
le
ca
n/
G
A
PD
H
Co
ntr
ol
TG
F1
0
Ac
tiv
in1
00
CT
GF
10
0
0
1
2
3 !
Gene expression of perlecan in HAC
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
of
 p
er
le
ca
n/
G
A
PD
H
Co
ntr
ol
TG
F1
0
Ac
tiv
in1
0
CT
GF
0
1
2
3
ns 
* 
ns 
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n/
G
A
PD
H
 
Type I collagen 
!
Gene expression of type I collagen in HAC
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
of
 C
O
LI
/G
A
PD
H
Co
ntr
ol
TG
F1
0
Ac
tiv
in1
00
CT
GF
10
0
0.0
0.5
1.0
1.5
2.0
2.5 !
Ge e expression of type I collagen in HAC
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
of
 C
O
LI
/G
A
PD
H
Co
ntr
ol
TG
F1
0
Ac
tiv
in1
0
CT
GF
0.0
0.5
1.0
1.5
2.0
2.5 * 
Chapter 4                                                          Effects of recombinant CTGF on articular chondrocytes 
! 82 
CTGF. After 24hr stimulation, both cultured medium and cell lysates were acetone 
precipitated and run on a 4-12% SDS-PAGE to detect CTGF (Figure 4.5B). In the medium, 
CTGF was only detected when cells were stimulated with TGFβ1 in the presence of heparin, 
while in the lysates CTGF protein was expressed constitutively and its level increased 
slightly upon TGFβ stimulation (Figure 4.5B). To examine the efficiency of CTGF knockdown 
at protein level, stimulation with TGFβ1 in the presence or absence of heparin was carried 
out in siRNA transfected cells. These cells showed significant reduction at the protein level 
of CTGF for both siCTGF oligo A and B, compared to siSCR oligo transfected cells (Figure 
4.5C). 
 
 
 
                                    
 
 !!!
 
 
 
 
 
 
 
 
 
 
Figure 4.5 CTGF was effectively silenced by siRNA oligos A and B at both gene and protein levels. 3 x 105 
HAC was plated for 18hr and transfected with 15nM of siCTGF oligos (A or B) or siSCR (SCR) with lipofectamine 
for 48hr. RNA was extracted from the cells and gene expression of CTGF was measured relative to GAPDH (A). 
For protein detection, untransfected (B) or transfected (C) HACs were stimulated with TGFβ1 (10ng/ml) with or 
without heparin (100ug/ml) for further 24hr. The conditioned medium and cell lysates were collected for acetone 
precipitation and run on 4-12% Bis-Tris gels. CTGF was detected on western blot using an anti-CTGF antibody. 
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4.2.6 CTGF knockdown did not affect the gene expression pattern of ECM molecules 
in human chondrocytes 
Having validated CTGF knockdown by siRNA, it was now possible to test the effect of 
purified recombinant CTGF on the expression of candidate ECM molecules in human 
chondrocytes in the absence of constitutive levels of CTGF. It was also possible to examine 
whether the effects of TGFβ on chondrocytes were occurring, as some have proposed, 
through induction of CTGF. HACs transfected with either scrambled or CTGF siRNA were 
stimulated with TGFβ1 (10ng/ml) or CTGF (100ng/ml) for 24hr. Gene expression (CTGF, 
perlecan, type I collagen and fibronectin) was measured relative to GAPDH (Figure 4.6). 
CTGF RNA was reduced by 82% (average of four experiments) by siCTGF oligo A, 
compared to siSCR, confirming good knockdown. Despite this, the expression of perlecan, 
type I collagen and fibronectin remained unchanged between the two groups (siSCR and 
siCTGF), indicating firstly that constitutively expressed CTGF is not significantly contributing 
to expression of these genes and secondly that the induction of the genes by TGFβ was not 
dependent upon CTGF mRNA. In these experiments (at 24hr stimulation) CTGF does not 
stimulate the synthesis of perlecan, fibronectin nor type I collagen.   
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Figure 4.6 CTGF knockdown did not affect the gene expression of candidate ECM molecules in human 
chondrocytes. 3 x 105 HACs were plated for 18hr and transfected with 15nM of siRNA oligos (A for siCTGF and 
siSCR as control) with lipofectamine for 48hr. Transfected cells were stimulated with either TGFβ1 (10ng/ml) or 
CTGF (100ng/ml) for 24hr. RNA was extracted from the cells and gene expression of CTGF, perlecan, type I 
collagen and fibronectin was measured relative to GAPDH. Bars represent the mean of three separate 
experiments, with error bars representing the standard error of the mean. Statistical test suggested no significant 
difference between the two groups (siSCR and siCTGF) (ns: not significant; *** p<0.001,* p<0.05). 
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4.2.7 CTGF is induced strongly by activin A and recombinant CTGF in both HACs and 
NHDFs 
As TGFβ induces CTGF in human chondrocytes, we examined whether activin A, another 
TGF β family member, also induced CTGF. Activin A was especially of interest to us 
because it was one of the proteins found overexpressed from human OA cartilage 
(Alexander et al. 2007) and it is a highly regulated early gene following induction of OA in 
mouse (Burleigh et al. 2012). Moreover, it is induced upon cartilage injury in vitro and in vivo 
in an FGF2-dependent manner (FGF2 is stored and released from the PCM upon cartilage 
injury) (Chong et al. 2013). Activin A and CTGF have been both found overexpressed in 
osteoarthritis (Hermanson et al. 2002) while Activin A’s role in articular cartilage is unclear.  
An activin A dose response was first carried out in order to determine the optimal 
concentration of activin A induced gene expression of CTGF. Normal human dermal 
fibroblasts (NHDFs) were used during optimisation as they are easily obtained and 
maintained in culture and it is known that TGFβ induces CTGF in this cell type. NHDFs were 
stimulated with either TGFβ1 (10ng/ml) as a positive control or increasing concentrations of 
activin A (2ng/ml to 200ng/ml) for 24hr. RNA was then extracted and gene expression of 
CTGF was measured relative to GAPDH using RT-PCR. As the concentration of activin A 
increased, the relative gene expression of CTGF also increased, peaking at 100ng/ml 
(Figure 4.7A). At this dose the fold induction was similar to that seen with TGFβ. Protein 
levels of CTGF were also determined in response to activin A stimulation in the presence of 
heparin. Following stimulation, conditioned medium was collected and loaded onto 4-12% 
gradient gels to detect CTGF by western blotting. Strong induction of CTGF by TGFβ1 and 
activin A can be observed in both cultured HACs and NHDFs in the presence of heparin 
(Figure 4.7B). No obvious accumulation of CTGF was seen with heparin alone, suggesting 
that addition of heparin alone did not cause the induction of CTGF in these cells. In a 
separate experiment, when cells were stimulated with CTGF (100ng/ml) we observed that 
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RNA of CTGF was also induced about 5 fold in HACs and 4 fold in NHDFs (Figure 4.7C and 
D), suggesting that CTGF induces itself. 
                     
!
!!!!!!!!!!
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Induction of CTGF in P1 HACs and NHDFs. NHDF were stimulated with TGF β (10ng/ml) or activin 
A (2 to 200ng/ml) for 24hr and the relative gene expression of CTGF was measured (A). For protein, conditioned 
media were collected after treating the cells with TGFβ (10ng/ml) or activin A (100ng/ml) in the presence or 
absence of heparin (10mg/ml) for 24hr and western blotted to detect CTGF (B). HACs (C) or NHDFs (D) were 
stimulated with TGFβ1 (10ng/ml), activin or CTGF (100ng/ml) for 24hr and gene expression of CTGF was 
measured (A: n=1, B: one representative results of three experiments, n=3, C: n=3 *p<0.05 and D: n=1).  
 
These experiments were important as they demonstrated a biological activity for our 
recombinant CTGF (induction of CTGF) and provided a possible biological link between 
CTGF and activin A (activin A strongly induced CTGF). 
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4.2.8 Optimisation for microarray study 
So far CTGF was the only target gene shown to be induced by CTGF and activin A in human 
chondrocytes. Therefore it was decided to carry out a microarray study to identify novel 
target genes prior to studying their functions. Prior to microarray, the optimal concentration 
and time course for stimulation was determined. HACs were stimulated with increasing 
concentrations of recombinant CTGF (40ng/ml to 200ng/ml) or activin A (10ng/ml and 
100ng/ml) for 24hr and gene expression of CTGF was measured relative to GAPDH using 
RT-PCR (Figure 4.8A). A dose response curve was demonstrated for each ligand and we 
decided to use 100ng/ml for both ligands. NHDFs were used for the time course experiment. 
NHDFs were stimulated with CTGF and activin A at 100ng/ml for different time periods 
ranging from 4 to 48hr. Relative gene expression of CTGF was measured (Figure 4.8B). 
CTGF and activin A stimulations gave different temporal responses: the gene response to 
CTGF stimulation was early (peaking at 8hr), while activin A stimulation was late (optimal at 
48hr). These results explain the low fold induction of CTGF with recombinant CTGF 
stimulation in experiment 4.2.7 (at 24hr). 
 
 
 
 
 
 
 
Figure 4.8 Optimisation of CTGF gene expression in response to CTGF and activin A stimulations. HACs 
were stimulated with increasing concentrations of purified CTGF (40ng/ml to 200ng/ml) or activin A (10ng/ml and 
100ng/ml) for 24 hours and gene expression of CTGF was measured relative to GAPDH using RT-PCR (A). 
NHDFs were stimulated with CTGF and activin A at 100ng/ml for increasing time periods ranging from 4hr to 48hr. 
Relative gene expression of CTGF was measured (B) (n=1). 
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4.2.9 Design and preparation for microarray 
In order to accommodate biological variation, HACs from three donors (N15, N51 and N75, 
all P1) were used. HACs were either transfected with siSCR or siCTGF oligo A or B and 
stimulated with the recombinant CTGF or activin A at 100ng/ml for 8hr. CTGF and activin A 
induced gene expression of CTGF peaked at 8hr and 48hr respectively (Figure 4.8B). For 
the microarray study, the earlier time point (8hr) was chosen because the regulation of 
immediate responsible genes would likely be captured after short time stimulation. RNA 
prepared from these experiments was first measured to determine the efficiency of the 
knockdown by RT-PCR. All three experiments showed high knockdown efficiency: 95% for 
oligo A and 82% for oligo B in N15 HAC, 98% for A and 97% for B in N51 HAC and 89% for 
A and 87% for B in N75 HAC (Figure 4.9A). Stimulation with the recombinant CTGF or 
activin A induced CTGF RNA in all three experiments but by different folds, which appear to 
be due to different basal levels of CTGF and activin A in these cells. Indeed the 
measurement of CTGF RNA in the unstimulated cells confirmed different basal levels of 
CTGF RNA in the HACs of different donors (Figure 4.9B). The result showed that the RNA 
level of CTGF in the unstimulated N75 HAC was about 4 times that of N51 HAC while N15 
was about 4.7 times that of N51. This probably explains why we observed less induction in 
N75 (5 and 6 fold) and N15 HAC (2 and 3 fold) compared with N51 (14 and 20 fold) (Figure 
4.9A). 
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Figure 4.9 HACs from three donors showed high knockdown efficiency and different CTGF induction.  
HACs from three donors (N15, 51 and 75) were transfected with siSCR, siCTGF oligo A or oligo B, and 
stimulated with or without purified CTGF and activin A (100ng/ml). RNA was extracted and measured for the 
gene expression of CTGF relative to GAPDH (A). Basal level of CTGF (normalised to each patient specific 
GAPDH) was measured in the HACs of the three donors (B) (n=1). 
 
4.2.10 Microarray analysis 
Prior to sending the RNA samples for microarray analysis, the quality and quantity of the 
total RNA was examined. All RNA samples used (Table 6) satisfied the selection criteria 
detailed in 2.8.4. The microarray study was carried out by the Cambridge genomic centre at 
University of Cambridge. The hybridised chips were scanned with the BeadArray Reader 
(Illumina, San Diego, CA) to detect Cy3 fluorescence emission. The Genome Studio Data 
Analysis software (Illumina, San Diego, CA) was used to extract the fluorescence intensity 
measurements for each probe and to measure the quality of the hybridisations. Illumina 
BeadChips have internal control features to measure data quality control. The extracted 
features were processed in the R environment using the bioconductor package software lumi 
(Gentleman et al. 2004; Du et al. 2008). Selection of detected probes is performed using the 
detection p-value (p < 0.01) provided by Illumina. It represents the confidence that a given 
transcript is expressed above the background defined by the negative control probe. Probes 
need to be successfully detected in at least one sample to pass selection. 21886 probes 
were successfully detected. Data were log transformed and variance stabilised prior to 
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normalisation by quantile normalisation. Quality control was also performed using the 
arrayQualityMetrics R package in lumi. No samples failed or are outliers to their replicates. 
We analysed the data using the Multiexperiment Viewer (MEV v.4.6) software (Saeed et al. 
2003; Saeed et al. 2006). The non-parametric method significance analysis of microarrays 
(SAM) was used to identify genes that were differentially regulated among the treatment 
variables (Tusher et al. 2001; Chu et al. 2002). SAM computes a statistic for each probe in 
the dataset that measures the strength of the relationship between probe intensity and the 
response variable. It uses repeated permutations of the data to determine if the expression 
of any probe is significantly related to the response. The cut-off for significance is 
determined by tuning a parameter delta, based on a 0 false positive rate. 50 genes were 
found to be differentially regulated among the groups. These 50 genes were hierarchically 
clustered (Eisen et al., 1998) into a tree whose branch lengths reflect the degree of similarity 
in the expression change amongst the genes measured based on Pearson correlation 
(Figure 4.10). By adjusting the gene tree lengths we got 5 clusters. Cluster 1 contained 
BMPR2, which was up-regulated by CTGF and activin A compared to unstimulated samples 
and down-regulated by both siCTGF oligo A and oligo B compared to siSCR. Cluster 2 
contained 31 genes that were down-regulated by the siCTGF oligo A only. Cluster 3 
contained PMEPA1 and LTBP2 which were up-regulated by CTGF and activin A, but 
showed no change upon knockdown of CTGF. Cluster 4, similar to cluster 1, contained 
CTGF only, and was up-regulated by CTGF and activin A and down-regulated by both 
siCTGF oligo A and B. Cluster 5 contained 13 genes that were only down-regulated by 
siCTGF oligo B. BMPR2, PMEPA1, LTBP2 and CTGF were the only genes found to be 
differentially regulated by CTGF or activin A. The remaining genes were either down-
regulated by siCTGF oligo A or siCTGF oligo B alone, which suggests non-specific off target 
effects of the two siCTGF oligos. 
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Table 6 Summary of the RNA samples used for microarray study. RNA was extracted from HACs isolated 
from cartilage of three donors: N15, 51 and 75, aged 15, 51 and 75 respectively, either transfected with siSCR, 
siCTGF oligo A or B and stimulated with or without CTGF and activin A at 100ng/ml. RIN number of each RNA 
sample was measured prior to microarray analysis. 
Donor’s'code'''''''''
N'(donor’s'age)'
'
Sample'
No.'
Samples'name' RIN'NO.' siRNA' Stimulation'
N51'
1' N51_CTRL' 9.7' SCR' none'
2' N51_CTGF' 9.1' SCR' CTGF100'
3' N51_Activin' 8.7' SCR' Activin100'
4' N51_CTRL_siA' 8.8' CTGF'(A)' none'
5' N51_CTGF_siA' 8.9' CTGF'(A)' CTGF100'
6' N51_Activin_siA' 9' CTGF'(A)' Activin100'
7' N51_CTRL_siB' 9.6' CTGF'(B)' none'
8' N51_CTGF_siB' 9' CTGF'(B)' CTGF100'
N75'
9' N75_CTRL' 9.3' SCR' none'
10' N75_CTGF' 9.7' SCR' CTGF100'
11' N75_Activin' 9.2' SCR' Activin100'
12' N75_CTRL_siA' 9.1' CTGF'(A)' none'
13' N75_CTGF_siA' 9' CTGF'(A)' CTGF100'
14' N75_Activin_siA' 9.6' CTGF'(A)' Activin100'
15' N75_CTRL_siB' 9.7' CTGF'(B)' none'
16' N75_CTGF_siB' 9.9' CTGF'(B)' CTGF100'
N15'
17' N15_CTRL' 10' SCR' none'
18' N15_CTGF' 9.5' SCR' CTGF100'
19' N15_Activin' 8.7' SCR' Activin100'
20' N15_CTRL_siA' 8.3' CTGF'(A)' none'
21' N15_CTGF_siA' 8.7' CTGF'(A)' CTGF100'
22' N15_Activin_siA' 9.2' CTGF'(A)' Activin100'
23' N15_CTRL_siB' 8.6' CTGF'(B)' none'
24' N15_CTGF_siB' 9' CTGF'(B)' CTGF100'
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Figure 4.10 Heat map of the genes regulated from microarray analysis. 50 genes were found significantly 
regulated in the microarray study, whose signals were presented in heat map and orders were arranged in 5 
clusters without supervision, according the degree of similarity between the gene responses. Samples were also 
arranged in 5 groups (colour boxes under samples’ names) without supervision according the similarity between 
two treatments: green = unstimulated siA transfected group, blue= CTGF or activin A stimulated siA transfected 
group, red= unstimulated siSCR group, yellow= CTGF or activin A stimulated siSCR group and purple = 
unstimulated or CTGF stimulated siB transfected group. Gene expression levels are presented in heat map on a 
log scale (heat map bar on the top): red (up-regulation), green (down-regulation) black (no change). 
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4.2.11 Validation of microarray results using RT-PCR 
The four genes (CTGF, PMEPA1, LTBP2 and BMPR2) were identified from the microarray 
study. Each was significantly regulated by CTGF and activin A. Before identifying their 
function, expression of these four genes was first validated in human chondrocytes and 
fibroblasts using RT-PCR.  HACs or NHDFs were treated with CTGF or activin A at 
100ng/ml for 8hr and the expression of the four genes were measured relative to GAPDH 
(Figure 4.11). In NHDFs, all four genes were regulated in response to activin A and CTGF 
whereas in HACs only PMEPA1 showed strong regulation. This may be due to the high 
basal level of CTGF and activin A in chondrocytes or the gene response to these stimulators 
may be optimal at different times. This will be addressed in the next section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Validation of the four identified genes in HACs and NHDFs using RT-PCR. HNDFs or HACs 
were stimulated with CTGF or activin A at 100ng/ml for 8hr. Gene expression of CTGF, BMPR2, LTBP2 and 
PMEPA1 was measured relative to GAPDH. Bars represent fold change in gene expression (n=1). 
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4.2.12 Time dependent induction of the four identified genes by CTGF and activin A 
NHDFs were stimulated with either CTGF or activin A (100ng/ml) for increasing time points 
ranging from 2hr to 48hr. Gene expression for CTGF, PMEPA1, LTBP2 and BMPR2 were 
measured relative to GAPDH. All four genes responded to CTGF stimulation earlier than to 
activin A (Figure 4.12). CTGF induced CTGF expression peaked at 8hr and declines 
afterwards while activin A induced CTGF expression became plateaued at 24hr. PMEPA1 
again showed strongest induction in response to stimulation. It was induced by CTGF by 12 
fold after 2hr stimulation, peaked at 23 fold after 4hr and declined beyond 8hr.  Upon activin 
A stimulation, the PMEPA1 induction started at 2hr (9 fold), peaked at 4hr (17 fold) and 
declined from 8hr (8 fold). At 24hr, the induction of PMEPA1 by CTGF has returned to basal 
level, whereas for activin A, the expression was maintained up to 48hr. The induction of 
LTBP2 increased as the time of stimulation increased; it peaked at 24hr for both stimuli but 
had declined by 48hr for CTGF, while persisting for activin A. BMPR2 responded the least to 
the stimuli, was induced to the maximal 2.3 fold at 8hr by CTGF and 1.7 fold at 24hr by 
activin A.  
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Figure 4.12 Validation of the four identified genes in time course experiments. NHDFs were stimulated with 
CTGF (100ng/ml) or activin A (100ng/ml) for increasing times from 2hr to 48hr. Gene expression of BMPR2, 
LTBP2, PMEPA1 and CTGF were determined using RT-PCR. Bars represent mean gene expression levels with 
error bars representing the standard error of the mean (n=4). All differences are significant compared with time-
matched controls apart from those indicated (ns).  
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4.2.13 Activin A induced gene expression can be inhibited by cycloheximide 
The late and persistent responses by activin A indicate that induction of gene responses 
could be mediated by an intermediate molecule. To test this, the protein synthesis inhibitor 
cycloheximide (CHX) was used. NHDFs were stimulated either with or without activin A in 
the presence or absence of CHX for 24hr. RNA was extracted for RT-PCR analysis. CHX 
significantly abolished the late gene expression (at 24hr) of CTGF, PMEPA1 and LTBP2 by 
activin A (Figure 4.13A). Activin A induced BMPR2 expression at 24hr in the absence of 
CHX was very modest and therefore non-interpretable. CTGF protein level was also 
measured in the presence or absence of CHX to examine the inhibition efficiency of CHX on 
protein synthesis. Under this condition CTGF protein induced by activin A was reduced by 
approximately 80% upon addition of CHX (Figure 4.13B). These results suggest that the late 
induction of genes by activin A may be indirect through a secondary mediator. Alternatively it 
could indicate that the CHX treatment used in the experiment was toxic to the cells. To test 
this, the CHX experiment was performed with TGFβ stimulation as a control. When CHX 
was added to TGFβ stimulated cells no reduction in gene expression of CTGF was 
demonstrated (at 24hr), indicating that the reduction in activin A induced gene expression 
after 24hr was not due to CHX toxicity to the cells (Figure 4.13C). 
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Figure 4.13 Induction of genes by activin A was inhibited by CHX at later stimulation time course. NHDFs 
were stimulated with or without activin A (100ng/ml) in the presence or absence of CHX (10µg/ml) for 24hr. RNA 
was extracted and analysed for the relative gene expression of CTGF, PMEPA1, LTBP2 and BMPR2 to GAPDH 
(A).  Bars represent the mean of three experiments with error bars representing the standard error of the mean 
(n=3).  For protein, cells were stimulated in the presence of heparin (10µg/ml) for 24hr. Conditioned medium was 
collected and acetone precipitated. CTGF protein was detected by western blotting using an anti-CTGF antibody 
(B). The effect of CHX on the gene expression of CTGF was also examined in CTGF and TGFβ stimulation, 
where no significant reduction was seen (C).   
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4.2.14 Activin A induced gene expression was not through expression of CTGF 
The CHX experiment provided evidence that the late effect of activin A was through a 
secondary mediator. As activin A induced CTGF and CTGF could induce the three target 
genes, it was possible that the late gene effect of activin A was through induction of CTGF. 
To test this, activin A treatment was performed in NHDFs in which CTGF had been knocked 
down by siRNA. NHDFs were transfected with either siSCR oligo or siCTGF oligo A and 
then stimulated with or without activin A (100ng/ml) for 4hr or 24hr. Gene expression of 
CTGF, PMEPA1, LTBP2 and BMPR2 were compared between siSRC and siCTGF cells. 
90% of CTGF RNA was silenced using siRNA oligo A, however, the gene expression of 
PMEPA1, LTBP2 and BMPR2 were unchanged (Figure 4.14). This suggests that activin A- 
induced gene expression was not dependent upon the induction of CTGF. 
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Figure 4.14 Activin A induced gene expression was not in part through CTGF. NHDFs were transfected with 
siSCR or siCTGF oligo for 48hr and stimulated with or without activin A at 100ng/ml for 4hr or 24hr. Gene 
expression of CTGF, PMEPA1, LTBP2 and BMPR2 was measured using RT-PCR. CTGF mRNA was reduced by 
90% upon knockdown. Gene expression of the other three genes did not significantly change between siSCR 
and siCTGF treated cells. Bars represent mean of gene expression with error bars representing the standard 
error of the mean (n= 4). 
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4.3 Discussion 
Central to the success of this project is the expression and purification of active recombinant 
CTGF; I used a previously established protocol using stably transfected HEK293 cells. The 
process of making of my own recombinant CTGF has been relatively easy and 
straightforward. The advantage of using HEK293 cells has been that they can be easily 
cultured and stably transfected. The fact that they are mammalian cells makes it a good 
source for expressing human recombinant protein and increases the likelihood that the 
expressed protein will be folded correctly. The purified recombinant CTGF was detected at a 
molecular weight of 37kDa by western blot and appeared as doublet on the silver stained gel. 
This is consistent with the published observations where recombinant CTGF appears as two 
bands at 36 and 38kDa. The higher molecular weight form is thought to be due to 
glycosylation of the protein (Grotendorst and Duncan 2005). From the silver stained fractions, 
the purity of the recombinant CTGF was high, estimated above 90%. Although the yield of 
my CTGF purification was not very high, about 16µg protein per 150ml of conditioned 
medium, the procedure is straightforward and new batches can be prepared easily.  
The first challenge was to determine whether the purified CTGF was active or not. Although 
there are several published biological activities reported in the literature, many of the cellular 
responses e.g. phosphorylation of signalling molecules such as p38 and ERK1/2 (Nagai et 
al., 2008), inhibition of Wnt signalling (Luo et al. 2004), and gene expression of ADAMTS 
and MMPs (Blaney et al. 2006) have not been reproduced in our hands (Celia McLean PhD 
thesis, 2009). Some of these inconsistences may be due to the different recombinant CTGF 
preparations used in different labs and some may be cell type dependent. Early on we were 
concerned that negative results might also be due to high basal levels of endogenous CTGF 
protein in chondrocytes. We preformed CTGF RNA knockdown using two CTGF siRNA 
oligos. We achieved high knockdown efficiencies; 98% and 80% for oligo A and B 
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respectively. However, CTGF silencing did not affect putative CTGF inducible gene 
expression (type I collagen and perlecan etc). By chance during these experiments I found 
that the purified CTGF induced CTGF itself at gene and protein level as also shown in 
other’s study (Parada et al. 2013). This response occurs early and is relatively transient 
(gone by 24hr) and is similar to that observed for TGFβ stimulation (see next chapter). 
These findings showed activity in our recombinant CTGF although it could not ruled out that 
there might be contamination with TGFβ (or similar) in the purified sample. As CTGF and 
TGFβ bind to one another (Abreu et al. 2002), it is possible that these proteins co-purified 
during chromatography. This is addressed in detail later in this chapter.   
We were also interested in activin A as it was one of the elevated proteins identified in the 
conditioned medium of human OA articular cartilage (Hermansson et al. 2004). Activin A 
mRNA was up-regulated following induction of OA in mouse (Chong et al. 2013) and protein 
was induced upon cartilage injury in vitro and in vivo in a FGF2 dependent manner (Chong 
et al. 2013; Burleigh et al. 2012; Alexander et al. 2007). However the role of activin A in 
normal articular cartilage remains unclear. Activin A null mice show similar musculoskeletal 
phenotypes to CTGF null mice, therefore I suspected there might be some link between the 
two proteins. Activin A was able to induce CTGF at gene and protein level but with a 
relatively delayed time course. This finding is significant as our group had previously been 
unable to identify specific target genes of activin A in human chondrocytes (Alexander, PhD 
thesis, 2007; Alexander et al. 2007). I also intended to identify other target genes for activin 
A in the microarray study. 
Having confirmed biological activity of the purified CTGF, I proceeded to a microarray 
analysis. The aim of the microarray study was to identify specific target genes of CTGF as 
well as activin A following the recombinant CTGF and activin A stimulation respectively, with 
or without removing basal CTGF by siRNA silencing in these cells. Human articular 
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chondrocytes used in this experiment were from three donors. This is to accommodate 
biological variations in the specimen and provide sample replication for statistics. These 
human chondrocytes were passaged once (P1) before used for the experiment. Freshly 
isolated (P0) chondrocytes are less suitable for siRNA transfection as P0 cells are likely to 
disassociate from the monolayer culture plate during transfection and have low transfection 
efficiency (personal communication within the lab). Cultured chondrocytes beyond three 
passages (P3) in monolayer system are likely to lose chondrocytic phenotype (reduced type 
II collagen and aggrecan expression and increased type I collagen expression) and become 
more fibroblastic (Benya and Shaffer 1982). Two validated siRNA oligomers were used to 
minimise off-target effects. Both recombinant CTGF and activin A stimulations were included 
in the experiment to identify their specific target genes. It would be interesting if TGFβ 
stimulation had been included in the study. However, considering the complexity of the study 
and many TGFβ inducible genes have already been identified in chondrocytes, I decided not 
to include TGFβ. From the microarray data, only four genes were found to be up-regulated 
by CTGF as well as activin A stimulation at 8hr. It is interesting that CTGF and activin A up-
regulated the same four genes in chondrocytes, suggesting they may have related roles in 
cartilage. To understand it better I looked the four genes into details. 
The four genes identified were: CTGF, bone morphogenetic protein receptor II (BMPR2), 
latent TGF binding protein 2 (LTBP2) and transmembrane prostate androgen induced 
protein (TMEPAI also known as PMEPA1). Aside of CTGF, the other three genes have 
activities related to TGFβ family protein signalling transduction. BMPR2 is the type II 
receptor of BMPs; upon binding to ligand, the type II receptor recruits BMP type I receptor 
and together phosphorylate SMAD molecules which then translocate to the nucleus to act as 
transcription factors. LTBPs are important molecules that control the bioavailability of TGFβ. 
Latent TGFβ molecules are shielded in an ECM sequestering complex consisting of TGFβ, 
LTBP and latency associated peptide (LAP) (more will be discussed in chapter 5). In human 
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there are 4 types of LTBPs, of which LTBP-1, -3 and -4 contain cysteine repeats that are 
responsible for the binding to TGFβ/LAP complex. LTBP2 does not bind any of the 
TGFβ/LAP complexes, but it does bind microfibrils where it may play a structural role or 
participate in formation of microfibril-associated protein complexes by competing with other 
LTBPs for binding to fibrillin-1 (Hirani et al. 2007). PMEPA1 has been found to negatively 
regulate growth of androgen responsive cells, and these functions may be mediated through 
the interaction of PMEPA1 with NEDD4 protein (neural precursor cell expressed 
developmentally down-regulated protein 4) involved in the ubiquitin-proteasome pathway (Li 
et al. 2008). Reduced PMEPA1 expression was found in prostate cancer but elevated 
expression in breast cancer (Xu et al. 2003). PMEPA1 has been found to be strongly 
induced by TGFβ (Brunschwig et al. 2003) and involved in a negative feedback loop in TGFβ 
signalling pathway by inhibiting the phosphorylation and translocation of SMAD3 (Watanabe 
et al. 2010).  
The effects of CTGF and activin A stimulations on the four target genes were validated using 
single Taqman RT-PCR. The same results were reproducible in both human chondrocytes 
and dermal fibroblast, where CTGF and PMEPA1 gene expression showed the greatest 
change, followed by LTBP2 and BMPR2. Time course experiments showed that the 
response of BMPR2 and PMEPA1 gene expression to CTGF were early and transient 
whereas the response to activin A was late and persistent. The gene expression of LTBP2 
following both CTGF and activin A stimulation was late, but declined after 24hr with CTGF 
stimulation while staying constant beyond 48hr with activin A stimulation. This result 
suggested the induction of a secondary mediator in activin A stimulated cells.  
Cycloheximide (CHX), which inhibits all newly synthesised protein, abolished the late gene 
response of activin A while not to that of TGFβ, confirming that there is a secondary protein 
being synthesised during activin A treatment. One candidate gene induced by activin A that 
could lead to late gene induction was CTGF. Knockdown of endogenous CTGF was unable 
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to reduce the late gene induction caused by activin A, indicating that CTGF was not the 
intermediate molecule involved in activin A’s action. PMEPA1 and BMPR2 are also likely to 
be the early-induced mediator (expression peaked at 4hr and 8hr respectively) of activin A 
for its late gene induction. To test this, knockdown effect of these genes can be looked at 
and whether PMEPA1 and BMPR2 can induce other genes (e.g. CTGF and LTBP2) can 
also be examined. 
The data obtained from the microarray study has been very interesting; I have identified four 
strongly CTGF-induced genes. These same four genes were also induced by activin A in 
human chondrocytes although the effects of activin A were not dependent upon CTGF 
expression. The reason why CTGF and activin A share similarities in gene regulation and 
share a relatively restricted gene expression profile remains unanswered. However it is 
notable that both molecules are closely linked to TGFβ; activin A is a TGFβ family member 
and signals through the SMAD signalling pathway; CTGF is known to bind to TGFβ itself to 
modulate signalling at the TGFβ receptor (Abreu et al. 2002); and finally all four genes that 
were identified on the microarray are known to be TGFβ-induced. The role of CTGF in TGFβ 
signalling and bioavailability was next investigated.  
!
!
!
!
!
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Part II Role of CTGF in TGFβ  signalling and bioavailability 
4.4 Introduction 
CTGF has been proposed to act closely with TGFβ. During wound repair and fibrotic 
disorders, both CTGF and TGFβ mRNA and protein levels are found elevated at sites of 
damage (Igarashi et al. 1993; Kulozik et al. 1990) and increased connective tissue formation 
by TGFβ has been proposed to occur via an indirect mechanism involving CTGF 
(Grotendorst, 1997). The CTGF gene is strongly induced by TGFβ, but is not induced to any 
significant level by other growth factors including EGF, FGF, PDGF and insulin or IGFs 
(Igarashi et al. 1993). Many activities exhibited by CTGF are also similar to the actions of 
TGFβ. For example, CTGF stimulates cell proliferation in monolayer cultures of normal rat 
kidney (NRK) fibroblasts, which is a characteristic of TGFβ stimulation in the same assay 
(Frazier et al. 1996). CTGF is also reported to induce type I collagen, fibronectin and α5 
integrin expression in NRK fibroblasts, which is another action shared with TGFβ (Frazier et 
al. 1996). A number of studies suggest that CTGF acts as a mediator or cofactor for TGFβ 
family members.  Abreu et al (2002) showed that CTGF binds to both TGFβ1 and BMP4. 
This stabilises the binding of TGFβ to its receptor but inhibits the binding of BMP-4 to its 
receptor. The same authors also showed that CTGF was able to potentiate the effect of 
TGFβ on phosphorylating SMAD2 (Abreu et al. 2002). Song et al (2007) showed that 
silencing of CTGF expression using siRNA could inhibit mesenchymal cell condensation 
mediated by TGFβ, and Kothapalli et al (1997) showed antisense of CTGF was able to 
inhibit TGFβ induced anchorage independent growth of cells (Song et al. 2007; Kothapalli et 
al. 1997). 
In human chondrocytes, we found CTGF was strongly up-regulated by TGFβ1 and activin A 
(Figure 4.13C). The three genes (PMEPA1, LTBP2 and BMPR2) that it induced were known 
to be TGFβ-induced and were related to TGFβ family signalling pathways. This suggested 
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that CTGF might act indirectly by modulating the effects of TGFβ family proteins. Therefore it 
was decided to investigate the role of CTGF in TGFβ-induced responses. 
4.5 Results 
4.5.1 TGFβ also induces the expression of the four identified CTGF inducible genes 
If CTGF was acting indirectly through the action of TGFβ family proteins, it was first 
important to investigate whether TGFβ was also able to induce the expression of the four 
identified genes itself. A time course experiment was first carried out in NHDFs with TGFβ1 
stimulation for 4hr, 8hr and 24hr and the RNA was extracted for the analysis of relative gene 
expression of CTGF, PMEPA2, LTBP2 and BMPR2 using RT-PCR. Unsurprisingly, TGFβ 
was able to induce these four genes strongly (Figure 4.15). Similar to that which we had 
observed for CTGF stimulation, the regulation of PMEPA1 and BMPR2 to TGFβ stimulation 
was also early and transient: peaked at 4hr and declined after 8hr. For LTBP2, the fold of 
induction increased at late time points, from 3.5 fold at 4hr and 8hr to 5.5 fold at 24hr. 
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Figure 4.15 TGFβ induces the gene expression of CTGF, PMEPA1, LTBP2 and BMPR2 in NHDFs.  NHDFs 
were stimulated with or without TGFβ1 at 10ng/ml for 4, 8, or 24hr. Gene expression of CTGF, PMEPA1, LTBP2 
and BMPR2 were measured using RT-PCR. Bars represent one experiment (n=1). 
 
4.5.2 CTGF knockdown did not affect TGFβ1 induced gene expression 
Strong induction of CTGF by TGFβ1 can be seen at early time points (as early as 4hr). 
Therefore it was possible that TGFβ induced gene expression was through CTGF. To test 
this, CTGF RNA expression was silenced by siRNA oligo A (siCTGF) (siSCR was used as 
control) in cells prior to stimulation with or without TGFβ for 8hr. RNA was then extracted 
and analysed for gene expression (CTGF, PMEPA1 and LTBP2). 90% of CTGF RNA was 
silenced using siRNA oligo A (Figure 4.16). In cells transfected with siSCR, CTGF mRNA 
increased by 105.52 fold (mean of several experiments) upon TGFβ1 stimulation. siCTGF 
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transfected cells showed approximately 90% reduction in CTGF gene expression either with 
or without TGFβ1 stimulation. No change was observed in gene expression of PMEPA1 and 
LTBP2 upon TGFβ stimulation when CTGF had been silenced, indicating that the effects of 
TGFβ on these genes were not dependent upon induced or constitutive CTGF. 
 
 
 
 
!
!
!
!
!
 
Figure 4.16 CTGF knockdown did not affect TGFβ induced gene expression. NHDFs were transfected with 
siSCR or siCTGF oligo A for 48hr and stimulated with or without TGFβ1 at 10ng/ml for 8hr. Gene expression of 
CTGF, PMEPA1 and LTBP2 was measured using RT-PCR. RNA of CTGF was reduced by 90% upon silencing. 
Gene expression of PMEPA1 and LTBP2 did not show significant change between siSCR and siCTGF treated 
cells. Bars represent fold change in gene expression with error bars representing the standard error of the mean 
(n=3, ns: not significant, *** p<0.001). 
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4.5.3 TGFβ family type 1 receptor inhibitor SB431542 attenuated CTGF induced gene 
expression and SMAD2 activation 
So far, TGFβ, activin A and CTGF have all been showed to induce the PMEPA1, LTBP2 and 
BMPR2 but the pathway through which this occurs has not been examined. It is known that 
the canonical signalling pathway of TGFβ family members is via phosphorylation of SMAD 
proteins. Ligands first bind to their specific type II receptor which recruits the type I receptor. 
A small molecule inhibitor SB431542 selectively inhibits ALK4 (activin A type I receptor) and 
ALK5 (TGFβ type I receptor), thus suppresses activin A and TGFβ SMAD2/3 signalling but 
not BMP SMAD1/5/8 signalling. Therefore, by using a receptor inhibitor we can determine 
whether CTGF induces the three genes through the TGFβ/activin A receptor signalling 
pathway. NHDFs were treated with TGFβ1, activin A, CTGF or BMP2 in the presence or 
absence of SB431542 for 8hr and the gene expression of CTGF and PMEPA1 was 
measured (CTGF and PMEPA1 are most strongly induced by these ligands). SMAD 
activation was detected using anti-phospho-SMAD antibodies by western blotting. 
Stimulation of cells in the presence of SB431542 reduced TGFβ and activin A induced gene 
expression, confirming that the canonical TGFβ pathway was responsible for this TGFβ and 
activin A mediated change in gene expression (Figure 4.17). SB431542 also inhibited CTGF 
induced gene expression. This suggested that CTGF was acting through the ALK5 or ALK4 
receptor (perhaps as a cofactor for TGFβ or activin A), or that the inhibitor had non-specific 
inhibitory effects or caused toxicity to the cells. This latter possibility was unlikely as similar 
quantities of good quality of RNA were extracted from all samples (with and without 
SB431542). Also, no inhibition of phosphorylation of BMP2 activated SMAD1/5/8 was seen 
after 45min, while phosphorylation of SMAD2 upon stimulations of TGFβ, activin A and 
CTGF was abrogated (Figure 4.18). This indicates that the effects of CTGF are acting 
through the TGFβ/activin A signalling pathway. 
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Figure 4.17 CTGF induced gene expression was inhibited by TGFβ/activin A type I receptor SB431542. 
NHDFs were treated with TGFβ1 at 10ng/ml, activin A at 100ng/ml, BMP2 at 100ng/ml or CTGF at 100ng/ml for 
8hr in the presence or absence of SB431542 at 5µM.  Gene expression of CTGF and PMEPA1 was measured 
using RT-PCR. Figure shows mean of gene expression with error bars represent the standard error of the mean 
(n=3 ** p< 0.01, *p <0.05). Only two experiments were performed on BMP2 stimulation, therefore no statistical 
test was done for BMP2.  
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Figure 4.18 CTGF activated SMAD2 but not SMAD1/5/8, which was inhibited by TGFβ/activin A type I 
receptor SB431542. NHDFs were treated with TGFβ1 at 10ng/ml, activin A at 100ng/ml, BMP2 at 100ng/ml or 
CTGF at 100ng/ml for 45min in the presence or absence of SB431542 at 5µM. Lysates were western blotted for 
phospho-SMAD2 or phospho-SMAD1/5/8. Tubulin was used as a loading control. n=3 
 
4.5.4 CTGF does not act synergistically with either TGFβ or activin A 
In order to investigate whether CTGF acts independently through the TGFβ receptor or as a 
cofactor for TGFβ family ligands, we looked for a synergistic effect of CTGF and TGFβ 
proteins. First, a dose response experiment was carried out (Figure 4.19). NHDFs were 
treated with either CTGF (0-400ng/ml), activin A (0-400ng/ml) or TGFβ1 (0-10ng/ml) for 8hr 
and gene expression of CTGF, PMEPA1 and LTBP2 was measured. CTGF induced gene 
expression increased gradually with the increasing concentration of CTGF from 10 to 
400ng/ml, with a strong induction in gene expression of PMEPA1 and CTGF (Figure 4.19A). 
Activin A induced CTGF and PMEPA1 expression showed an increasing pattern from 5 to 
400ng/ml, while gene expression of LTBP2 plateaued at 20ng/ml (Figure 4.19B). TGFβ was 
able to induce the genes strongly at as low as 2ng/ml, suggesting that TGFβ is a potent 
ligand. TGFβ induced gene expression increased with the concentration of TGFβ from 2 to 
10ng/ml (Figure 4.19C). 
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Figure 4.19 Genes responded to ligands in a dose dependent manner. NHDFs were treated with either 
CTGF (A), activin A (0.2 to 400ng/ml) (B) or TGFβ1 (0.1 to 10ng/ml) (C) for 8hr. Gene expression of CTGF, 
PMEPA1 and LTBP2 was measured relative to GAPDH. Bars represent relative gene expression from one 
experiment (n=1). 
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For synergistic experiments, NHDFs were treated with suboptimal dose of CTGF (40ng/ml), 
activin A (50ng/ml) and TGFβ1 (1ng/ml) alone or in combinations for 8hr. CTGF and 
PEMPA1 mRNA levels were measured and the fold changes were compared between the 
‘alone’ and combined treatments. Optimal dose stimulations of activin A (400ng/ml) and 
TGFβ (10ng/ml) were also used to illustrate the maximal inductions for the two genes. For 
the synergy experiment of CTGF and activin A, the fold change in each ‘alone’ stimulation 
adds up to that of the combined stimulation, suggesting a possible additive effect of CTGF to 
activin A on the expression of the two genes (n=1, not statistically tested) (Figure 4.20A and 
B). For CTGF and TGFβ, addition of a suboptimal dose of CTGF to TGFβ did not show an 
additive effect. Indeed, there was no significant difference between TGFβ alone and in 
combination for either CTGF or PMEPA1 mRNA regulation (Figure 4.20C and D). I was able 
to confirm that at these suboptimal doses in all four experiments maximal gene induction had 
not been reached. 
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Figure 4.20 CTGF showed additive effect to activin A while no additional effect to TGFβ in the gene 
expression of CTGF and PMEPA1. NHDFs were treated with CTGF (40ng/ml) or activin A (50ng/ml) (A and B 
n=1) /TGFβ1 (1ng/ml) (C and D n=3) alone or in combination. Gene expression of CTGF and PMEPA1 was 
measured relative to GAPDH. Result shows additive effect of CTGF to activin A (not statistically tested) and no 
effect of CTGF on TGFβ1 induced gene expression. ns= not significant. 
 
4.5.5 Anti-TGFβ neutralising antibody abolishes CTGF induced SMAD2 activation and 
gene regulation 
It is known that TGFβ and activin A are constitutively expressed by articular chondrocytes 
(Vivien et al. 1995; Hermansson et al. 2004). Thus it was possible that CTGF was able to 
interfere, in some way, with the activity of these endogenous proteins. To test this, CTGF 
induced SMAD2 activation and gene expression were now analysed in the presence or 
absence of neutralising antibody specific to TGFβ or activin A. Porcine articular 
chondrocytes were treated with TGFβ1, activin A or CTGF in the presence of IgG (as an 
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isotype control), anti-TGFβ or anti-activin A. Figure 4.21A shows strong activation of SMAD2 
by all the stimulators in the presence of the control immunoglobulin IgG. In the presence of 
the anti-TGFβ antibody, the signal of the pSMAD2 induced by TGFβ1 was largely inhibited 
and interestingly the activation by CTGF was also completely inhibited by the anti-TGFβ 
antibody, whereas anti-activin A antibody had only minor effect on the action of CTGF. 
CTGF induced gene expression of CTGF was also inhibited by anti-TGFβ neutralising 
antibody by about 70%, suggesting the action of CTGF in articular chondrocytes is likely to 
be TGFβ dependent (Figure 4.21B). 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 The activity of CTGF in SMAD2 activation and gene expression was inhibited by anti-TGFβ 
neutralising antibody. Porcine articular chondrocytes were treated with TGFβ1 (10ng/ml), activin A (100ng/ml) 
or CTGF (100ng/ml) in the presence of mouse IgG, anti-TGFβ, anti-activin A antibodies. The signal of pSMAD2 
was measured by western blot (A). The gene expression of CTGF/GAPDH was measured by RT-PCR (B) n=2. 
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4.5.6 No detection of TGFβ protein contamination in the CTGF recombinant protein 
sample 
The inhibitory effect of the TGFβ neutralising antibody on CTGF suggests that the action of 
CTGF requires the presence of TGFβ protein. Therefore it was important to determine the 
source of the protein. The first consideration was that whether our recombinant CTGF 
protein sample was contaminated with TGFβ protein. To test this, I immunoblotted our 
recombinant CTGF protein with an antibody against all the TGFβ isoforms, i.e. TGFβ1, 2 
and 3.  Commercially purchased recombinant TGFβ1 protein was used as a positive control. 
The presence of TGFβ1 monomer (12.5kDa) and dimer (25kDa) were detected from 0.1ng 
by western blot and were seen to increase with increasing doses of TGFβ1 (0.1 to 4ng). 
TGFβ1 propeptide (60kDa) also started to appear from 0.5ng. No TGFβ was detected in the 
CTGF sample at either 40 or 100ng despite strong CTGF immunostaining evident in these 
lanes. From the previous dose experiment of TGFβ (Figure 4.19), at least 0.2ng of TGFβ 
was needed to change gene expression (Figure 4.19C), thus ruling out significant TGFβ 
contamination as an explanation for the above observation. 
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Figure 4.22 No detection of TGFβ1, 2, 3 in the recombinant CTGF samples. Recombinant TGFβ (rTGFβ1) 
and CTGF (rCTGF) were analysed by western blot at 0.1 to 4ng and 40 and 100ng respectively for TGFβ1, 2, 3 
and CTGF. n=1 
 
4.5.7 Recombinant CTGF increases TGFβ protein level  
Knowing that the activity observed for CTGF was not due to TGFβ contamination, I decided 
to determine whether CTGF could control level of TGFβ protein. To test whether CTGF 
induces TGFβ protein synthesis, porcine chondrocytes were treated with recombinant CTGF 
at 100ng/ml for different time points and the relative gene expression level of TGFβ1 was 
measured against GAPDH. As shown in figure 4.23A, there was no significant gene 
induction was observed at any time point used in the experiment (Figure 4.23A). The protein 
level of TGFβ was also studied. Porcine chondrocytes were treated with TGFβ1 at 10ng/ml 
or CTGF at 100ng/ml for 45min. After the stimulation, the conditioned medium was collected 
and western blotted for TGFβ. The cell layer was then washed and lysed in RIPA buffer and 
the lysates were western blotted for pSMAD2, TGFβ and tubulin.  Again CTGF and TGFβ1 
strongly induced the phosphorylation of SMAD2. TGFβ protein was strongly detected in the 
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lysate of TGFβ1 treated cells, which possibly contained internalised recombinant TGFβ 
protein as not much TGFβ was detected in the conditioned medium after exogenous TGFβ 
was added. In the CTGF treated cells, a small amount of TGFβ was detected in the cell 
lysate, slightly stronger than the control; and no detection of TGFβ in the conditioned 
medium (Figure 4.23B). CTGF did not seem to increase the level of TGFβ protein in isolated 
chondrocytes. However, when I used porcine cartilage explants (with an intact ECM), I was 
able to detect TGFβ protein accumulation in the conditioned medium after 1hr CTGF 
stimulation (Figure 4.23C). These results suggest that CTGF can rapidly modulate TGFβ 
protein levels in tissues with an intact extracellular matrix. From the basis of these 
experiment I formulated a novel hypothesis that CTGF can control the bioavailability of 
matrix-bound TGFβ. 
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Figure 4.23 CTGF did not induce TGFβ protein synthesis but the release from the extracellular matrix. 
Porcine chondrocytes were treated with recombinant CTGF at 100ng/ml for 5min to 48hr and the relative gene 
expression of TGFβ was measured by RT-PCR n=3 (A). For protein porcine chondrocytes were treated with 
TGFβ (10ng/ml) or CTGF (100ng/ml) for 45min and the cell lysates and the conditioned medium were analysed 
for pSMAD2 and TGFβ (B). Porcine cartilage was treated with CTGF at 100ng/ml for 1 or 4hr and the conditioned 
medium was analysed for TGFβ (C). 
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4.6 Discussion 
The bioactivities of the four genes identified from microarray suggested that CTGF may be 
involved in somehow TGFβ induced activities. We first tested whether TGFβ also induced 
the four genes.  Unsurprisingly (from the literature), TGFβ strongly induced PMEPA1 (90 
fold), LTBP2 (5 fold) and BMPR2 (2.5 fold) in addition to CTGF (100 fold). The pattern of 
expression of the genes induced by TGFβ1 in the time course experiments was similar to 
that which we observed following CTGF stimulation. The response of PMEPA1 and BMPR2 
appeared to be early and transient whereas LTBP2 expression was persistent and increased 
at later time points. One possibility was that TGFβ regulated gene expression through CTGF. 
To test this, CTGF RNA was silenced using siRNA in these cells prior to stimulation with 
TGFβ. Upon CTGF knockdown, no change was seen in the gene expression levels of 
PEMPA1 and LTBP2 following TGFβ stimulation.  
The type I receptor inhibitor SB431542 significantly reduced gene induction of CTGF, 
PMEPA1 and LTBP2 induced by CTGF, TGFβ and activin A stimulation. The specificity of 
the inhibitor was examined by showing that it did not inhibit phospho-SMAD1/5/8 following 
BMP2 stimulation. In the blot, we observed the pSMAD2 band for CTGF stimulation with 
relative lower intensity and this band disappeared when SB431542 was added. It is unlikely 
that CTGF directly acts through the TGFβ or activin A receptor to activate SMAD2/3 
signalling pathway as there has not been any report showing CTGF directly binds to the 
receptors of TGFβ family proteins. It is more likely that CTGF indirectly elevates basal 
SMAD2/3 signals by binding to endogenous TGFβ or activin A, which stabilises their binding 
to the receptors thus potentiating SMAD2/3 signalling. This supports one published theory 
that CTGF acts as a cofactor to promote TGFβ signals (Abreu et al. 2002). A second 
possibility is that CTGF promotes SMAD2/3 signals by disturbing the negative feedback loop; 
there have been reports to suggest that CTGF suppresses the gene expression of the 
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negative regulator SMAD7 (Wahab et al. 2005). Both of these latter responses dependent 
upon some endogenous production of TGFβ or activin A, or require it to be present within 
cultures (it could be bound to matrix). Either way inhibiting TGFβ or activin A (by siRNA or 
neutralising antibody) should suppress the apparent biological effects of CTGF. Experiments 
looking for synergy between CTGF and TGFβ or activin A would provide further evidence for 
this. When suboptimal doses of CTGF and activin A or CTGF and TGFβ were used, no 
synergistic effect on regulation of CTGF or PMEPA1 was seen, indicating that CTGF does 
not potentiate the activity of activin A or TGFβ. When using neutralising antibodies to 
endogenous TGFβ (but not activin A), CTGF-induced SMAD2 activation and gene regulation 
was inhibited, suggesting that the effects of CTGF require the presence of TGFβ protein. I 
confirmed that this TGFβ protein was not from our recombinant CTGF preparation as a 
contaminant and was not newly synthesised upon CTGF stimulation.  
TGFβ is known to be synthesised as a propeptide and secreted as a latent complex stored 
in the extracellular matrix through binding to the LTBP protein. The activation of TGFβ 
involves the release of latent complex from the matrix pool and dissociation of mature TGFβ 
dimer from the latent complex (Taipale et al. 1998). It is possible that the endogenous TGFβ 
involved in the action of CTGF has been released from its matrix pool. Indeed only 
stimulation of articular cartilage explants, which possess an extensive extracellular matrix, 
caused rapid release of TGFβ into the medium. This suggests that CTGF increases the 
bioavailability of matrix bound TGFβ. Appropriate control of TGFβ bioavailability is important 
for correct cell responses. Inappropriate TGFβ activation observed in the Marfan syndrome 
causes excessive production of matrix, resulting abnormalities in various tissues such as 
limbs, heart and lungs (Neptune et al. 2003). The question how CTGF may be involved in 
latent TGFβ activation in articular cartilage is addressed in the chapter 5. 
!
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Part I Study of injury response using normal porcine cartilage 
5.1 Introduction 
5.1.1 Response of articular cartilage to mechanical injury  
Mechanical injury on cartilage predisposes the joint to OA. Cuts or damage made on the 
surface of mature articular cartilage are thought to make an attempt at repair when defects 
extend to the subchondral bone. This leads to a fibro-cartilaginous tissue which fills the 
defect albeit with inferior mechanical integrity compared with hyaline cartilage. This was 
demonstrated by Ghadially’s group who produced partial-thickness defects (not extending to 
subchondral bone) in the articular cartilage of rabbits and found no evidence for repair over a 
2-year period. In these cases, a thin layer of matrix was formed over the injured surface 
early after injury, although they concluded that it was abraded away by joint movement 
(Ghadially et al. 1976). The lack of repair may be due to the inability of mature articular 
chondrocytes to divide or mount a sufficient repair reaction in magnitude to fill the defect 
(Bennett and Bauer 1932). Conversely, deeper defects that violate the underlying bone are 
rapidly filled with blood containing red and white blood cells and bone marrow elements 
(Campbell et al. 1969). These white and undifferentiated cells, which likely contain 
mesenchymal progenitor cells, form vascular fibroblastic repair tissue at the base of the 
wound (De Palma et al. 1966). Mitchell and Shepard demonstrated that such repair tissue 
was then converted to a hyaline-like chondroid tissue in the early course of deep defects in 
rabbits, with increased mitotic activity and histological staining showing increased 
proteoglycan. Despite this, after 12 months of the injury the repairing tissue became more 
fibrous rather than cartilaginous (Mitchell and Shepard 1976). Such tissue has reduced 
mechanical material functions, which may be acceptable if the defect is not too large. For 
larger defects, excessive mechanical load on newly constructed tissue is likely to result the 
development of OA (Radin et al. 1991). 
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5.1.2 Growth factors released upon mechanical stimuli to articular cartilage 
These historical studies suggest that there are early innate cellular responses in place to 
respond to cartilage injury. Such cellular responses are likely to be mediated in part by the 
mechanically induced release of growth factors. Tonia Vincent’s group discovered that 
mechanically injured or compressed articular cartilage led to the release of fibroblast growth 
factor 2 (FGF2) from a pericellular matrix-bound pool (Vincent et al. 2004). Released FGF2 
activated the ERK MAPK pathway and induced the synthesis and secretion of tissue inhibitor 
of metalloproteinase 1 (TIMP-1) from injured cartilage explants (Vincent et al. 2004).  
 
In my study (chapter 3) I found that explanting (cutting cartilage at the osteochondral junction) 
or recutting (cutting previously explanted and rested) articular cartilage resulted in the 
release of CTGF into the medium. This is perhaps not surprising as CTGF has similar 
physical properties to sequestered FGF2, and is also localised in the pericellular matrix and 
binds to perlecan through the heparan sulphate chains (chapter 3). In this chapter I will 
describe the consequences of CTGF release with specific reference to TGFβ activation. 
 
5.1.3 TGFβ  latency 
5.1.3.1 Latent form of TGFβ  
TGFβ is synthesised as a pre-pro-peptide containing an N-terminal secretion signal peptide, 
a latency associated peptide (LAP) or propeptide and a C-terminal TGFβ active peptide. Two 
TGFβ proprotein monomers associate to form homodimers linked by disulfide bonds (Gray 
and Mason 1990). During secretion, mature TGF-β is cleaved from its propeptide (LAP) by 
furin-like endoproteinase at a cleavage site (R-X-R/K-R) at the end of the propeptide (LAP) 
sequence (Leitlein et al. 2001). The LAP dimer remains associated with the TGF-β dimer by 
non-covalent interactions while both the mature TGF-β dimer and the LAP dimer are 
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disulfide bonded (Shi et al. 2011). The latent TGF-β complex consisting of LAP and TGF-β is 
referred as TGF-β small latent complex (SLC). The association between active TGF-β and 
its LAP propeptide is reversible and involves extensive structural changes in the LAP (Shi et 
al. 2011). The type of LAP is named after the TGFβ isomer that it associates with, for 
example LAP1 for TGFβ1. In cartilage, 40% of TGFβ produced is in TGFβ1 isoform with 
TGFβ2 and 3 at lesser abundance (Kanaan and Kanaan 2006). Therefore the antibody used 
to detect LAP in the injury-conditioned medium (CM) in the following experiments was only 
specific to LAP1 (see section 5.2.2). 
When latent complexes of TGFβ were characterised, the complexes were found to contain 
another high molecular weight protein, which was cloned and named as latent TGFβ binding 
protein (LTBP) (Miyazono et al. 1991). LTBP is able to form a disulfide bond with the 
propeptide (LAP) of TGFβ to form large latent complexes (LLCs). It was subsequently found 
that TGFβs are mainly secreted as LLCs, consisting of TGFβ SLC covalently bound to LTBP 
(Taipale et al. 1996). In vitro studies have shown that the SLC is secreted very slowly and 
the majority of it is retained in the Golgi body (Miyazono et al. 1991). LTBP is secreted very 
rapidly, and enhances the secretion of TGFβ into LLCs (Taipale et al. 1996; Miyazono et al. 
1991). LTBP also plays a role to target TGFβ to the extracellular matrix (ECM). This is 
achieved by interaction between LTBP and fibronectin or fibrillin. Fibrillins show structural 
homology with LTBP in the epithelial growth factor (EGF) like repeats and eight cysteine 
residue repeats. There are four LTBP isomers have been characterised, amongst which 
LTBP-1, -3 and -4 (LTBP-2, cannot bind TGF-β) are able to form LLCs (Munger and 
Sheppard 2011). 
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5.1.3.2 TGFβ  activation 
Most cells secrete TGFβ in a latent form. The activation of latent TGFβ involves the release 
of the SLC from the ECM pool followed by disruption of the non-covalent interaction between 
LAP and TGFβ or direct release of active TGFβ from matrix bound LLC, enabling TGFβ to 
bind its cell surface receptors. The existence of different TGFβ isoforms and latent forms, as 
well as the number of different LTBPs suggest that multiple pathways exist for the activation 
of TGFβs.  
The in vitro activation methods of TGFβ include acidic or basic pH, heat treatment or 
different chaotropic agents (Lawrence et al. 1985). These in vitro conditions are used in 
many TGFβ purification procedures, thus the purified TGFβ is frequently obtained in its 
active state.  
Proteolysis (Lyons et al. 1988; Lyons et al. 1990; Abe et al. 1998), acidic cellular 
microenvironments (Jullien et al. 1989), the matrix protein thrombospondin (TSP) (Schultz-
Cherry and Murphy-Ullrich 1993) as well as integrin αvβ6 (Munger et al. 1999) have all been 
proposed to mediate TGFβ activation under physiological conditions. Proteolysis is involved 
in the release of the SLC from the ECM through cleavage of LTBP as well as the release of 
active TGFβ by degrading the LAP propeptide. TSPs are large, multimeric proteins that are 
able to activate both the LLC and recombinant SLC (Schultz-Cherry and Murphy-Ullrich 
1993). The activation mechanism involves the interaction of N-terminal end of LAP and the 
type I repeats of TSP possibly by inducing a conformational change in LAP thus it is no 
longer able to trap the active TGFβ dimer (Schultz-Cherry and Murphy-Ullrich 1993). This 
activation can be achieved with small peptides having the KRFK amino acid sequence. 
Integrins such as αvβ6 are also able to activate TGFβ1 (Munger et al. 1999). The LAP 
propeptide contains an RGD-motif that is recognised by integrins αvβ1 and αvβ6 (Munger et al. 
1999). Similarly, binding of integrin to LAP also induces a conformational change in LAP, 
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which as a result releases active TGFβ. The action of integrin can also be combined with 
proteolysis. The SLC presented by integrin on the cell surface becomes accessible by 
proteases such as MMP2 and 9 (Yu and Stamenkovic 2000). However, mice with mutations 
in MMP2 and MMP9 genes can still activate TGFβ and do not show any TGFβ deficiency 
phenotypes possibly suggesting redundancy among the activating enzymes (Annes et al. 
2003). 
5.1.3.3 TGFβ  in cartilage 
In cartilage, TGFβ is one of the most extensively studied regulators (Blaney Davidson et al. 
2007) due to well-characterised ability to regulate the biosynthesis of a large number of 
cartilage extracellular matrix molecules (Chandrasekhar and Harvey 1988; O’Keefe et al. 
1988; Recklies et al. 1998; Redini et al. 1988; Niikura and Reddi 2007; Schmidt et al. 2008). 
However, the extracellular regulation of TGFβ activity and the physiologic mechanisms 
through which chondrocytes access the growth factor continue to be unclear.  In articular 
cartilage, TGFβ is also secreted in latent form and stored in the cartilage ECM as LLCs 
(Annes et al. 2003; Hyytiäinen et al. 2004). Although various mechanisms of TGFβ activation 
have been characterised in a number of tissues, studies have rarely addressed these 
mechanisms in articular cartilage. MMP3 (Maeda et al. 2001), MMP13 (D’Angelo et al. 2001) 
and transglutaminase (Le et al. 2001) have been shown in vitro to play a role in TGFβ 
activation in growth plate cartilage or aging articular cartilage. Mechanical forces may also 
activate TGFβ. This idea was originally demonstrated in myofibroblasts, where integrin-
mediated cellular contractions were shown to pull on matrix bound latent TGFβ to induce 
activation (Wipff et al. 2007). This was then followed by a study by Ahamed et al, who 
demonstrated that mechanical shearing of blood serum was able to activate soluble TGFβ in 
the absence of integrins and cells (Ahamed et al. 2008; Ahamed et al. 2009). Using the 
same concept, Albro’s group reported that shearing synovial fluid could also activate the 
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latent TGFβ present in it (Albro et al. 2012). It was postulated that hyaluronan 
macromolecules present in the synovial fluid, when sheared, become entangled with the 
latent TGFβ complex to break its weak non-covalent bond between LAP and TGFβ. When 
the same group carried out mechanical loading of bovine articular cartilage they were unable 
to demonstrate TGFβ activation (Albro et al. 2013). The studies I will now present show that 
TGFβ is activated by mechanically damaged articular cartilage and reveal a novel 
mechanism of TGFβ release and activation. 
 
5.2 Results 
5.2.1 Release of TGFβ protein in response to porcine cartilage injury 
Having demonstrated that recombinant CTGF increased TGFβ release from rested porcine 
articular cartilage (section 4.5.7) and cartilage injury led to the release of endogenous CTGF 
in the conditioned medium (section 3.2.4), I next investigated whether the endogenous 
CTGF released from cartilage matrix in response to cartilage injury had effect on the 
bioavailability of TGFβ.  
Porcine cartilage explants were rested in serum free medium for 48hr and recut conditioned 
medium (CM) was collected at various time points. Cumulative collection (collecting 
everything over the entire time period) of recut CM was made in the presence or absence of 
CHX. Samples were western blotted for CTGF and TGFβ. In these experiments, CTGF was 
detected as early as 15min and these levels were maintained over longer time points (1hr, 
18hr and 24hr) (Figure 5.1A). In contrast, TGFβ was detected only after 1hr following 
recutting and increased in the medium at later time points (Figure 5.1A). In the presence of 
CHX, both CTGF and TGFβ could still be detected, with a slight reduction in the amount of 
CTGF at longer time points (Figure 5.1B). This suggests that both CTGF and TGFβ are 
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passively released rather than require protein synthesis. They also suggest that CTGF is 
released first followed by a delayed release of TGFβ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Cartilage injury causes early release of CTGF, followed by delayed release of TGFβ. Dissected 
porcine cartilage explants were rested in serum free medium for 48hr and recut in fresh medium in the absence 
(A) or presence (B) of CHX (10ug/ml). The recut CM was collected cumulatively at various time points (from 5min 
to 24hr) and western blotted for CTGF and TGFβ. 
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5.2.2 TGFβ protein released in the CM in a latent complex containing LAP 
As described in the introduction, TGFβ is secreted in a large latent complex (LLC) and 
stored in the extracellular matrix through the interaction with LTBP. TGFβ activation involves 
liberation of the small latent complex (SLC) from the matrix and the release of the active 
TGFβ dimer at the cell surface. It was therefore important to determine whether the TGFβ 
protein detected in the cartilage injury CM was in a latent form. The CM had thus far been 
analysed in the presence of the reducing agent dithiothreitol (DTT) with boiling, which breaks 
disulfide bonds and non-covalent bonds respectively to linearise protein peptides. TGFβ 
protein detected under this reducing condition runs at 12.5kDa on gel electrophoresis, which 
represents the molecular weight of monomeric TGFβ. A small TGFβ latent complex consists 
of a disulfide bonded TGFβ dimer enclosed by a disulfide bonded LAP dimer via a non-
covalent interaction. To determine whether TGFβ detected in the CM was in the latent form, 
I electrophoresed the injury CM (explantation 48hr) under non-reducing conditions (without 
DTT) in addition to the reducing (with DTT) condition and western blotted with antibodies 
against TGFβ and LAP1. I also ran alongside positive controls of recombinant latent TGFβ1 
(latent TGFβ1) (10ng) and recombinant active TGFβ1 (TGFβ1) (1ng).  
As shown in figure 5.2, under the non-reducing conditions (lane 1 to 3), no immunoreactive 
material could be detected by the anti-TGFβ antibody in the latent TGFβ1 sample (lane 1) 
nor the injury CM (lane 3). However, this antibody was able to detect the TGFβ dimer 
(25kDa) band as well as a higher molecular weight band which was likely a multimer of 
TGFβ present in the TGFβ lane (lane 2). This suggests that there is no free TGFβ molecule 
in the latent TGFβ1 sample nor in the injury CM. In contrast, under reducing conditions (lane 
4 and 5), a protein band of 60kDa could be seen in the latent TGFβ1 sample (lane 4) and a 
strong 12.5kDa, 25kDa and a weak 37kDa bands were observed in the CM lane (lane 5). 
The 60kDa band observed in the latent TGFβ is likely to be the TGFβ pro-peptide, which has 
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been reported between 50 to 60kDa in other studies. The strong 12.5kDa and 25kDa bands 
seen in the CM are TGFβ monomer and dimer respectively. The strong detection of TGFβ in 
the CM under reducing condition but not non-reducing condition suggests that TGFβ 
released in the injury CM of porcine cartilage was in the latent form. Under non-reducing 
conditions, the TGFβ dimer is trapped in a ‘shield’ of LAP thus the antibody was unable to 
access its epitope probably explaining why no detection of TGFβ was seen under this 
condition. This phenomenon has also been reported by others (Kaur and Reinhardt 2012).  
On the right hand panel where anti-LAP1 antibody was used, under non-reducing conditions 
no band could be seen in the latent TGFβ1 (lane 6), whereas several intense high molecular 
weight bands (80kDa, 120kDa, 150kDa and 250kDa) were detected in the CM (lane 7). 
Under reducing conditions, the same 60kDa band (TGFβ propeptide) could be seen in the 
latent TGFβ1 lane (lane 8) and several weak bands between 80kDa and 30kDa were 
detected by the antibody in the CM lane (lane 9) (Figure 5.2). These results suggest that the 
purchased recombinant latent TGFβ is largely intact TGFβ proprotein and does not contain 
much SLC. The immunoreactive material detected by LAP antibody in the CM under non-
reducing condition had large molecular weight, implying the latent complex. It is not clear 
why there are so many immunoreactive LAP bands when the sample was reduced. The 
strong band at 75kDa is likely to be a LAP dimer. 
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Figure 5.2 Non-reducing analysis of injury CM revealed released TGFβ  molecules in latent form 
containing LAP. Explantation (48hr) CM was analysed under both non-reducing (no DTT) and reducing 
(containing DTT) conditions with heating and western blotted using antibodies against TGFβ (lane 1 to 5) and 
LAP1 (lane 6 to 9).  Arrows indicate the speculated protein for each band in the lanes. 
 
Although the TGFβ molecules released in the CM appeared to be in a latent form, I next 
examined whether this CM was capable of activating SMAD2 in porcine chondrocytes. 
Freshly isolated porcine chondrocytes were rested in serum free medium for 24hr and then 
treated with or without the explantation (48hr) CM in the presence or absence of anti-TGFβ 
neutralising antibody for 45min. The CM was also passed through a 50kDa cut-off 
ultracentrifuge spin column to separate protein molecules larger (>50kDa) or smaller 
(<50kDa) than 50kDa and then the two separated fractions were used to treat the cells at 
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equivalent concentration for 45min. Figure 5.3 shows the western blot of the cell lysates for 
phospho-SMAD2 (pSMAD2). The CM was able to activate SMAD2 similar to the positive 
control (TGFβ1). This activation was inhibited by TGFβ neutralising antibody, suggesting that 
activity is from TGFβ rather than another SMAD2 activator. This activity was present in the 
high molecular weight fraction (>50kDa) rather than the filtrate (<50kDa). This provides 
further support that TGFβ in the CM is present in a large complex. 
 
 
 
 
 
 
 
Figure 5.3 The explantation CM containing large TGFβ  protein molecules was able to activate SMAD2 in 
isolated porcine chondrocytes. Rested (24hr) porcine chondrocytes were treated with or without explantation 
(48hr) CM in the presence or absence of TGFβ neutralising antibody (left panel). Molecules in the CM were 
separated by a 50kDa cut-off spin column and the resulted fractions were used to treat rested porcine 
chondrocytes for 45min (right panel).  The lysates were analysed for pSMAD2 and tubulin for loading control.  
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5.2.3 TGFβ  activation in cartilage injury CM is not through integrins or MMPs 
There was no detection of free (active) TGFβ in the injury CM under non-reducing conditions 
suggesting that TGFβ activation took place at cell surface of the stimulated porcine 
chondrocytes. Reported mechanisms of TGFβ activation under physiological state involve 
mainly cell surface molecules including integrins and MMPs, which induce conformational 
change and cleavage of LAP respectively to release active TGFβ (Munger and Sheppard 
2011). To test whether integrins or MMPs are involved in TGFβ activation in cartilage I 
treated porcine chondrocytes with cartilage explantation CM in the presence or absence of 
integrin and MMP antagonists: synthetic RGD peptide and GM6001 respectively. Rested 
porcine chondrocytes were pre-incubated with or without RGD (500µM) or GM6001 (100µM) 
for 1hr before being stimulated with the explantation (48hr) CM in the presence or absence 
of the inhibitors for 45min. The cell lysates were then analysed for pSMAD2. As shown in 
figure 5.4, there is no difference in the pSMAD2 signal with and without the inhibitors. This 
may suggest that TGFβ activation in cartilage in not solely mediated by integrins or MMPs. 
 
 
 
 
 
Figure 5.4 Inhibitors of integrin or MMPs did not inhibit TGFβ  activation in chondrocytes. Rested porcine 
chondrocytes were pre-incubated with or without RGD (500µM) or GM6001 (100µM) for 1hr before being 
stimulated with the explantation (48hr) CM in the presence or absence of the inhibitors for 45min. The lysates 
were analysed for pSMAD2 and tubulin for loading control.  
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5.2.4 CTGF and LAP in the injury CM 
Since there was both LAP and TGFβ in the injury CM and activity was exclusively associated 
with a high molecular weight complex, I explored the relationship between these molecules 
further. Rested porcine cartilage explants were treated with recombinant CTGF (100ng/ml) 
for 1hr or recut and medium was collected cumulatively at various time points. The resulting 
CMs were analysed under reducing condition for CTGF, LAP and TGFβ. As shown in figure 
5.5, release of CTGF (37kDa) occurred within 5min of recutting and the protein level 
remained constant over time. The level of TGFβ protein (12.5kDa), as shown previously, 
was increased upon recombinant CTGF stimulation. TGFβ was not increased immediately 
after cutting, but accumulated in the CM over time as shown previously (Figure 5.5). 
Interestingly, LAP1 was also elevated by recombinant CTGF stimulation, and recutting 
caused LAP1 accumulation in the CM within the first 5min, decreasing at later time points 
(Figure 5.5). The predominant band picked up by the anti-LAP1 antibody in these 
experiments was at 75kDa, which coincides with the molecular weight of the LAP dimer. 
Repeated western blots under the same conditions also revealed LAP1 at 75kDa rather than 
its monomeric form of 37kDa, suggesting that reduction has been incomplete. 
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Figure 5.5 Reducing analysis of injury CM revealed release of LAP. Rested porcine cartilage explants were 
treated with recombinant CTGF (100ng/ml) for 1hr or recut and medium was collected for various times. The 
resulting CMs were analysed under reducing condition for CTGF, LAP and TGFβ. 
 
Analysis of the injury CM under reducing conditions showed that the accumulation of LAP1 
correlated better with levels of CTGF than TGFβ, so I examined the relationship between 
CTGF and LAP in the injury CM further. Explantation CM (5 to 120min and 4 to 48hr) was 
western blotted for CTGF and LAP1 under non-reducing conditions. Instead of running at 
37kDa and 75kDa for CTGF and LAP respectively, both CTGF and LAP ran at a high 
molecular weight (around 150kDa) on non-reducing SDS-PAGE (Figure 5.6), suggesting that 
CTGF and LAP may associate in a large molecular weight complex. Samples in the first blot 
were overloaded; strong bands were detected at various high molecular weights. These may 
be CTGF oligomers or complex with other proteins. Only a small portion of monomeric 
CTGF was detected at 37kDa at 24 and 48hr. This monomeric CTGF may be newly 
synthesised protein or be disassociated from the large complex. The early detection (within 
5min upon explantation) of both LAP and CTGF in the form of large complex may suggest 
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that SLC is released together with CTGF (in a pre-existing complex or independently and 
then rapidly bind to one another) in response to cartilage injury. Increased accumulation of 
high molecular weight CTGF and LAP at later time points may suggest continuous release of 
SLC as more CTGF being synthesised and complexes with the SLC to assist its release 
from the matrix pool. 
 
 
 
 
 
 
 
 
Figure 5.6 Non-reducing analysis of the explantation CM reveals that CTGF and LAP ran at high 
molecular weight. Porcine cartilage explants were dissected in serum free medium and the CM was collected 
after 5 to 120min or 4 to 48hr and then western blotted under non-reducing condition for CTGF and LAP.   
 
The explantation CM (48hr) was also analysed for TGFβ and LTBP1 under both the reducing 
(R) and non-reducing (N) conditions. As shown before, no TGFβ could be detected in the 
CM under non-reducing conditions, whereas under reducing conditions 12.5kDa (monomeric 
TGFβ) and 100kDa bands (may be SLC) could be detected by the same anti-TGFβ antibody 
(Figure 5.7). LTBP1 antibody could detect bands under both reducing and non-reducing 
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conditions at around 150kDa, which coincided with the molecular weight of the monomeric 
LTBP1. Under the non-reducing conditions, a higher molecular weight band (around 250kDa) 
was also detected by the LTBP1 antibody, which may be the large latent complex (LLC). 
CTGF was usually detected in the CM under non-reducing conditions at around 150kDa, 
which is likely in a complex that only contains a SLC. Therefore I only investigated the 
relationship between CTGF and LAP in the following studies. 
 
 
 
 
 
 
 
Figure 5.7 Non-reducing and reducing analysis of the explantation CM for TGFβ  and LTBP1. Porcine 
cartilage explants were dissected in serum free medium and after 48hr the explantation CM was collected and 
western blotted under both non-reducing conditions (N) and reducing conditions (R) for TGFβ and LTBP1.   
 
To confirm that the 150kDa band contained CTGF and LAP and to determine whether it also 
contained TGFβ, I extracted the protein from the gel piece containing the band and analysed 
it by western blot under reducing condition. The explantation (48hr) CM was electrophoresed 
under both reducing (R) and non-reducing (N) conditions. After electrophoresis, the gel was 
Coomassie-blue stained to visualise the bands of interest. I then cut off the gel piece around 
the 150kDa band (where CTGF and LAP co-migrate to under non-reducing conditions) from 
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the N lane and the 75kDa (LAP dimer), 37kDa (CTGF) and 12.5kDa (TGFβ) bands from the 
R lane. The gel pieces were transferred into new eppendorf tubes containing 100µl of 
extraction buffer (see 2.5.8). The gel pieces were minced using a scalpel and incubated in 
the buffer at 30°C overnight with shaking. The tubes were then centrifuged to spin down the 
gel pieces and the supernatant was collected and analysed by SDS-PAGE under reducing 
conditions. In figure 5.8, the left image shows the position where gel pieces were cut from 
the Coomassie-blue stained gel. The right image shows the western blot of the samples 
extracted from the gel pieces respectively (N1, R1, R2 and R3). The same blot was cut and 
probed for LAP, CTGF and TGFβ. As seen in figure 5.8, N1 contains a 100KDa protein that 
was also detected in R1 by anti-LAP1 antibody. N1 also contained a 37kDa protein that was 
detected in R2 by the anti-CTGF antibody. Despite seeing a clear TGFβ band in the reduced 
CM sample, the high molecular weight band did not appear to contain TGFβ. The 37KDa 
bands observed in N1 and R2 and the 12.5kDa band observed in R3 are CTGF and TGFβ 
respectively. The 100kDa picked up by the anti-LAP antibody has been seen in other 
experiments and may be the small latent complex of TGFβ although its mobility has not 
changed under reducing conditions. Overall, this experiment implies that the protein band 
around 150kDa observed on the non-reducing western blot contains CTGF, but it does not 
convincingly demonstrate the presence of small latent TGFβ.  
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Figure 5.8 The high molecular weight protein in injury CM contains CTGF. Cartilage explantation CM was 
electrophoresed under both reducing (R) and non-reducing conditions (N). The gel was Coomassie- blue stained 
and bands of interest were cut at appropriate molecular weights (150kDa from N1, 100~75kDa from R1, 37kDa 
from R2 and 12.5kDa from R3) (left image). Protein extracted from these gel pieces and analysed under reducing 
conditions by western blot for LAP, CTGF and TGFβ (right image).  
 
5.2.5 Purification of CTGF/TGFβ  SLC complex by chromatography 
I next attempted purification of the complex to determine whether CTGF and the SLC would 
co-purify. I used 2 methods of purification. The first method was ion exchange 
chromatography that separates proteins according to their charge. The second method was 
size exclusion chromatography which separates proteins according to size.  
5.2.5.1 Ion exchange chromatography 
For ion exchange, I used a 1ml HiTrap SP HP column which is an cation exchange column 
containing negatively charged resin that interacts with positively charged protein molecules. 
After removing debris by centrifugation, 1ml explantation (48hr) CM was diluted in 4ml 
binding buffer (1:5) and passed through the column. After adequate washing, resin bound 
proteins were eluted in 1 ml size fractions with increasing concentrations of NaCl. Figure 
5.9A is the profile of the ion exchange assay showing two large absorbance (280nm) peaks 
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between fractions 6 to 8 and several small peaks at fractions 3 to 4. The fractions (2 to 10) 
were analysed, alongside the starting material before (CM) and after (SM) 5 folds dilution in 
binding buffer. Western blots for CTGF and TGFβ (under reducing conditions) (Figure 5.9B) 
and LAP (under non-reducing conditions) (Figure 5.9C) are shown. As shown in the blot, 
CTGF (37kDa) could be detected in both the CM and SM (5 fold less concentrated than CM) 
and in the fractions of 3, 4, 5, 6 and 7 amongst which fractions 4, 5, 6 showed more CTGF. 
This detection correlated with that of TGFβ (12.5kDa), which was also observed in CM, SM 
and fractions 4, 5 and 6. The non-reducing analysis of the fractions showed LAP1 (150kDa) 
in fractions 3, 4, 5 and 6. Although the positive fractions are slightly shifted in position, strong 
detection for LAP1, CTGF and TGFβ could be seen in fractions 4 and 5. The pI (pH of 
isoelectronic point) values of porcine CTGF (Kozlowski LP. 2007-2013 Isoelectric Point 
Calculator) and latent TGFβ1 (Beatson et al. 2011) are 8.0 and 5.5 respectively. At the 
working pH 7.4 (i.e. the pH of the binding buffer), only the positively charged CTGF is likely 
to bind to the negatively charged column while the negatively changed latent TGFβ is 
supposed to be washed through. Therefore, the detection of both proteins in the same 
fractions suggests that they may associate in a single complex. 
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Figure 5.9 Purification of CTGF/TGFβ  SLC by cation exchange chromatography 1ml of explantation (48hr) 
CM was centrifuged and diluted in 4ml of binding buffer (SM). SM was then passed through a 1ml cation 
exchange HiTrap SP HP column and the flow through (FT) was collected in a new tube. Following several 
washes the bound protein was eluted in 1ml fractions using NaCl in a linear gradient from 0 to 1M (A). The 
Fractions were then electrophoresed under reducing conditions for CTGF and TGFβ1 (B) and non-reducing 
conditions for LAP1 (C). 
 
5.2.5.2 Gel filtration chromatography 
Gel filtration column contains polymer beads with pores of different sizes. Large molecules 
cannot pass through the small pores so they run straight down the column, while smaller 
molecules enter the pores between the beads so travel slowly through the column. As a 
result, protein molecules with large molecular weight are eluted first from the column, 
followed by smaller molecules. The protein (CTGF/TGFβ SLC) I aimed to purify is between 
100 and 250kDa, so I used a Superose 12 PC3.2/30 column, which works in a SMART 
system (for small volume samples) with a separation range of 1 to 300kDa.  
I pooled the positive fractions 3, 4, 5 and 6 from ion exchange together and concentrated the 
sample down to 50µl for size exclusion chromatography to determine whether these proteins 
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were still running in a high molecular weight complex. Before loading the sample onto the gel 
filtration column, I first carried out a standard run using 15µl of mixed standard proteins of 
various molecular weights (Figure 5.10A). The dotted line on the profile shows the 
separation of the 6 standard proteins, represented as 6 sharp peaks. The tested sample was 
then passed through the same column and collected in 100µl fractions (No.1 to 27). The 
profile generated from this test run (blue solid line) was overlapped with that of the standard 
proteins to identify approximate molecular weights of the complex of interest. The magnitude 
of peaks of tested protein is small compared with the standard peaks suggesting low protein 
concentration. CTGF/SLC was expected to have a molecular weight of around 150kDa, so I 
analysed the fractions No. 8 to 15 containing peaks between 2000kDa and 44kDa of the 
standard profile (Figure 5.10B). The samples were western blotted alongside the SM, for 
CTGF under both reducing and non-reducing conditions and TGFβ under reducing 
conditions only. As shown in figure 5.10C, a high molecular band (between 150 and 250kDa) 
was detected on the non-reducing blot by the anti-CTGF antibody in fraction 13. From the 
profile of the standard proteins, fractions 13 should correspond to proteins at around 160kDa. 
Proteins migrate differently on column compared with SDS-PAGE, in which denaturing 
agents (SDS and boiling) linearise proteins to cause retardation in gel. However, under 
reducing conditions, no CTGF or TGFβ was detected in fraction 13 nor in the other fractions. 
This may be because the protein concentration in the starting material was low, likely lost 
when the sample was concentrated using a spin cut-off column. 
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Figure 5.10 Gel filtration analysis of the ion-exchanged sample containing CTGF, TGFβ  and LAP1. 
Positive ion exchange fractions (3 to 6) were pooled together and concentrated down to 50µl (~0.2mg/ml). A 
mixture of standard proteins (A) was first passed through the Superose 12 PC3.2/30 column. The profiles from 
standard and test samples were overlapped (B). Fractions (8 to 15) (black arrows indicated) containing a peak 
around 160kDa were western blotted for CTGF and TGFβ under either non-reducing or reducing conditions (C). 
n=2  
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Crude injury CM was also analysed by gel filtration chromatography. In order to minimise 
abundant plasma proteins and matrix macromolecules, I used recutting (24hr) CM, which 
was generated after the cartilage explants had been rested in serum free medium for 48hr. 
Crude recutting CM was first centrifuged to remove insoluble material and injected onto the 
column. The profile of the test sample was again compared to a standard sample containing 
known proteins (Figure 5.10A). In this experiment several peaks were generated by the CM 
with higher protein absorbance, suggesting a higher concentration of proteins present in the 
sample (Figure 5.11A). I chose to analyse fractions 8 to 15 covering the two short peaks 
positioned between 2000kDa and 44kDa. Each fraction was western blotted alongside the 
SM for both CTGF and TGFβ under the reducing conditions. In the SM lane, both CTGF and 
TGFβ were detected with strong intensity (Figure 5.11B). Fractions 9, 10 and 11 contained 
an unknown band at 45kDa showing immunoreactivity with the anti-CTGF antibody. Proteins 
in fractions 9 and 10 eluted from the column in the void volume, suggesting that they were 
aggregated in a large mass that was unable to enter the resin of the column. The weak band 
detected in fraction 14 migrated at the correct position for monomeric CTGF (just below the 
37kDa). TGFβ1 was also detected in this fraction as well we fraction 13. From the standard 
profile, fraction 14 suggested a molecular weight between 160kDa and 75kDa. This 
coincides with the expected molecular weight of CTGF/SLC complex. These results support 
the hypothesis that CTGF released in the injury CM is associated with the SLC of TGFβ. The 
definitive way to determine whether molecules are in stable complexes is to 
immunoprecipitate one protein and look for whether the others are present in the precipitated 
sample. 
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Figure 5.11 Gel filtration analysis of crude injury CM. Crude recutting (24hr) CM was centrifuged and passed 
through the Superpose 12 PC3.2/30 column. The profiles from standard (dotted line) and test samples (green 
solid line) were overlapped (A). Fractions (8 to 15) (black arrows indicated) containing two peaks between 
2000kDa and 44kDa were western blotted for CTGF and TGFβ under reducing conditions (B). Fraction 14 (in red) 
shows detection of both CTGF and TGFβ, suggesting the possible association between the two protein 
molecules. n=1 
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5.2.6 Immunoprecipitation of CTGF an LAP from the injury CM 
I carried out immunoprecipitation (IP) assays to pull out CTGF or LAP from the injury CM 
and then western blot to see if LAP or CTGF was associated with each other. Protein A/G 
agarose beads were incubated with the explantation (48hr) CM in the presence or absence 
of polyclonal goat anti-CTGF or anti-LAP1 antibody while goat IgG was used as an isotype 
control. Incubated beads were then washed, spun down and analysed under reducing 
conditions. Figure 5.12A shows the IP assay for CTGF, western blotted for both LAP1 and 
CTGF. In order to reduce non-specific background, protein G-HRP was used instead of IgG 
HRP. Protein G-HRP detects exclusively the Fc region of intact antibodies from various 
species (Lal et al. 2005). This can avoid the detection of antibody used for IP as those 
molecules have been denatured during sample preparation by boiling. Even so, non-specific 
bands were still detected in these blots including the heavy (50kDa) and light (25kDa) chains 
of the IP antibody but luckily this did not interfere with the detection of proteins of interest. 
Following immunoprecipitation by anti-CTGF, western blotting for LAP1 showed the usual 
immunoreactive band at 75kDa in the ‘anti-CTGF’ fraction, which is likely to be the LAP 
dimer. This band was absent in the ‘beads only’ and ‘IgG control’ lanes showing that it is 
specific for CTGF (Figure 5.12A). The band was also absent in starting material (input). This 
was most likely because the concentration of LAP1 is very low relative to the concentrated 
IP fraction. The membrane was stripped and re-blotted for CTGF and TGFβ. A strong CTGF 
band can be seen in the ‘anti-CTGF’ fraction with less in the ‘IgG control’ and ‘beads only’ 
samples, demonstrating effective pull-down. A usual 12.5kDa anti-TGFβ immunoreactive 
band was seen in all fractions, not correlating with either LAP or CTGF. This may be non-
specific detection as a similar molecular weight band (12.5kDa) was also seen in the anti-
LAP blot. I was unable to immunoprecipitate successfully using the LAP antibody; CTGF 
was present in all fractions (Figure 5.12B). 
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Figure 5.12 Immunoprecipitation of injury CM for CTGF and LAP to determine their interaction. 
Explantation (48hr) CM was immunoprecipitated with protein G agarose beads and anti-CTGF or anti-LAP1 
antibodies; goat IgG was used as an isotype control. The pull-down was western blotted for CTGF and/or LAP. 
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5.2.7 Localisation of latent TGFβ  in human articular cartilage 
I next determined the localisation of latent TGFβ in articular cartilage. Frozen normal human 
articular cartilage was processed as described before (section 2.3) and then immunostained 
for LAP1 and type VI collagen as a marker of the PCM. As shown in figure 5.13, the 
immunofluorescent staining of LAP1 co-localised significantly with that of type VI collagen, 
suggesting that latent TGFβ is also sequestered in the PCM in normal human articular 
cartilage.  
 
 
 
 
 
 
 
Figure 5.13 Immunofluorescent staining of LAP1 in human articular cartilage. Frozen sections (7µm) of 
normal human articular cartilage were pre-treated with chondroitinase ABC (10mU/ml for 120min). Sections were 
stained with primary antibodies to LAP1 (1:500) (green) and type VI collagen (1:1000) (red). Sections were 
washed and incubated with secondary FITC-labeled antibodies (1:1000) and propidium iodide (PI) (1:2000) (blue). 
Fluorescence signals were detected by UltraView confocal microscopy (x60 oil) n=3 
 
5.3 Discussion 
Intensive mechanical injury predisposes cartilage to OA. However, there is substantial 
evidence that cartilage attempts to repair damaged tissue. One injury-induced response in 
cartilage that might trigger this repair is release of FGF2. Release of such growth factors 
from the PCM appears to act as a ‘mechanotransducer’ converting mechanical stimuli into 
cellular responses in articular cartilage (Vincent et al. 2002). This mechanism of 
bioavailability now also appears to be true for CTGF and indirectly TGFβ. CTGF is rapidly 
released from porcine cartilage explants and accumulated in the CM within the first 5 
 LAP                       COL VI                  PI                            Merge 
 10µm 
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minutes upon cartilage injury. The rapidity of CTGF release, and the observation that the 
protein synthesis inhibitor CHX could not abolish the initial accumulation of CTGF supports 
its release from a matrix, rather than cellular source. Such a mechanism allows for very rapid 
responses following injurious mechanical insults. The binding of CTGF into the heparan 
sulphate within the PCM and its rapid extracellular clearance through the LRP receptor 
means that bioavailable CTGF is present only in short bursts at time of injury.  
In cartilage, TGFβ is known to stimulate extracellular matrix production such as collagen and 
proteoglycan (Redini et al. 1988). Increased synthetic activity in early OA is accompanied by 
an up-regulation of TGFβ expression (Goldring et al. 2004). In disease, it is generally felt that 
the increased anabolic activity generated by TGFβ cannot compensate for the overall 
catabolic insult to cartilage.Western blot analysis of the injury CM revealed the release of 
TGFβ protein from injured cartilage. Unlike CTGF, TGFβ builds up in the CM over time 
following injury. The addition of CHX does not prevent the build-up of TGFβ protein in the 
CM, suggesting no active protein synthesis event is involved. As mentioned in the 
introduction, TGFβ is normally synthesised and secreted in a latent complex containing LAP. 
In a SLC, a disulfide-bonded dimer of LAP encloses a disulfide-bonded dimer of mature 
TGFβ through a non-covalent interaction. When I analysed the injury CM in the absence of 
reducing agent (the non-reducing condition), TGFβ was not detected by western blot. This 
happens regardless whether samples had been boiled. In theory, boiling should break the 
non-covalent interaction between TGFβ and LAP to liberate the dimer of TGFβ. However 
western blotting under these conditions was unable to detect any form of TGFβ in the injury 
CM. This is consistent with most of the TGFβ molecules released from injured cartilage 
being in an unusually stable latent form. It is generally accepted by others in the field that the 
antibody cannot access its epitope when the TGFβ dimer is enclosed by LAP.  
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Although the injury CM apparently contains only the latent form of TGFβ, this medium was 
able to activate SMAD2 in rested porcine chondrocytes, which was inhibitable by a TGFβ 
neutralising antibody. This suggests that in chondrocytes, like in many other cells, latent 
TGFβ is activated on the cell surface. A number of mechanisms involving activation of TGFβ 
have been reported. Tests using inhibitors GM6001 or RGD peptide implies that TGFβ 
activation in cartilage is not solely mediated by MMPs or integrins respectively. Under 
reducing conditions, LAP was predominately detected in the CM at early time point following 
recutting, correlating with the dynamic of CTGF release rather than TGFβ (slow 
accumulation at later time points). Under non-reducing conditions, both CTGF and LAP were 
detected in a large (~150kDa) complex within 5min following injury. These together suggest 
that both CTGF and SLC are released as an early response to cartilage injury.  
Consistent with what I found using recombinant CTGF (chapter 4), a new model of CTGF-
induced activation of TGFβ following cartilage injury emerges. CTGF may be involved in 
both the release of SLC from matrix pool and the liberation of active TGFβ from the SLC at 
cell surface. This model predicts a direct interaction between CTGF and the SLC. CTGF is 
able to interact with a number of molecules through its cysteine rich (CR) von Willebrand 
type c (VWC) domain, including active TGFβ and BMP protein (Abreu et al. 2002). The VWC 
domain of CTGF has 10 cysteine residues that are evolutionally conserved amongst the CR 
domains of von Willebrand factor, thrombospondin (TSP), procollagens I and II and chordin 
(Abreu et al. 2002). SLC and LTBP are joined by disulfide bonds at one of CR domains of 
LTBP (Munger and Sheppard 2011). A similar association may be apparent between CTGF 
and SLC through the homologous CR domain.  
I attempted 3 further methods to determine a direct interaction between CTGF and 
TGFβ/LAP. Firstly, protein extracted from the gel piece containing the 150kDa band was re-
run under reducing conditions revealed both CTGF and LAP were present within these 
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samples. TGFβ was absent from this band, but this may have been due to low abundance of 
the starting material. The second method involved purification of the 150kDa complex by a 
combination of ion exchange chromatography and gel filtration. These experiments were 
challenging but the ion exchange chromatography was at least supportive of a CTGF 
complex which containing TGFβ and LAP. Finally and most definitively I was able to show 
immunoprecipitation of LAP from the CM (explantation) using a CTGF antibody. This 
strongly supports direct binding of CTGF to the SLC of TGFβ or possibly LLC. We are 
exploring this further with Prof. Cay Kielty’s group at University of Manchester to determine 
whether CTGF binds to TGFβ, LAP or LTBP directly (by BIAcore). 
Studies for the activation of TGFβ in cartilage have been very limited. The studies in Albro’s 
group highlighted the importance of mechanical force -induced TGFβ activation in cartilage 
(Albro et al. 2012; Albro et al. 2013) This includes synovial fluid shearing and mechanical 
loading. However, their recent study of mechanical loading did not successfully demonstrate 
TGFβ activation in bovine cartilage explants. This may be because that the mechanical 
forces introduced in these studies are not sufficient to induce TGFβ activation, which 
requires additional interaction with other molecules or that activator is restricted to the 
pericellular space and cannot be easily measured in culture medium. My studies using a 
much cruder method of mechanical injury have revealed a potentially novel CTGF- 
dependent mechanism for TGF activation.  
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Part II: Study of injury response using CTGF knockout murine cartilage 
5.4 Introduction  
Another system used to study the role of CTGF is the CTGF knockout mouse (ctgf-/-). The 
purpose of using the knockout mouse is first to study in vitro injury response in cartilage 
tissue that depleted of CTGF; second is to study the in vivo role of CTGF in response to 
surgically induced joint destabilisation, a validated model of OA. CTGF is essential for 
chondrogenesis; constitutive CTGF knockout mice die at birth from respiratory failure due to 
axial skeletal defects. Osteogenesis is impaired due to compromised chondrogenesis and 
growth plate angiogenesis (Ivkovic et al. 2003). Due to the embryonic lethality, we generated 
inducible conditional CTGF knockout mice models using Cre-mediated recombination under 
the control of the ubiquitin promoter. CTGF floxed mice (ctgfflox/flox) were acquired through 
collaboration with Prof. David Abraham at University College London and Prof. George Bou-
Gharios at the University of Liverpool. Crossing the floxed mice with the Ubiquitin (Ub) Cre 
ERT2 generated pan tissue CTGF deleted mice (ctgfflox/flox ERT2cre/+).       
5.4.1 Ubiquitin Cre-Lox P knockout system 
The Cre–loxP recombination system is well characterised and widely used as a simple tool 
for genetic modification (Sauer and Henderson 1988). Cre (cyclization recombination) gene 
encodes a 38kDa site-specific DNA recombinase (Cre), which recognises the 34bp loxP 
(locus of X-over of P1) site, and catalyses both intra- and intermolecular recombination 
between two loxP sites. The loxP site consists of an 8bp core region flanked by two 13bp 
inverted repeats (Deng 2012). Cre-loxP-mediated recombination between two directly placed 
loxP sites excises all DNA sequences located within the two sites as a covalently closed 
circle (Figure 5.14).  
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The Ub-Cre/ERT2 transgenic mouse line was purchased from the Jackson Laboratory and 
originally made by Eric Brown at the University of Pennsylvania using a self-inactivating 
lentiviral vector containing the human ubiquitin promoter sequence upstream of a Cre-ERT2 
fusion gene.  The Cre-ERT2 fusion protein consists of Cre recombinase fused to a triple 
mutant form of the human estrogen receptor, which does not bind its natural ligand (17β-
estradiol) at physiological concentrations but will bind the synthetic estrogen receptor ligand 
hydroxytamoxifen (Brocard et al. 1998). Cre-ERT2 can only gain access to the nuclear 
compartment after exposure to tamoxifen. When these Cre-ERT2 mice are bred with mice 
containing a loxP-flanked sequence (exon4) of ctgf i.e. ctgfflox/flox, tamoxifen-inducible Cre-
mediated recombination results in the deletion of ctgf exon 4 in widespread tissues and the 
gene becomes unstable for protein synthesis (Araki et al. 1997). Figure 5.14 shows the 
mechanism of Cre mediated deletion of ctgf in a schematic diagram. 
 
 
 
 
 
 
 
 
Figure 5.14 The schematic diagram of ctgf exon 4 deletion by the Lox-Cre recombination system. 
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5.5 Results 
5.5.1 Generation of homozygous ctgfflox/flox /cre mice  
Homozygous ctgfflox/flox mice were crossed with mice that carrying the Cre-ERT2 insert 
(Cre+ve) to give rise to the first generation (F1) of heterozygous ctgfflox/+/Cre+ve or 
ctgfflox/+/Cre-ve offspring. Those ctgfflox/+/Cre+ve litters in F1 were then inter-bred to produce 
the second generation (F2) of mice with mixed genotypes including homozygous ctgfflox/flox, 
heterozygous ctgfflox/+ and wild-type ctgf+/+ either carrying or not carrying the Cre gene. The 
genotypes of the litters were determined by genotyping using primers that were designed to 
amplify across the loxP sites and as a result the floxed allele will generate a longer PCR 
product compared with the wild type ctgf allele. The resultant PCR products of different 
lengths can be differentiated on agarose gel, thus determining the presence of one, two or 
absence of the floxed allele. Ear biopsy tissue was obtained from mice at the age of 4 weeks, 
and from which genomic DNA was extracted (method described in 2.8.6). Figure 5.15 shows 
the genotyping result from F2 mice that were generated by the F1 cross (ctgfflox/+/Cre+). 
There are three genotypes generated in F2: homozygous (HO) ctgfflox/flox, heterozygous (HE) 
ctgfflox/+ and wild-type (WT) ctgf+/+, and these mice were either Cre+ve or Cre-ve. The DNA 
samples from the mice (ID: 304/0-5 and 305/4&5) were amplified by PCR using primers for 
ctgf or Cre gene. The resultant PCR products were electrophoresed on 1.5% agarose gel, 
and visualised in the Gel-doc UV system. The PCR products of the heterozygous ctgfflox/+ 
DNA show two bands on the gel at 1000 basepairs (bp) and 800bp, while the homozygous 
ctgfflox/flox and the wild-type ctgf+/+ produce single bands at 1000bp and 800bp respectively. 
For the presence of Cre gene, a band at 400bp can be seen on the gel. In this way, the 
genotype can be determined for each individual mouse. The presence of the Cre band does 
not allow distinction between hemizygous and homozygous expression. This is because the 
exact site and copy number of Cre insert in this line is unknown. The HO ctgfflox/flox /Cre+ 
mice were then bred to give rise the F3 generation of ctgfflox/flox /Cre+ mice, which were 
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induced for ctgf deletion.  It is important to bear in mind that as the Cre may be hemizygous 
rather than homozygous, the F3 generation may be Cre-ve. Genotyping was checked on 
every mouse for all experiments. 
 
 
Figure 5.15 Genotyping results of mice (F2) generated from inbred ctgfflox/+ Cre+ mice. PCR products were 
electrophoresied on 1.5% agarose gel and bands were visualised using GelDoc system for WT ctgf+/+ (single 
band at 800bp), HE ctgfflox/+ (double bands at 1000bp and 800bp) or HO ctgfflox/flox (single band at 1000bp) with 
either positive (band at 400bp) or negative (absent) Cre. The number under each lane is the ID (case No./litter 
No.) of the mouse from which DNA was obtained. 
 
5.5.2 Deletion of ctgf gene by tamoxifen induction 
Mice from the F3 generation at age of 4 weeks were injected with three doses of tamoxifen 
at 50mg/kg (100ul of 50mg/ml in corn oil) on three consecutive days to induce the deletion of 
the ctgf gene. The genotypes of these mice were confirmed before the tamoxifen treatment, 
and after two weeks of the injection, mice were culled for tissues. Hip cartilage was collected 
by avulsing the hip cap off the head of femur from both hip joints of 6-week-old mice (before 
ossification) using forceps and cultured separately in serum free medium. The conditioned 
medium from the injured cartilage explants was analysed for released proteins (i.e. CTGF 
and TGFβ) and the difference in protein intensity compared between the WT and knockout 
mice. Figure 5.16 shows the genotyping results of F3 mice (ID: 372/0-1 and 373/0-5) using 
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DNA extracted from their ear biopsy tissue. All these analysed mice from the F3 generation 
were homozygous for the floxed ctgf allele but not every mouse carried the Cre allele.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 Genotyping results of mice (F3) generated from breeding ctgfflox/flox Cre+ mice. PCR products 
were electrophoresed on 1.5% agarose gel and bands were visualised using GelDoc system for WT ctgf+/+ 
(single band at 800bp) (control), HE ctgfflox/+ (double bands at 1000bp and 800bp) (control) or HO ctgfflox/flox 
(single band at 1000bp) with either positive (band at 400bp) or negative (absent) Cre. The number above each 
lane is the ID (case No./litter No.) of the mouse from which DNA was obtained. 
 
5.5.3 Determination of CTGF and TGFβ  protein level in the knockout mice 
CTGF is described as a matricellular protein; down-regulation in the mRNA level may not 
necessarily reflect the depletion of protein already made and stored in the matrix before 
deletion. Therefore it was important to determine the knockout efficiency at protein level. The 
released CTGF as well as TGFβ were analysed in the conditioned medium of cartilage 
tissue harvested from the knockout mice. F3 generation mice with ID number 373 were 
injected with tamoxifen as described above whereas mice with ID 372 were used as 
untreated controls. Hip cartilage explants from each mouse (372/0 & 1 and 373/0-5) were 
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cultured in serum free medium for 24hr, and the CM was western blotted for CTGF and 
TGFβ under reducing conditions (Figure 5.17). The two control mice (372/0 &1) and three of 
the tamoxifen treated mice (373/1, 2 & 3) showed high levels of CTGF protein, two of these 
(373/2 & 3) were negative for the Cre gene. The third one (373/1) had reduced amount of 
CTGF, compared with the controls (Figure 5.17). The other three tested mice (373/0, 373/4 
and 373/5) had very weak detection of CTGF protein. Three out of the four Cre+ve mice 
showed nearly 100% depletion of CTGF compared with the control mice, implying high 
knockout efficiency at protein level. The same CM was also western blotted for TGFβ. 
Interestingly, levels of TGFβ did not correlate with that of CTGF nor with genotype (Figure 
5.17). 
 
 
 
 
 
 
 
 
 
 
Figure 5.17 Western blot of CM from mice hip cartilage explants (ID 372 and 373). The CMs of mice (372 
and 373) hip cartilage explants were western blotted for CTGF and TGFβ under reducing conditions. From the 
protein level of CTGF, it shows good knockout efficiency in three out of four tamoxifen treated mice that were 
positive for Cre. However, the levels of TGFβ protein did not correlate with that of CTGF. 
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Further ctgf knockout mice were generated, and their genotypes were confirmed before 
tamoxifen treatment. Hip cartilage explants were again cultured and the CM was analysed 
for CTGF and TGFβ. Figure 5.18 shows the western blot result from another set of ctgf 
knockout mice (427/4, 428/1 and 431/1-4). To control for possible Cre leakage, the control 
mice used here are litters from the pure ctgfflox/flox line (116/1 and 118/3 & 4) (not carrying the 
Cre allele). All mice were treated with tamoxifen. As shown in figure 5.18, WT mice (116/1, 
118/3 & 4 and 431/1) showed strong CTGF protein detection in the CM. Out of the five 
Cre+ve mice, four (427/4, 428/1, 431/2 and 431/4) showed nearly complete CTGF 
knockdown at protein level, while one (431/3) showed 50% reduction compared with the 
controls. When the same CM samples were western blotted for TGFβ, the protein 
abundance for TGFβ again did not correlate with that of CTGF protein levels (Figure 5.18). 
The genotypes and predicted phenotypes are indicated for each mouse below the western 
blot result.!!!
!
!
!
!
!
!
!
Figure 5.18 Western blot of CM from mice hip cartilage explants (ID 427, 428 and 431). The CMs of mice 
(116,118, 427,428 and 431) hip cartilage explants were western blotted for CTGF and TGFβ under reducing 
conditions. From the protein level of CTGF, it shows approximately 100% of knockout efficiency in four out of five 
Cre+ tested mice. However, the abundance of TGFβ protein does not correlate with that of CTGF. 
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The protein bands of CTGF and TGFβ on each blot were quantified using ImageJ which 
calculates pixel value statistics in each selected area that above the threshold of the 
background. The relative levels of CTGF or TGFβ were calculated using the pixel value of 
each band of the knockout mouse against that of the wild-type mouse on the same blot. 19 
knockout and 15 wild-type mice were analysed for CTGF protein while 14 knockout and 14 
wild-type mice were analysed for TGFβ protein. The difference between the wild-type and 
knockout groups were statistically tested. The p values shown in these tests suggest that the 
protein level of CTGF was significantly reduced by 75% in the knockout mice group whereas 
TGFβ protein showed no significant difference between the knockout and wild-type groups 
(Figure 5.19). 
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Figure 5.19 Quantification of CTGF and TGFβ  protein bands from western blot. Protein bands were 
quantified using ImageJ and the pixel values from knockout mice were compared against the wild-type mice on 
the same blot. The relative protein levels for both CTGF (A) and TGFβ (B) were calculated. ***p<0.001 ns=not 
significant.!
***
ns 
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5.5.4 Determining the activity of the injury CM from CTGF knockout mice 
The injury CM generated from porcine cartilage explants contained both CTGF and TGFβ 
protein, which was able to activate SMAD2 in isolated porcine chondrocytes. The injury 
medium conditioned from CTGF knockout mice hips showed reduced amount of CTGF 
protein compared with that of wild-type mice while the level of TGFβ does not correlate. 
Therefore it was interesting to investigate whether CTGF depletion affects the SMAD2 
activity of the injury CM. Mice carrying ctgfflox/flox Cre+ve alleles were generated and their 
genotypes were confirmed before tamoxifen treatment as before. Two hips from each mouse 
were cultured separately in serum free medium for 24hr. One hip was further recut in fresh 
serum free medium whilst the other was kept intact as a control. After 24hr, these 
control/recut CM were collected and used to stimulate isolated serum starved porcine 
chondrocytes. SMAD2 activation was then analysed in these cells by western blot. Litters 
(112/1, 2 & 3) from the pure ctgfflox/flox line were used as control and tested against litters 
(408A/1, 2 & 3 and 408B/1 & 2) generated from the Cre crossed line. Three (408A/1, 2 & 3) 
mice were Cre+ve and two (408B/1 & 2) were Cre-ve. All mice were treated with tamoxifen 
at age of week 4 and culled after 2 weeks of tamoxifen induction. In the western blot of 
CTGF (Figure 5.20A), the WT mice (112/1, 2 & 3 and 408B/1 & 2) showed high levels of 
CTGF protein compared with the three Cre+ve KO mice (408A/1, 2 & 3). Although some 
level of CTGF could be detected in one of the Cre+ve mice (408A/1), the significant 
reduction of CTGF protein in the Cre+ve mice suggests good knockout efficiency. In this 
experiment, unlike the previous ones, the western blot of TGFβ showed strong bands in the 
control mice and weaker intensity bands observed for the CTGF depleted ones. Having 
determined the level of CTGF and TGFβ protein in these mice, it was decided to further 
analyse the CM of the control mouse 112/3 and KO mice 408A/1, 2 & 3 (indicated in red) for 
SMAD2 activation. Both the control (non recut) and recut CM generated from the left and 
right hip of each mouse were used to treat isolated porcine chondrocytes and the level of 
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phospho-SMAD2 protein was compared by western blot. As shown in the figure 5.20B, the 
recut CM of the WT mouse (112/3) caused strong SMAD2 activation, and of the three KO 
hips tested, two out of three showed reduced SMAD2 activity. In this experiment the signal 
intensity of pSMAD2 did correlate reasonably well with CTGF but not with TGFβ protein 
detected in the explantation CM from these mice. Taken together these results suggest that 
CTGF is required for SMAD2 phosphorylation.! 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 SMAD2 activity and CTGF/TGFβ  levels in injured hips (ID112 and 408A). The hip cartilage 
explants from mice (116, 408A and 408B) were used to generate explantation CM (24hr) then re-cut to generate 
recut CM (over 24hr). The explantation CM was western blotted for CTGF and TGFβ (A). The recut CM (from 
112/3, 408A1, 2 and 3) (indicated in red) was used to stimulate isolated porcine chondrocytes to induce SMAD2 
activation (B).  
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This SMAD2 activation experiment was repeated three further times. Even though the 
knockout efficiency was variable in some of these experiments, all results reproducibly 
supported the role of CTGF in SMAD2 activation because phosphorylation of SMAD2 
appeared to correlate with levels of CTGF in the medium. Figure 5.21, 5.22 and 5.23 show 
the western blot results of three further SMAD2 activation experiments demonstrating this.  
In the experiment shown in figure 5.21A, the explantation CMs from tamoxifen treated mice 
(114/3, 424/1 - 3 and 432/1- 5) were western blotted for CTGF and TGFβ. Although the Cre 
gene had been detected in 424/1 & 2 and 432/1, strong detection of CTGF was seen in 
these mice with similar intensity observed in the control (114/3). The CM from other Cre+ve 
mice 432/3, 4 & 5 also contained CTGF protein but in lower amounts compared with the 
control. TGFβ was detected in the control 114/3 and two Cre+ve mice 424/1 and 424/2 with 
stronger intensity compared with other mice. The recut CM from mice 114/3, 424/1, 424/2 
and 432/1 (indicated in red) were used for the pSMAD2 experiment. The CM from 424/1 and 
424/2 mice (massive amount of CTGF was detected) caused strong activation of pSMAD2 
while the CM with lower amounts of CTGF (432/1) had little pSMAD2 activity.  Both CTGF 
and TGFβ could be detected in the explantation CM of the control mouse (114/3), however 
its recut CM could not activate SMAD2. Although the exact reason for this is not known, one 
thing to note here is that the measurements of CTGF and TGFβ were made on the initial 
explantation CM whereas SMAD2 activity was measured in the medium that had been 
generated when the same explants had be further recut. It is possible that the amount of 
protein released during recutting differs from explantation. Because the entire CM generated 
from recutting was used to treat cells for SMAD2 activation, it is not possible to determine 
the protein level in this material. However most of time the pSMAD2 signal activated by the 
recutting CM correlates with the CTGF signal detected in the explantation CM. 
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Figure 5.21 SMAD2 activity and CTGF/TGFβ  levels in injured hips (ID 114, 424 and 432). The hip cartilage 
explants from mice (114, 424 and 432) were used to generate explantation CM (24hr) then re-cut to generate 
recut CM (over 24hr). The explantation CM was western blotted for CTGF and TGFβ (A). The recut CM (from 
114/3, 424/1, 2 and 432/1) (indicated in red) was used to stimulate isolated porcine chondrocytes to induce 
SMAD2 activation (B).  
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Figure 5.22 shows the western blot result of SMAD2 activation using recutting CM harvested 
from another set of ctgf knockout mice. Mice 412B/1 and 412A/1-3 are all Cre+ve but 412B/1 
was not treated with tamoxifen thus used as an untreated control. The pSMAD2 signal 
detected for the control mouse is again stronger than that of KO mice. However the protein 
levels of CTGF and TGFβ have not been analysed by western blot in these mice to confirm 
whether the pSMAD2 intensity correlates with that of the CTGF.  
 
 
 
 
 
 
Figure 5.22 Inhibited pSMAD2 activation was observed for ctgf knockout mice (ID 412A and 412B). The 
hip cartilage explants from mice (412B untreated and 412A tamoxifen treated) were used to generate recut CM, 
which was used to stimulates isolated porcine chondrocytes to induce SMAD2 activation. 
 
In the next experiment, explantation (rather than recut) CM was used to study SMAD2 
activity. Figure 5.23 showed the pSMAD2 blot from cells that had been stimulated with the 
explantation CM harvested from mice 437/1-4. All four mice had been injected with 
tamoxifen but two (437/2 and 437/3) were Cre-ve while 437/1 and 437/4 are Cre+ve. As 
shown in the blot, the CM generated from the two Cre-ve mice induced SMAD2 activation 
while no/little activation was observed for the two Cre+ve mice. This again suggests that 
depletion of CTGF inhibits SMAD2 activity of injury CM. 
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Figure 5.23 No/little pSMAD2 activation was observed for ctgf knockout mice (ID 437). The hip cartilage 
explants from mice (437/2 & 3 Cre- and 437/1 & 4 Cre+) were used to generate explantation CM, which was 
used to stimulates isolated porcine chondrocytes to induce SMAD2 activation. Activation could only be detected 
in the samples from Cre- mice. 
 
The protein bands of phospho-SMAD2 on each blot were also quantified using ImageJ. 11 
knockout mice and 4 wild-type mice were analysed. The level of phospho-SMAD2 resulted 
by the recut CM was first calculated relative to the uncut controls in both the wild-type and 
knockout groups. The relative level of phospho-SMAD2 in knockout mice was then 
calculated relative to the wild-type mice and the difference was statistically tested. Figure 
5.24 shows a significant reduction of phospho-SMAD2 level in the knockout group. 
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Figure 5.24 Quantification of pSMAD2 protein bands from western blot. Protein bands were quantified using 
ImageJ and the pixel values from recut group were calculated against the control group, and then the value of 
knockout mice were compared against the wild-type mice from the same blot. 11 knockout mice and 4 wild-type 
mice were analysed. ** p<0.01!!
5.6 Discussion 
CTGF knockout mouse model was used to study the effect of in vivo CTGF depletion on the 
bioavailability and activity of TGFβ in injury-conditioned medium. Due to embryonic lethality, 
postnatal inducible knockout mice were generated by crossing homozygous ctgf floxed mice 
with ubiquitin Cre ERT2 mice. Upon tamoxifen injection, the expression of the Cre 
recombinase under the ubiquitin promoter leads to widespread deletion of CTGF. This 
allowed us to determine the importance and function of released pericellular CTGF from 
damaged hips cartilage explants.  
The genotypes of the knockout mice were confirmed using conventional PCR primers that 
were specific for the floxed ctgf gene and the Cre gene. The PCR products generated from 
floxed allele and wild type ctgf allele have little difference in length (1000bp and 800bp). This 
difference sometimes is difficult to be visualised on agarose gel. Therefore, ctgfflox/flox/Cre+ 
mice were continuously bred for several generations to ensure every mouse is homozygous 
for the ctgf floxed allele before experiments. The presence of the Cre allele was determined 
by the detection of the 400bp PCR product generated using Cre primers. Mice that did not 
** 
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show the Cre band after genotyping were used as wild-type controls. However, sometimes 
the absence of the Cre band was due to technical errors, which did not reflect the true 
genotype of a mouse. Another type of wild-type control was to use mice that untreated with 
tamoxifen. However, Cre leakage was sometimes observed, where Cre fused estrogen 
receptor binds its natural ligand (17β-estradiol) to achieve deletion regardless the induction 
of tamoxifen. To avoid Cre leakage I decided to use the mice that were bred from the pure 
ctgfflox/flox line as wild-type controls. These Cre-ve wild-type mice as well as the Cre+ve mice 
were both treated with tamoxifen to ensure that the conditions applied to both groups are 
comparable. 
Out of the 19 KO (Cre+ve) mice studied, 15 mice achieved at lease 50% CTGF protein 
reduction; 10 of these showed nearly complete depletion. This implies good knockout 
efficiency. However, this is also surprising because CTGF is a matricellular protein and there 
should be CTGF molecules that are already made and stored in the matrix of the cartilage 
explants before deletion was induced. It is not likely that 100% of pre-existing matrix bound 
CTGF had been turned over during the two weeks of tamoxifen induction. One may 
speculate that the reason for no or very little CTGF detection in the CM of knockout mice is 
because the medium analysed had been conditioned by the damaged cartilage explants for 
24hr. The released CTGF protein during that period might have been internalised through 
the LRP receptor. A priority for future experiment is to culture the hip explants for shorter 
periods (e.g. 1hr), and then western blot the CM for CTGF to determine whether good 
knockout efficiency can still be achieved. Further tests are also required to confirm that the 
SMAD2 phosphorylating activity in the CM of CTGF knockout mice cartilage was mediated 
by TGFβ rather than other TGFβ family protein such as activin A. This can be achieved 
using specific neutralising antibodies.  
Chapter 5                                  Effect of endogenous CTGF on mechanically injured articular cartilage 
! 170 
Taken together where CTGF protein depletion is evident, there is quite consistent data that 
indicates the importance of CTGF in TGFβ activation in the injury CM. There is little 
correlation between TGFβ and CTGF release in the CM implying that CTGF may be more 
important in activating latent TGFβ than in causing release of latent complexes from the 
pericellular matrix. However, these experiments are not compared like with like; as 
mentioned previously, CTGF and TGFβ levels were measured in the explantation CM 
whereas activity was generally measured in the recut CM. Moreover the collections were all 
taken over a 24hr period. During this time it is possible that CTGF and/or TGFβ levels are 
being modulated by other cellular activities. Despite this, the activity of the CM for SMAD2 
activation correlates well with the amount of CTGF in the CM, suggesting that CTGF may be 
required for its activation at the cell surface. This provides a novel role for CTGF in 
connective tissue and has important functional implication. It would also tie in nicely with 
data that link CTGF and TGFβ, for example, in the fibrosis literature (Leask and Abraham 
2004; Gore-Hyer et al. 2002; Mori et al. 1999; Rachfal 2003). Whether CTGF is also involved 
in the release of TGFβ from the PCM remain unanswered although one hopes that this will 
become more apparent once experiments have been repeated at shorter time points. It is 
possible that CTGF has two roles: the first to liberate the SLC from its matrix-bound LLC; the 
second to activate the SLC at the cell surface, allowing TGFβ to signal through the canonical 
pathway. 
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This project is a continuation of the work from a former PhD student Celia McLean who 
identified CTGF from a proteomic analysis of porcine articular chondrons and determined the 
localisation of CTGF in porcine cartilage by immunofluorescent staining. She also 
established a method to express and purify human recombinant CTGF protein from a stably 
transfected HEK293 cell line. I started this project by repeating these approaches to confirm 
the pericellular localisation of CTGF but this time in human articular cartilage; later I found 
that like FGF2, CTGF also binds to perlecan and is rapidly released from the PCM of 
cartilage upon mechanical injury. In the following years of research my main aim was to 
investigate the role of CTGF in articular cartilage. 
CTGF has been reported to promote proliferation, maturation, adhesion and differentiation of 
chondrocytes and osteoblastic cells in culture (Yosimichi et al. 2001; Hoshijima et al. 2006; 
Nishida et al. 2003). Takigawa’s group in Japan and Lyons’s group in USA reported that 
CTGF was important in chondrogenesis and angiogenesis during skeletal development. In 
Lyons’s study CTGF deficiency is perinatal lethal and led to skeletal dysmorphism in mice. 
These CTGF mutants have decreased expression of specific extracellular components and 
matrix metalloproteinases, suggesting that CTGF is a crucial regulator of cartilage 
extracellular matrix remodeling (Ivkovic et al. 2003).  
CTGF is also important in damaged cartilage and may have repairing roles.  Our group 
found that CTGF was one of the up-regulated proteins from OA cartilage (Hermansson et al. 
2004). Injection of recombinant CTGF into the joints of mice with MIA-induced OA or in situ 
injured articular cartilage repaired the defects. CTGF treated wounds repaired with new 
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cartilage which wasn't evident in the vehicle-treated controls (Nishida et al. 2004). Another 
group implanted CTGF modified bone marrow mesenchymal stem cells into injured articular 
cartilage in rabbit knee joints and showed regeneration with hyaline like cartilage (Zhu et al. 
2014). 
These studies indicate that CTGF is an important molecule in cartilage, however the 
molecular mechanism by which CTGF exerts these effects was not known. Abreu et al shed 
light on the role of CTGF in modulating TGFβ signalling in epithelial cells. In their study, they 
reported that CTGF directly binds to TGFβ through its cysteine rich domain, which 
potentiated TGFβ’s binding to its both type I and type II receptors and increased TGFβ-
mediated SMAD2 activation in cultured epithelial cells (Abreu et al. 2002). This finding was 
attractive as it also explained the shared properties observed between CTGF and TGFβ in 
fibrosis. TGFβ and CTGF are both over expressed in various fibrotic diseases (Leask et al. 
2002). TGFβ induced fibroblast proliferation and fibroblast collagen production was inhibited 
by CTGF antibodies and CTGF silencing (Duncan et al. 1999; Kothapalli et al. 1997). 
Subcutaneous injection of TGFβ and CTGF into neonatal mice caused similar fibrotic 
reactions, which was not mimicked by other growth factors (Frazier et al. 1996; Shinozaki et 
al. 1997; Ball et al. 2003). Although TGFβ and CTGF share pro-fibrogenic properties, anti-
inflammatory and immunosuppressive properties are unique to TGFβ (Rachfal 2003).  
My findings suggest that CTGF plays a role in TGFβ activation in response to cartilage injury. 
I propose a molecular mechanism by which TGFβ latent complex and CTGF are both 
sequestered in the PCM in rested articular cartilage and both are released upon injury. From 
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my experiments it is not clear whether there is a pre-existing association between CTGF and 
latent TGFβ or whether CTGF and latent TGFβ are released independently and rapidly bind 
to one another. Evidence that they are bound to one another in the CM comes from the 
observations that: both CTGF and LAP were detected as large complexes (150kDa) in the 
CM under non-reducing conditions following injury; SMAD2 phosphorylating activity was 
present within a high molecular fraction of the injury conditioned medium; 
immunoprecipitation experiments indicated that CTGF was bound to LAP in the conditioned 
medium.  
The possibility that CTGF is already associated with TGFβ in the matrix is suggested by the 
observation that neither CTGF nor the SLC are detectable in the CM after injury in their 
predicted monomeric molecular weight forms. However, this does not sit comfortably with 
the observation that when CM time courses were run under reduced conditions, TGFβ levels 
in the medium accumulated slowly over time and did not correlate with CTGF levels. This 
may be because early released SLC saturates its activation sites on the cell surface of 
adjacent chondrocytes and then is internalised through its receptor. This would also fit with 
the detection of LAP in the CM at early time points following cartilage injury.  
Using CTGF deficient tissue from CTGF conditional knockout mice I have been able to ask 
whether CTGF is important for release of TGFβ from the matrix upon injury and/ or is 
responsible for activation of the latent complex. The ability of CTGF to release TGFβ from 
the matrix was suggested by my experiments showing TGFβ release when cartilage 
explants were treated with exogenous recombinant CTGF. However, there appeared to be 
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poor correlation between the amount of TGFβ and CTGF in the CM when CTGF knockout 
hips were injured, despite demonstrating good knockdown of CTGF. As the conditioned 
medium in these experiments were collected over a 24hr period it is conceivable that there is 
residual CTGF release from the matrix early on that facilitates TGFβ release but is 
subsequently cleared. Repeating these experiments but examining the CM at early time 
points following injury will be a priority.  
On the other hand, these experiments did suggest that CTGF is more likely to be involved in 
activating the SLC at the cell surface because the injury CM from CTGF deficient cartilage 
had reduced SMAD2 activity compared with that of wild-type hip cartilage despite having 
similar levels of latent TGFβ.  
There are still remaining questions, which need to be answered with further investigation. 
These include whether CTGF binds to latent TGFβ through LAP, LTBP or through another 
unknown partner. LTBP has not been studied extensively in my research and may be 
involved in the interaction between CTGF and latent TGFβ when being sequestered in the 
cartilage matrix. Both CTGF and LTBP contain conserved cysteine rich domains, thus it is 
possible to form disulfide bonds between the two molecules. Binding assays (Biacore) 
between CTGF and LAP or LTBP are to be carried out in collaboration with Cay Kielty’s 
group at Manchester.  LTBP2 is one of the genes identified in response to CTGF and activin 
A stimulation. LTBP2, unlike other LTBP isomers, does not bind to TGFβ SLC and has been 
reported to compete with other LTBPs from binding to filibrillin and heparin (Hirani et al. 2007; 
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Sideek et al. 2014). It would be interesting to investigate whether LTBP2 is also involved in 
latent TGFβ liberation from cartilage matrix. 
Another question is how CTGF assists the SLC to be activated at its cell surface. Molecules 
that have been reported to be involved in TGFβ activation at the cell surface include TSP1, 
integrin (mainly alpha V) and MMPs (Khalil 1999). I have briefly examined whether integrins 
and MMPs are involved in the CTGF-mediated TGFβ activation using integrin and MMPs 
inhibitors. However, these experiments have not been optimised in the cartilage system 
before, and thus need to be repeated. Integrin alpha v is thought to be very low in cartilage 
(Woods et al. 1994), which makes it unlikely to be involved in TGFβ activation in cartilage.  
The involvement of TSP1 also needs to be tested using its specific inhibitor. TSP1 and 
CTGF have homology in the conserved TSP1 domain (Ribeiro et al. 1999; Bork 1993), thus 
CTGF may be able to cause a conformational change in LAP to release active TGFβ like 
TSP1. 
TGFβ is a critical molecule for normal skeletal growth and development. In vivo murine 
studies have provided important insights into the contribution of TGFβ to the processes of 
chondrogenesis, chondrocyte maturation and joint morphogenesis. Mice lacking TGFβ type 
II receptor in chondrocytes show defects in the postnatal regulation of chondrocyte 
maturation in the axial skeleton (Baffi et al. 2004). Deletion of TGFβ type II receptor in limb 
mesenchyme resulted delayed cartilage formation, reduced chondrocyte proliferation and 
malformation of joints in the digits (Seo & Serra 2007).  Some of these observations are also 
reported in CTGF knockout mice, suggesting some shared activities in skeletal development.  
Chapter 6                                                                                                                         Final discussion  
! 177 
In mature cartilage, TGF-β signalling is crucial for maintaining articular chondrocyte 
homeostasis in synovial joints (Serra et al. 1997). Loss of TGF-β signalling in cartilage 
induces chondrocyte hypertrophy, ultimately resulting in cartilage degeneration (Yang et al. 
2001), and pharmacological activation of the TGF-β pathway has been proposed to preserve 
articular cartilage integrity during osteoarthritis (Blaney Davidson et al. 2007).  
Conversely, recent studies are showing more interest in the catabolic effect of TGFβ in 
osteoarthritis. Zhen et al provided new evidence using several models of osteoarthritis to 
show that TGF-β is involved in aberrant bone remodelling and cartilage degeneration in 
osteoarthritis. Increased TGF-β activity in the subchondral bone may be an early key event 
in disease (Zhen et al. 2013). The opposite effects of TGFβ may have been attributed to the 
different signalling mediated through the different TGFβ type I receptors. Recent studies on 
endothelial cells have identified ALK1 as a second type I TGFβ receptor and have shown 
that ALK1 and ALK5 have opposing functions in these cells (Finnson et al. 2008). Inhibition 
of ALK5 using SB431542 in my study showed increased accumulation of large CTGF 
complex (150kDa) in the explantation CM (data not shown). This may imply that CTGF-
mediated activation of SLC on the cell surface involves TGFβ receptor, specifically ALK5. 
Moreover, chondrocytes treated with recombinant CTGF in my experiment only showed 
activation of SMAD2 not SMAD1 and 5 which are downstream of ALK1 activation. Therefore 
CTGF may be important in controlling the direction (anabolic or catabolic) of TGFβ’s activity 
in cartilage.  
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To summarise, my work has led to a new model, involving CTGF, for how TGFβ is activated 
upon cartilage injury: 
 
Figure 6.1 The schematic diagram of the proposed model, for how CTGF may be involved in TGFβ  
activation upon cartilage injury. 
1. CTGF and LLCs are bound into the pericellular matrix of articular cartilage. 
2. Upon injury, both become liberated where they rapidly bind to one another. 
3. The CTGF/latent TGFβ complex binds to the cell surface where TGFβ is released (in a CTGF-
dependent manner) from the latent complex, binds the ALK5 TGFβ receptor and is internalised. 
4. Free CTGF and latent complexes are rapidly cleared by an LRP1-dependent manner. 
5. Matrix bound stores are replaced by constitutively produced CTGF and LLCs until homeostasis is once 
again restored.  
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